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ABSTRACT
TNP-470, a synthetic derivative of the natural product fumagillin, and the
synthetic teratogen thalidomide are both in clinical trials for cancer due to their ability to
inhibit angiogenesis. The mechanism of action for either of these compounds, however, is
not understood at the molecular level. TNP-470 and the related natural product ovalicin
were found to covalently and specifically inhibit methionine aminopeptidase 2, and a
significant correlation was found for a series of drug analogs for their ability to inhibit the
enzyme and inhibit the growth of cultured endothelial cells. Endothelial cells treated with
TNP-470 were found to be defective in their ability to remove the amino-terminal
methionine residue from a subset of cellular proteins, providing a potential mechanism for
the growth inhibitory activity of the drug. Ovalicin was initially discovered as an
immunosuppressive agent, and it was found that TNP-470 also possesses
immunosuppressive activity. A strong correlation was found between the ability of drug
analogs to inhibit the proliferation of endothelial cells and lymphocytes, suggesting that
the two activities share a common molecular basis. Studies on the effect of TNP-470 on
the cell division cycle in endothelial cells revealed that the drugs inhibits the induction of
cyclin E-dependent kinase activity, suggesting that the compounds inhibit growth during
the mid- to late-Gl phase of the cell cycle.
Thalidomide has also been shown to possess anti-inflammatory properties,
perhaps due to its ability to inhibit the production of TNF-a from activated monocytes.
Thalidomide was found to bind to a-acid glycoprotein, a serum protein which has been
implicated in cytokine regulation. A series of tetrafluorophthalimide analogs of
thalidomide were synthesized and shown to be highly potent inhibitors of TNF-a
production. These novel compounds appear to act by a mechanism distinct from
thalidomide. Two specific tetrafluorophthalimide binding proteins were identified: a
novel homolog of the redox protein thioredoxin and a glutathione-dependent
dehydroascorbate reductase homolog. These proteins may play a role in the oxidative
regulation of signal transduction pathways leading to inflammatory cytokine induction.
Thesis Supervisor: Jun 0. Liu
Title: Associate Professor of Chemistry and Biology
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Chapter 1
Angiogenesis and small molecule angiogenesis inhibitors
Angiogenesis
The formation of blood vessels during embryonic development in vertebrates
occurs by two distinct mechanisms. The vascular framework is initially laid down by
vasculogenesis, the de novo formation of blood vessels concomitant with the
differentiation of angioblast precursors into endothelial cells, the cells which line all blood
vessels (1,2). Subsequent blood vessel growth occurs by angiogenesis, whereby new
vessels are formed by either splitting or sprouting from previously existing ones.
Whereas splitting angiogenesis predominates in some embryonic tissues, such as the lung
and heart, sprouting angiogenesis is responsible for vascularization of the developing brain
and kidney, and is the only type known to occur in adults (2). Further vascular
remodeling occurs after the onset of circulation, which involves both additional
angiogenesis and regression of pre-existing vessels to produce the hierarchical system of
veins, arteries, and capillaries characteristic of the adult circulatory system.
Sprouting angiogenesis is a complex process which involves the coordination of a
series of component events (3,4). The vessel from which the new sprout arises must be
rendered discontinuous by local breakdown of the basement membrane, the layer of
extracellular matrix (ECM) which surrounds the endothelial cell tube. Vascular
discontinuity is enhanced by endothelial cell retraction. Endothelial cells then change
shape and invade the surrounding tissue, accompanied by mitogen-driven cell proliferation
at the leading edge of the developing sprout. Cells more proximal to the original vessel
cease proliferation and adhere tightly to each other, giving rise to the new capillary tube.
Eventually, the sprouting endothelial cell tubes fuse into loops which support circulation.
Whereas extensive angiogenesis occurs in the developing embryo and during
postnatal growth, angiogenesis in the adult is restricted to aspects of the reproductive
cycle in females, such as follicle maturation during ovulation and the regrowth of the
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endometrium following menstruation, to wound healing, and to pathological states such as
cancer, retinal neovascularization, and arthritis (5,6). Accordingly, endothelial cells are
among the most quiescent in the body, with an estimated 0.01% believed to be in the cell
cycle at a given time, compared to 14% for gut epithelial cells (5). In response to the
appropriate physiological or pathological signals, however, these cells rapidly switch to a
highly proliferative state.
Tumor growth is angiogenesis-dependent
A variety of evidence supports the theory that the growth of solid tumors and
metastases are dependent on angiogenesis (6,7,8,9). Vascularization promotes tumor
progression both by providing a means for the exchange of nutrients, oxygen, and waste
products and by releasing paracrine growth factors that act on the tumor cells. Thus
without the induction of new blood vessels, a tumor will be restricted to a microscopic
size. In some cases it has been documented that cells in such microscopic tumors in fact
proliferate at the same rate as do cells in larger, vascularized solid tumors, but that cell
numbers are kept in check by an increased rate of cell death due either to necrosis or
apoptosis. Seminal experiments by Judah Folkman and co-workers in the early 1970s
first illustrated the requirement for angiogenesis in tumor growth (10). Tumors were
implanted into the iris of a rabbit, an avascular site. Initially, a tumor would grow slowly,
but induced the outgrowth of vessels from the host, presumably due to the action of a
secreted factor. In a manner of days, these vessels would reach the tumor implant. The
tumor would then become vascularized and grow rapidly and exponentially. If the tumors
were instead implanted in the anterior vitreous chamber such that blood vessels could not
reach them, they failed to grow beyond a millimeter in diameter, though the cells would
continue to proliferate. Such tumors could be left in the vitreous chamber for over a
month and then retransplanted to the retina, which would result in vascularization and
rapid growth.
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In addition to primary tumors, the development of metastases also requires
angiogenesis (7,9). Vascularization of the primary tumor promotes the shedding of tumor
cells into the circulation, particularly because angiogenic vessels are leaky and thus
permeable to cells. High hydrostatic pressure within the tumor mass arising from the
leaky vasculature also promotes efflux of cells. In addition, matrix-degrading enzymes
which are active during endothelial cell invasion can promote dissociation of cells from the
tumor mass. Cells shed from angiogenic tumors are also likely to be angiogenic when they
arrive at the site of metastasis. Like primary tumors, those which are not are limited to a
microscopic size until they also become angiogenic (11).
The angiogenic switch
Observations in experimental animals and in human patients support the idea that
the switch from a non-angiogenic state to an angiogenic state, in which the developing
tumor now induces blood vessel growth and invasion from the surrounding tissue, is a
definable and requisite event in tumor progression (3). Tumor progression is generally
regarded as proceeding through discrete morphologically distinct stages, which reflect the
accumulation of genetic and epigenetic changes in the tumor cells. Such stages can be
detected in certain transgenic mouse models for cancer. Expression of the SV40 T antigen
under the insulin promoter in mice causes the development of pancreatic islet cell
carcinomas. While all islets are initially normal, about half eventually become
hyperplastic, in which proliferation increases but neovascularization has not occurred.
Only 1-2% progress to solid tumors, which are highly vascularized. A discrete angiogenic
stage occurs in about 10% of the islets as judged by the ability of explants to attract
endothelial cells in vitro (12). These observations imply that the ability to recruit new
blood vessels is necessary but not sufficient for the progression to full-blown solid
tumors. Similarly, biopsies reveal that discrete stages are evident during the development
of breast cancer in human patients, including carcinoma-in-situ, a more localized stage
which precedes invasive carcinoma. Using endothelial cell markers as a measure for the
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extent of vascularization in tumor biopsies it was shown that only a subset of
carcinomas-in-situ were vascularized and therefore angiogenic (13,14). This observation
places an angiogenic stage in between non-angiogenic carcinoma-in-situ and fully invasive
carcinoma.
The angiogenic switch reflects a shift in the balance of endogenous activators and
inhibitors of angiogenesis, which normally serve to keep the vasculature quiescent (3,6).
A number of secreted proangiogenic factors have been identified which can promote
angiogenesis in vitro and in vivo. In the context of tumor angiogenesis, these factors are
generally believed to be produced by the tumor itself, though some angiogenesis inducers
may be produced by hematopoietic cells (macrophages, lymphocytes, and mast cells)
recruited to the tumor, and perhaps by the surrounding stroma as a consequence of
induction by the tumor. Those which have been principally associated with tumor
angiogenesis include vascular endothelial growth factor (VEGF, also known as vascular
permeability factor, or VPF), and the acidic and basic fibroblast growth factors (aFGF and
bFGF). Each of these factors is sufficient to induce blood vessel growth when implanted
within an avascular site such as the rabbit cornea. These factors are able to trigger the
entire angiogenic cascade by means of their pleiotropic effects on endothelial cells (7,15).
VEGF increases vascular permeability, causing leakage of serum proteins into the
extravascular space. Serum plasminogen is activated to plasmin at the endothelial cell
surface as a consequence of VEGF-induced upregulation of urokinase plasminogen
activator (uPA) and its receptor (uPAR) in endothelial cells. Plasmin can thereby locally
catalyze the proteolytic activation of matrix metalloproteases (MMPs) necessary for
breakdown of the basement membrane. Plasmin and MMPs are also important for
penetration of the growing sprout through the fibrinous layer which forms as a
consequence of vascular leakage (15,16). VEGF also upregulates integrin ajP3, which is
considered to be a marker for vessels undergoing active angiogenesis. Ligation of cxJ3
imparts a survival signal to dividing endothelial cells and is required to prevent their death
by apoptosis (17). Integrin ayp3 promotes the directed degradation of the extracellular
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matrix by binding directly to MMP-2 (also called gelatinase A), thereby recruiting it to
the endothelial cell surface (18). bFGF has been shown to induce the expression of
proteases and CA(3 as well, and also to downregulate other integrins, such as a 6P4 , which
allows loosening of endothelial cell-basement membrane adhesion and thus promotes
vascular discontinuity and invasion (7,15). Both VEGF and bFGF are potent endothelial
cell mitogens, and synergize with each other in this regard. Several lines of evidence have
established roles for these factors in angiogenesis. Expression of VEGF correlates with
the onset of angiogenesis in tumors, during the female reproductive cycle, and during
embryogenesis, and its receptors (VEGF-R1 and VEGF-R2) are restricted in expression
to endothelial cells. Mice lacking either VEGF receptor or having only one copy of the
gene encoding VEGF die embryonically due to serious defects in vasculogenesis (19).
Though expression of bFGF is widespread, the protein lacks a standard signal sequence
and its release from cells does not appear to occur via the normal secretory pathway.
Thus bFGF expression may not correlate with the presence of the active factor (3,7). In
addition, secreted bFGF binds heparin and is likely to be sequestered in the extracellular
matrix, where it may be released during breakdown as described above. Antibodies
against either bFGF or VEGF will block or retard tumor growth in certain mouse models
(4). Retroviral delivery of a dominant negative mutant of the type 2 VEGF receptor
(VEGF-R2, also called Flk-1 in mice) to endothelial cells in a mouse brain tumor model
also decreased tumor growth (20).
Upregulation of angiogenesis inducers during tumor progression occurs by several
mechanisms. VEGF is activated in hypoxic cells (7). In several cases activation of
oncogenes has been tied to upregulation of angiogenesis inducers (6). For example,
activation of Ha-Ras and Src induce VEGF expression in some cell lines. Ras, Src, and
Yes can also upregulate uPA in some cell types, which promotes basement membrane
degradation as described above. The loss of the von Hippel Lindau tumor suppressor
gene results in stabilization of the VEGF mRNA (2).
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A variety of endogenous protein inhibitors of angiogenesis have also been
identified and there is evidence that their downregulation must occur in order for blood
vessels to grow (3,6). Among the first to be identified was thrombospondin, which is
produced in high levels by untransformed cells and at low levels in tumor cell lines. Loss
of wild type p53, a common event in tumor progression, results in downregulation of
thrombospondin, and is likely to be a genetic component of the angiogenic switch in some
cancers. More recently, several circulating antiangiogenic proteins have been identified in
mouse models for cancer metastasis. These factors include angiostatin, an internal
fragment of plasminogen, and endostatin, a carboxy terminal fragment of collagen type
XVIII (21,22). Both are in fact produced by primary tumors and act to suppress the
growth of metastases. Surgical removal of the primary tumor gives rise to rapid growth of
metastases, a situation observed with some human cancers (9). Presumably the growth of
the primary tumor is supported by high local concentrations of activators, as discussed
above. How these various protein inhibitors suppress angiogenesis is not well
understood. Angiostatin may work by inducing apoptosis of growing endothelial cells,
whereas endostatin appears to compete with angiogenesis inducers for binding to heparin
(23,24).
Angiogenesis inhibitors as anticancer drugs
The requirement of angiogenesis for tumor growth has led to the proposal that
inhibition of angiogenesis should represent a novel form of anticancer therapy. Indeed, a
number of antiangiogenesis drugs are currently in clinical trials for a variety of cancers
(Table 1.1, 25). Such inhibitors may be directed against any of the various steps in the
angiogenesis process, and may be either proteins or small molecules (4). MMP
inhibitors, such as marimastat, prevent ECM breakdown, an early step in angiogenesis,
and several are currently in phase III clinical trials for a variety of solid tumors. Their
efficacy may also reflect their ability to directly inhibit tumor cell invasiveness.
Interferon-ax inhibits endothelial cell growth and migration and has proven effective in
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Table 1.1. Angiogenesis inhibitors currently undergoing clinical trials for cancer (25).
Drug Mechanism Trial
Marimastat MMP inhibitor Phase III
Bay 12-9566 MMP inhibitor Phase III
Ag3340 MMP inhibitor Phase III
MM1270 MMP inhibitor Phase I
COL-3 MMP inhibitor Phase I
Platelet factor-4 Endothelial cell growth Phase II
inhibitor
Interleukin 12 Endothelial cell growth Phase I/Il
inhibitor
Vitaxin Antibody to a~P3  Pre-phase II
RhuMad VEGF Antibody to VEGF Phase II
SU5416 Inhibitor of VEGF-R Phase II
kinase
Interferon-a Endothelial cell growth Phase I/II
inhibitor
ZD0101 Targets inflammatory Phase II
response to blood vessels
TNP-470 Endothelial cell growth Phase II
inhibitor
Thalidomide Mechanism unknown Phase II
Carboxyaminotriazole Endothelial cell growth Phase I/II
and migration inhibitor
Squalamine Endothelial cell growth Phase II/II
inhibitor
IM862 Mechanism unknown Phase II
managing life-threatening childhood hemangiomas (8). Carboxyaminotriazole and platelet
factor-4 also inhibit the growth of endothelial cells and are in phase II trials for several
solid tumors. Blocking antibodies against integrin avP3 and VEGF are also undergoing
clinical trials for cancer. Highly anticipated due to striking results in animal models,
human clinical trials of the anti-angiogenic polypeptides angiostatin and endostatin have
not yet begun.
The advantages of antiangiogenesis therapy over conventional chemotherapy are
theoretically numerous (8,9). Angiogenesis inhibitors should be less generally cytotoxic
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than conventional drugs and therefore should not produce the severe side effects typically
associated with chemotherapy such as nausea, hair loss, and bone marrow suppression.
Since the endothelial cells targeted by anti-angiogenesis drugs are in direct contact with the
bloodstream, drug delivery problems should not be as much of an issue. Importantly,
drug resistance, which arises in 30% of patients undergoing chemotherapy, does not seem
to arise with anti-angiogenic therapy (9,26). Tumor cells develop drug resistance due to
their inherent genomic instability, which gives rise to selectable variants. Primary cells,
such as endothelial cells, should not be subject to the same selection because genetic
alterations occur much less frequently. This principle is evident in the clinic, where bone
marrow suppression continues to occur throughout repeated cycles of chemotherapy, and
where resistance to experimental antiangiogenic drugs has not been observed. In mouse
tumor models, repeated cycles of endostatin treatment allows for successive rounds of
tumor regression and regrowth without the development of resistance (27). Curiously, in
each of several different models, tumors failed to regrow following cessation of endostatin
treatment after a number of cycles, perhaps due to exhaustion of the proliferative
potential of the tumor-associated endothelial cells. Such results have raised hopes that
this next generation of anti-angiogenesis drugs may revolutionize the treatment of cancer.
Fumagillin, TNP-470, and ovalicin
Two classes of small molecule angiogenesis inhibitors to receive attention in recent
years are those related to fumagillin and thalidomide (Figure 1.1). Prior to its rediscovery
as an angiogenesis inhibitor, fumagillin had been known for over 40 years. In 1949, it was
first identified as an active fraction from culture supernatants of the fungus Aspergillus
fumigatus which could suppress replication of a Staphylococcus phage without affecting
the growth of the bacteria itself (28). Soon thereafter the drug was found to have potent
antiprotozoal activities, which prompted human clinical trials to test fumagillin as an anti-
amoebic agent (29,30). Dose-limiting side effects, however, prevented its widespread
clinical use. Interestingly, demonstration that the compound inhibited the growth of some
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tumor cells in culture led to testing of fumagillin in mice as an anticancer drug (31). The
increase in survival time and decrease in tumor growth observed in animals even prompted
testing in a small group of human patients. No clinical efficacy was observed, perhaps
due to the relatively low doses administered. Today fumagillin is sold principally for
agricultural use as an anti-protozoal agent to treat nosema disease, a hive-decimating
scourge of beekeepers.
0 0
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Fumagillin TNP-470 Ovalicin Thalidomide
Figure 1.1. Angiogenesis inhibitors related to fumagillin and thalidomide.
The accidental fungal contamination of an endothelial cell culture led to the
rediscovery of fumagillin as an angiogenesis inhibitor, in a manner which mirrored
Fleming's discovery of penicillin (32). Ingber, while a postdoctoral fellow in Folkman's
laboratory, noted that endothelial cells near the contaminant were rounded, suggesting that
their ability to proliferate was impaired. Purification of the active principle from culture
supernatants of the contaminating Aspergillus revealed it to be fumagillin. Subsequently,
fumagillin was demonstrated to inhibit endothelial cell proliferation in vitro and to inhibit
blood vessel growth in vivo. Due to the induction of severe weight loss in mice, the
compound could not be used in models of tumor growth in vivo. Accordingly, a series of
fumagillin analogs were prepared in an effort to find more potent angiogenesis inhibitors
which might have fewer side effects. Among those synthesized, the most potent was the
compound TNP-470 (originally named AGM-1470), in which the decatetraenoyl group
of fumagillin was replaced with a chloroacetylcarbamoyl moiety (Figure 1.1). TNP-470
reversibly inhibits endothelial cell proliferation with an IC 50 in the low picomolar range,
while micromolar concentrations of the drug are cytotoxic (33). TNP-470 has been
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shown to inhibit angiogenesis in a variety of contexts in vivo, including spontaneous
vascularization of the chicken egg chorioallantoic membrane and bFGF-induced blood
vessel growth in the rat cornea (32,33). Importantly, systemic administration of TNP-
470 inhibits the growth of both blood vessels and solid tumors in mice.
Another structural analog of fumagillin, the natural product ovalicin, was also
known for some time before it was found to be an angiogenesis inhibitor. Initially isolated
in 1962 from culture supernatants of the fungus Pseudeurotium ovalis, the compound
was shown to be potently immunosuppressive (34). In animals, the drug inhibits
antibody production, reduces spleen weight in immunized animals, prolongs the survival
of skin grafts, and reduces significantly the symptoms of experimental allergic
encephalomyelitis (35,36). In vitro, the drug inhibits mitogen-induced lymphocyte
proliferation, providing a potential explanation for its effects in animals (37). Human
clinical trials, however, were halted when it was found that ovalicin caused a dramatic
decrease in platelet count in some patients, ceasing further development of the drug (34).
Around the same time, ovalicin was also isolated from a separate fungus in a screen for
compounds that could stimulate lettuce seed germination in the dark (38). More recently,
the structural similarity between fumagillin and ovalicin prompted the finding that
ovalicin also inhibits angiogenesis, having a potency for the inhibition of endothelial cell
growth rivaling that of TNP-470 (39). The relationship between these varied activities of
ovalicin is unclear.
As the most active compound in its class, TNP-470 has been extensively studied
in animals as an anticancer agent. Compared with its high potency as an inhibitor of
endothelial cell growth, inhibition of tumor cell proliferation in vitro generally requires
much higher concentrations of the drug (32). The efficacy displayed by TNP-470 in a
variety of animal models for cancer has therefore been attributed to its effects on blood
vessels and not to direct inhibition of tumor cell growth. Systemic administration of
TNP-470 can inhibit the growth of a variety of solid tumors implanted subcutaneously in
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mice, including Lewis lung carcinoma, B 16 melanoma, M5076 reticulum cell sarcoma, and
Walker 256 carcinoma (32,40). In some cases inhibition of tumor growth has been
correlated with decreases in vascularization of the tumor. The drug also inhibits the
growth of several human tumors implanted into nude mice (41,42). In each case, tumors
grow more slowly as a consequence of drug treatment, but tumor regression does not
occur. TNP-470 on its own can dramatically decrease the number of metastases in several
rodent models, including tumors which spread to the lung, lymph nodes, and liver (40,43).
These observations are significant in that they support the notion that metastases require
the induction of blood vessels to grow to visible dimensions. In addition, these studies
illustrate that anti-angiogenic drugs can work in animal models in which the progression of
cancer parallels human cancer development more closely than when tumors are simply
implanted subcutaneously. In this regard, it is also notable that combination therapy with
TNP-470 and two other angiogenesis inhibitors, minocycline and interferon a/f, slows the
growth of islet cell carcinoma in transgenic mice expressing the SV40 T antigen under
control of the insulin promoter, in which tumors arise in the context of solid tissue (44).
In addition, TNP-470 alone could prevent formation of primary liver tumors in
carcinogen-treated rats (45). While these studies indicate that TNP-470 can prevent
tumor formation and growth, the effects combination therapy with conventional cytotoxic
drugs or radiation can be more than additive in mouse tumor models, leading in some cases
to long term survival (46,47). Such successes in animal tests have led to human clinical
trials with TNP-470 for several solid tumors, including Kaposi's sarcoma, prostate
cancer, cervical carcinoma, glioblastoma, pancreatic cancer, and renal cancer (48).
Preliminary results have not been conclusive with regard to efficacy, but as anticipated,
side effects have generally been much less severe than with conventional chemotherapy .
Despite having progressed to human clinical trials, little is known regarding the
molecular mechanism of action of the class of drugs comprising fumagillin, ovalicin, and
TNP-470. The drugs appear to cause their target cells to arrest in the G, phase of the cell
cycle, apparently subsequent to immediate early gene induction by mitogens (37,49,50,
23
51). How these compounds inhibit cell proliferation is not clear. Presumably cell cycle
arrest occurs as a consequence of inhibiting some protein or proteins essential for cell
cycle progression. Identification of such a protein would thus provide basic information
regarding the mechanisms of cell growth, and would identify a potential target for the
development of future angiogenesis inhibitors which could prove clinically important.
Thalidomide
Thalidomide, a synthetic derivative of glutamine, was first prepared in 1956 and
found to have sedative-hypnotic properties (52). Widely used as a tranquilizer in
Germany and other parts of Europe during the early 1960s, the drug was withdrawn from
the market when it was determined to be the cause of an outbreak of serious birth defects
in late 1961 (53,54). Nearly 10,000 children were born with thalidomide-induced
malformations. The most common was severe phocomelia, or shortening of the limbs,
though defects of the eyes, ears, respiratory system, and intestinal tract were also
reported. Despite years of research, no clear cellular or molecular mechanism has emerged
to explain the teratogenic effect of thalidomide. An intriguing observation, however, was
recently made by D'Amato in Folkman's group (55). D'Amato reasoned that given the
extensive angiogenesis which occurs during embryonic development, compounds which
inhibit angiogenesis would be expected to be potent teratogens. Therefore a subset of
known teratogenic compounds could in fact be angiogenesis inhibitors. Indeed,
thalidomide turned out to prevent bFGF-induced neovascularization of the rabbit cornea
when administered systemically, providing an attractive mechanism for its teratogenicity.
The drug has been shown to inhibit VEGF-induced corneal angiogenesis as well (56).
Interestingly, thalidomide did not inhibit endothelial cell growth in vitro, suggesting that
the drug affects other steps in the angiogenic cascade, such as cell movement or invasion.
Alternatively, thalidomide might require metabolic activation which can only occur in
vivo. Oxidation of thalidomide to an arene oxide has previously been proposed to
mediate the teratogenic action of thalidomide (57). The inhibition of endothelial cell
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growth by thalidomide treated with liver microsomes was recently reported in support of
this hypothesis (58). Microsomes from humans and rabbits, which are susceptible to
thalidomide's teratogenicity could activate the drug, whereas microsomes from rodents,
which are apparently insensitive to thalidomide, could not, supporting both the idea that
metabolic activation was essential for thalidomide's angiogenesis inhibitory activity and
that this activity underlies the teratogenic action of the drug. However, thalidomide has
been shown inhibit angiogenesis in vivo in rodents, and while thalidomide does not induce
the same types of malformations in mice and rats as it does in humans, a different
spectrum of birth defects and embryotoxicity do occur in thalidomide-treated rodents
(59,60,61). Thus a role for metabolic activation of thalidomide is still unclear, and further
work will be needed to determine if the ability of the drug to inhibit angiogenesis indeed
underlies its teratogenicity. The new findings, however, have prompted clinical trials for
thalidomide for cancer and angiogenesis-dependent retinopathy.
Like ovalicin, knowledge an effect of thalidomide on the immune system predates
its use as an angiogenesis inhibitor. In 1965 thalidomide was provided to soothe a
leprosy patient undergoing erythema nodosum leprosum (ENL), the most severe
inflammatory reaction associated with the disease (62). Surprisingly, the patient's
symptoms cleared up rapidly, prompting a systematic trial of thalidomide to treat ENL.
Thalidomide remains the drug of choice for this condition, and has proven to be effective
in other inflammatory diseases of the skin (63). The anti-inflammatory activity of
thalidomide has also led to its use against graft versus host disease following bone marrow
transplantation and in treating oral and esophageal ulcers and wasting associated with HIV
infection (64,65,66).
The anti-inflammatory activity of thalidomide has been attributed to its ability to
inhibit the production of the inflammatory cytokine tumor necrosis factor-a (TNF-a)
from lipopolysaccharide (LPS)-stimulated blood monocytes (67). Consistent with this
observation, thalidomide lowers circulating TNF-a levels in ENL patients, and the drug
can protect mice from lethal doses of LPS, a mouse model for septic shock (68,69). In
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cultured cells, however, high concentrations of thalidomide unlikely to be achievable in
vivo are required to inhibit production of the cytokine, indicating that either the drug's
activity is potentiated by metabolic activation or that other mechanisms operate in vivo.
In this regard thalidomide has been shown to lower levels of cell adhesion molecules
expressed on both leukocytes and endothelial cells, which mediate inflammation by
promoting extravasation of leukocytes from the bloodstream into surrounding tissues
(70, 71, 72). It is possible that the in vivo efficacy of thalidomide reflects the synergistic
effects of partial down-regulation of both inflammatory cytokines and adhesion
molecules.
Despite increasing clinical use, the molecular basis for the varied activities of
thalidomide is also not understood. The inhibition of TNF-a appears to be mediated by
destabilization of its mRNA (73). Activation of the MAPK family protein kinases p38
and c-Jun N-terminal kinase (JNK) by LPS has been implicated in post-transcriptional
regulation of TNF-a. A requirement for p38 for optimal TNF-x production has been
suggested by the discovery of a class of pyridinylimidazole TNF-a production inhibitors
which potently and specifically inhibit this kinase (74,75). Expression of a dominant
negative allele of JNK in a mouse macrophage cell line inhibits expression from a TNF-a
translational reporter construct but not a transcriptional reporter construct (76). Possible
roles of the signaling pathways leading to p38 and JNK activation in thalidomide
sensitivity have not been explored thus far. In addition, no protein target for thalidomide
has been identified. Such studies have perhaps been hampered by the low potency of the
drug; the IC50 for TNF-a production is approximately 200 RM, close to the solubility
limit for the compound in water. The molecular target for thalidomide is likely to play a
key role in the signaling cascade leading to cytokine induction in monocytes, and may
provide a novel target for anti-inflammatory drug discovery. Such a protein may prove to
play an important role in the regulation of angiogenesis as well.
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Chapter 2
Identification of methionine aminopeptidase 2 as the common
target for the angiogenesis inhibitors TNP-470 and ovalicin
Abstract
Inhibition of angiogenesis is emerging as a novel form of cancer therapy with numerous
advantages over conventional cytotoxic drugs. The synthetic compound TNP-470, a
derivative of the natural product fumagillin, was among the first anti-angiogenesis drugs to
enter clinical trials. A close structural homolog, the fungal metabolite ovalicin, was
originally identified as an immunosuppressive drug but has also been shown to inhibit
angiogenesis. The drugs act by inhibiting endothelial cell proliferation, but the molecular
basis for this activity is not known. We find that the two drugs bind to a common
protein, methionine aminopeptidase type 2 (MetAP2). The drugs covalently inactivate
the aminopeptidase activity of this enzyme, but do no effect the ability of the protein to
inhibit the phosphorylation of eukaryotic initiation factor-2a (eIF-2a) by inhibitory
kinases. Yeast deficient in MetAPI were unable to grow in the presence of either drug,
whereas the growth yeast deficient in MetAP2 was unaffected by either TNP-470 or
ovalicin, indicating that the compounds inhibit the type 2 enzyme specifically. A
significant correlation was found for a series of drug analogs between their activity as
inhibitors of MetAP2 aminopeptidase activity and their ability to inhibit endothelial cell
growth, which suggests that inhibition of MetAP2 mediates the anti-angiogenic activity of
these drugs.
Introduction
Angiogenesis, the formation of new blood vessels from pre-existing ones, occurs
extensively during embryonic development and postnatal growth in mammals (1). In the
adult, however, the process is normally restricted to a few physiological circumstances,
such as wound healing, corpus luteum formation, and regrowth of the endometrium during
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the menstrual cycle (2,3). A number of pathological states, however, including diabetic
retinopathy and arthritis, are angiogenesis-dependent (4). In particular, the growth of
solid tumors is severely restricted without the induction of new blood vessels to supply
nutrients and oxygen (4,5,6). Compounds which inhibit angiogenesis are therefore
currently being explored as novel therapies for cancer. Angiogenesis inhibitors appear to
lack the side effects and problems with drug resistance associated with conventional
cytotoxic chemotherapy (7).
TNP-470 (also known as AGM-1470, Figure 2.1), a synthetic analog of the
natural product fumagillin, was among the first small molecule angiogenesis inhibitors to
enter clinical trials (8,9). The closely related compound ovalicin, which was originally
identified as an immunosuppressive drug, has also been shown to inhibit angiogenesis
(10,11). Though they are potent inhibitors of endothelial cell proliferation in vitro and in
vivo, little is known about their mechanism of action. TNP-470 appears to arrest cells in
the G, phase of the cell cycle, but has no effect on early growth factor induced events,
such as tyrosine phosphorylation and induction of immediate early genes such as c-Myc
and c-Fos (12,13,14). The molecular basis for cell cycle arrest mediated by these drugs is
unknown. In order to elucidate these mechanisms, we sought to identify cellular binding
proteins for TNP-470 and ovalicin. We report the covalent binding of both drugs to a
bifunctional protein, methionine aminopeptidase 2 (MetAP2)/p67 inhibitor of eIF-2a
phosphorylation. TNP-470 and ovalicin are found to irreversibly inhibit the
aminopeptidase activity of the protein, and do not appear to affect the homologous
MetAP 1 enzyme. Using a series of drug analogs, we find a strong correlation between
inhibition of endothelial cell proliferation and inhibition of MetAP2, suggesting that this
enzyme mediates the anti-angiogenic activity of these compounds.
Materials and Methods
Synthesis of fumagillin and ovalicin analogs. All compounds used except the
photoaffinity label were synthesized in the Liu group by Zhuang Su. All analogs of
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Figure 2. 1. The chemical structures of fumagillin, ovalicin, ovalicin photoaffinity label, biotin
conjugates and synthetic analogs. (A) Fumagillin, TNP-470, and ovalicin. The epoxides at C-3
of TN-P-470 and ovalicin are highlighted by arrows and numbering of the six-membered ring system
is indicated. (B) Ovalicin photoaffinity label and its mimic. (C) Biotin-fumagillin and biotin-
ovalicin conjugates. (D) Synthetic analogs of fumagillin and ovalicin.
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fumagillin, including TNP-470, were synthesized according to literature procedures (15).
All analogs of ovalicin and the biotin-fumagillin and biotin-ovalicin conjugates were
synthesized using modified procedures. All compounds were characterized by 'H NMR,
IR and mass spectrometry.
Ovalicin photoaffinity label. Aminoethylcarbamoyldeoxyfumagillol (0.4 mg) was taken
up in EtOH (50 gL) and mixed with [1251] 3-(3-azido-4-iodophenyl)propionylsuccinimide
(carrier-free, 25 gCi) in 5 gL EtOAc in a reaction vial (16). The vial was sealed and
incubated in the dark for 1 hr. The reaction mixture was concentrated to dryness under a
stream of Ar, suspended in neat EtOAc, and chromatographed on silica gel. The product
eluted in 5% MeOH/EtOAc. Fractions containing product as judged by thin layer
chromatography were pooled and the solvent removed under a stream of Ar. The product
was suspended in neat MeOH and stored at -80'C in the dark.
Photoaffinity labeling. Labeling reactions (25 ii) included 4 mg/ml protein from cell or
tissue extract, cold competitor drug or 0.2% EtOH carrier as indicated, and 40 gCi/ml
ovalicin photolabel in labeling buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl).
Reaction mixtures were incubated on ice in the dark for 1 hr and then irradiated in a
Stratalinker (Stratagene) at 254 nm (0.2 J/cm 2) with samples 12 cm from the source
lamps. Reactions were quenched by adding 1.5 gl P-mercaptoethanol (to 5% final
concentration) followed by 7.5 pl 5 x SDS sample buffer (10% SDS, 0.5 M Tris-HCl, pH
6.8, 40% glycerol, 0.1 mg/mi bromophenol blue) and heated in a boiling water bath for 3
min. Samples were analyzed by 10% SDS/PAGE (see Chapter 3), followed by
autoradiography.
BAEC (bovine aortic endothelial cell) proliferation assay. The assay was performed
in the Liu lab by Eric Griffith. BAEC were trypsinized and plated into 96-well plates at
a density of 2000 cells per well. After the cells adhered to the plate, compounds
dissolved in ethanol (final concentration of 0.5%) were added to the cultures. Three days
later, 25 g1 of 2.5 mg/ml (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) solution was added to the cultures. After an additional 4 hr incubation, 100 pl of
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10% SDS/0.0l N HCl solution was added to the culture. The absorbance at 600 nm was
determined 12 hr later using a Titertek Multiscan Plus plate reader.
Affinity binding assay. Performed by Eric Griffith in the Liu lab. Mouse embryo
extracts were prepared from 14.5 d.p.c. (days post conception) mouse embryos.
Embryos were dissected and Dounce homogenized (30 strokes) in 4 ml/g lysis buffer (20
mM Tris*HCI, pH 7.1, 100 mM KCl, 0.2% Triton X- 100, 2 gg/ml leupeptin, 2 gg/ml
aprotinin, 2 gg/ml soybean trypsin inhibitor). Lysates were centrifuged at 10,000 x g for
20 min. The resulting supernatant was centrifuged at 50,000 x g for 30 min. The
supernatant was either used immediately or frozen at -80 *C for storage. Extract (200 pl)
was incubated for 30 min with 50 pM competitor or ethanol control at 4 *C. Following
competition, the extract was incubated with the conjugate ligands (1 pM) for 1 hr at 4 0 C.
Immobilized streptavidin (40 g1 of a 1:1 suspension in lysis buffer) was added and the
mixture was incubated at 4*C for 1 hr. The beads were pelleted at 10,000 rpm in a
microcentrifuge for 5 min and washed twice with 600 g1 lysis buffer for 5 min. SDS
sample buffer (40 pl) was added and the samples were boiled for 10 min. The mixture
was loaded on a 12% SDS-PAGE gel and silver stained.
Identification of p67 by mass spectrometry. Purification of p67 and tryptic digestion
was performed by Eric Griffith in the Liu lab as follows. The affinity binding experiment
was scaled up by using 3 mL of mouse embryo extract (16 mg/mL) and increasing the
amount of biotin-fumagillin, immobilized streptavidin and other reagents and solutions
proportionally. The partially purified p67 was released from immobilized streptavidin
by boiling in sample buffer for 10 min before loading onto a 10% SDS-polyacrylamide gel.
After electrophoresis, the gel was silver stained to visualize p67. The 67-kD band was
excised, reduced and alkylated with iodoacetamide, followed by digestion with trypsin
and extraction as previously described (17).
Mass spectrometry was performed by Zuchun Wu in the laboratory of Klaus
Biemann as follows. The extract of the tryptic peptide mixture was dried in a Speedvac
and the residue was dissolved in 3.5 p1 of 7% aqueous formic acid. About 0.5 g1 of this
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solution and 0.5 gi of the standard (peptides corresponding to amino acids 4-10 and 18-
39 of ACTH, 50-100 fmol each) were placed onto a thin film of a-cyano-4-
hydroxycinnamic acid deposited on the sample plate of a PerSeptive Biosystems
Voyager-Elite MALDI-TOF mass spectrometer and evaporated to dryness. Fig. 3B
represents the spectrum obtained by summation of 256 N2 laser pulses. The instrument
was operated in the reflectron mode with delayed extraction (18) Under these conditions,
the resolution is at least >4000, sufficient to resolve the isotopic multiplets with the mass
accuracy being over 50 ppm.
The human MetAP2 sequence (Swiss-prot Accession No. P50579) was used to
search the EST database. A total of 13 overlapping mouse clones were found (Accession
numbers: AA175951, AA172540, AA023796, AA185067, AA175099, AA138570,
L26708, AA204267, AA175131, AA212018, AA242695, AA408613 and D21545).
They were assembled into single cDNA encoding the full length MetAP2.
Western blotting. Performed by Eric Griffith in the Liu laboratory. Recombinant
human MetAP2 was expressed and purified as previously reported (19). Samples were
transferred to nitrocellulose at 50V for 1 hr at 4*C. The nitrocellulose was treated
overnight with blocking solution (5% BSA, 2% Nonfat milk, 0.02% NaN 3 in PBS). The
membrane was incubated with rabbit anti-human MetAP2 polyclonal antibodies (1:500)
for 1 hr at room temperature, followed by incubation with sheep anti-rabbit IgG-HRP.
MetAP2 was visualized with the chemiluminescent ECL kit (Amersham) as per
manufacturer's instructions.
Detection of biotin-fumagillin and biotin-ovalicin covalently associated with
MetAP2. Performed by Eric Griffith in the Liu laboratory. Recombinant human
MetAP2 (100 ng) was incubated in 40 gl binding buffer (20 mM Tris*HCl, pH 7.1, 100
mM KCl, 0.2% Triton X- 100) in the presence or absence of competitors for 1 hr
followed by incubation with the biotin conjugates (1 pM) at 4 *C for 2 hr. 40 [1 of 2 x
SDS sample buffer was added, and the samples were boiled for 10 min. Following SDS-
PAGE, the samples were transferred to nitrocellulose at 50V for 1 hr at 4 'C and blocked
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overnight in blocking solution (5% BSA, 2% Nonfat milk, 0.02% NaN 3 in PBS). The
membrane was incubated with rabbit anti-human MetAP2 antibodies (1:500) for 1 hr at
room temperature, followed by incubation with sheep anti-rabbit IgG-HRP or incubated
with streptavidin-HRP (1:1000) for 1 hr and visualized with the chemiluminescent ECL
kit (Amersham), as per manufacturer's instructions.
MetAP enzymatic assay. Performed by Shaoping Chen in the laboroatory of Yie-Hwa
Chang at St. Louis University. Recombinant human MetAP2 was expressed and purified
from insect cells as previously described (19). To determine the effect of ovalicin and
TNP-470 as well as their derivatives on MetAP activity, various amounts of these
inhibitors was added to buffer H (10 mM HEPES, pH 7.35, 100 mM KCl, 10% glycerol,
and 0.1 M Co 2+) containing 1 nM of purified human MetAP2, and incubated at 37 OC for
30 min. To start the enzymatic reaction, Met-Gly-Met-Met was added to a concentration
of 1 mM to the reaction mixture. Released methionine was quantified at different time
points (0, 2, 3 and 5 min) using the method of Zuo et al. (20).
Phosphorylation assay for eIF-2a. Performed by Maryam Rolfie-Kolpin and Jane-Jane
Chen of the MIT HST division and Eric Griffith in the Liu laboratory. Recombinant
human MetAP2 was incubated with TNP-470 or ethanol carrier alone and dialyzed into
20 mM Tris-HCl, pH 7.8, 100 mM KCl. Modified or control MetAP2 (0.6 gg) was
incubated with purified eIF-2 (0.3 jg) in 20 mM Tris*HCl, pH 7.8, 40 mM KC1, and 2
mM MgOAc2 on ice for 1 hr, Recombinant HRI (0.25 ng) and [y-32 P]ATP were then
added to a final total volume of 20 gl and the reaction mixture was further incubated at 37
'C for 10 min. The labeled eIF-2a was analyzed by 10% SDS-PAGE followed by
autoradiography. The phosphorylated bands were quantified by NIH Image 1.60
software.
Yeast growth assay. Performed by Shaoping Chen in the laboratory of Yie-Hwa Chang.
Wild-type (YPH500 (MATuura3-52 lys2-801 ade2-101 trpl-A63 his3-A200), mapi null
[XLP101 (map 1::HIS3)], and map2 null [XLP201 (map2::URA3)] yeast cells were grown
in YEPD at 30'C to an OD 600 of 1 and then plated out in parallel onto a YEPD plates
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containing either no drug, 50 nM TNP-470, or 50 nM ovalicin. The plates were
incubated at 30'C for four days.
Results
To identify proteins which bind to TNP-470 and ovalicin, we applied two approaches in
parallel, photoaffinity labeling and affinity chromatography. Structure-activity data on
fumagillin analogs indicated that modifications to the C-6 sidechain permitted retention of
activity, while other modifications were not tolerated (15). Accordingly, probes were
synthesized by affixing a radioactively tagged phenyl azide photocrosslinking moiety (16)
to this site in ovalicin, or by tethering biotin to the corresponding site in either ovalicin or
fumagillin (Figure 2.1). Each of the affinity probes retained significant, though reduced
activity when assayed in a bovine aortic endothelial cell (BAEC) proliferation assay.
Incubation of BAEC extracts with the ovalicin photoaffinity label followed by
irradiation resulted in the labeling of a series of proteins (Figure 2.2). Preincubation of the
lysate with excess ovalicin prevented the labeling of a single protein band of
approximately 67 kD, suggesting that this protein binds specifically to ovalicin, whereas
the other labeled proteins interact non-specifically with the photoaffinity probe.
Furthermore, labeling of the 67 kD protein could also be prevented by preincubation with
TNP-470, indicating that the two drugs bind to a common protein.
To facilitate purification of the 67 kD protein, we required a more abundant
source of protein than cultured cells. Given that extensive angiogenesis occurs in later
developing embryos, we examined extracts of mouse embryos (14.5 days post
conception) for the presence of the protein. Increased amounts of the protein could be
detected by photoaffinity labeling in the mouse embryo extracts over BAEC extracts
(Figure 2.2). Interestingly, treatment of mouse embryo extracts with the photoaffinity
label without subsequent irradiation still resulted in efficient labeling of the 67 kD protein
which could also be competed by ovalicin or TNP-470, indicating that the compounds are
likely to bind to the protein covalently.
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Figure 2.2. Photoaffinity labelling of BAEC and mouse
embryo extracts reveals a common binding protein for both
TNP-470 And ovalicin. Lanes 1-3, ovalicin photoaffinity
labeling of BAEC extracts: 1, no competitor; 2, + 1 pM
ovalicin; 3, + 1 pM TNP-470. Lanes 4-6, ovalicin photoaffin-
ity labeling of mouse embryo extract: 4, no competitor; 5, + 1
pM ovalicin; 6, + 1 pM TNP-470. Lanes 7-9, mouse embryo
extract incubated with ovalicin photoaffinity label without
irradiation: 7, no competitor; 8, + 1 pM ovalicin; 9, + 1 pM
TNP-470.
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To purify the 67 kD protein, mouse embryo extracts were incubated with either
the biotin-ovalicin or the biotin-fumagillin conjugate followed by isolation of the
complexes on immobilized streptavidin. SDS-PAGE followed by silver staining of the
isolated proteins revealed a bound 67 kD protein (Figure 2.3). Addition of excess ovalicin
or TNP-470 with the biotin conjugates resulted in the disappearance of this band. To
identify this protein, the affinity purification was performed on a larger scale and
approximately 600 ng of the protein was isolated. The protein band was excised from the
silver-stained gel and digested with trypsin. Tryptic peptides were extracted from the gel
atd subjected to matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF)
mass spectrometry. The resulting spectrum contained 17 tryptic peptide-derived peaks,
which were used to search the EMBL protein database (Figure 2.4). 15 of the peaks
corresponded to peptides predicted to be present in both rat and human MetAP2 (Figure
2.5). The peaks at m/z 2136.15 and 2122.11 are derived from the same peptide (residues
452-469) in which the carboxy-terminal cysteine residue (C468) has reacted partially with
monomeric acrylamide. The sole peak that was unaccounted for, m/z 1228.68, may have
resulted from an unidentified post-translational modification of MetAP2.
Rat MetAP2 has a calculated molecular mass of 53 kD, but has been shown to
migrate at 67 kD on SDS-PAGE (21). Though no mouse homolog of MetAP2 has been
cloned, a putative open reading frame (ORF) could be constructed from overlapping
sequences in the expressed sequence tag (EST) database. The mouse ORF has 97%
sequence identity at the amino acid level with rat MetAP2, which itself is 94% identical
to the human protein (Figure 2.5). All 16 tryptic peptides identified by mass
spectrometry matched the theoretical peptides from the mouse ORF. It is therefore
likely that the isolated protein is the mouse homolog of MetAP2.
To confirm the identity of the isolated protein as MetAP2, we repeated the
affinity purification using the biotin-drug conjugates and analyzed the proteins retained
on immobilized streptavidin by Western blot using polyclonal antibodies against human
MetAP2 (Figure 2.6). The bound proteins indeed reacted with the MetAP2 antibodies.
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Figure 2.3. Isolation of p67 from mouse embryo extracts using biotin-fumagillin and
biotin-ovalicin conjugates. Mouse embryo extracts were incubated with competing
drugs for 30 min followed by incubation with biotin-fumagillin or biotin-ovalicin con-
jugate for 1 hr. Immobilized streptavidin was added for 1 hr. Samples were analyzed
by SDS-PAGE followed by silver staining. Lane 1, immobilized streptavidin control;
2, biotin-fumagillin conjugate alone; 3, biotin-fumagillin conjugate with TNP-470
competition; 4, biotin-fumagillin conjugate with ovalicin competition; 5, biotin-
ovalicin conjugate alone; 6, biotin-ovalicin conjugate with TNP-470 competition; 7,
biotin-ovalicin conjugate with ovalicin competition.
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Figure 2.4. MALDI-TOF mass spectrum of tryptic digest of p67. The m/z values
are monoisotopic. Peaks marked (*) are also present in the spectrum from a blank
sample.
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Figure 2.5. MetAP2 is highly conserved among eukaryotes. The putative mouse MetAP2 sequence
is compared to those of rat, human and S. cerevisiae. Protein sequences were aligned using the pro-
gram MegAlign. The tryptic fragments identified by mass spectrometry are overlined. Sequence
identity is highlighted by shading.
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In addition, the isolated protein migrated at the same molecular weight on SDS-PAGE as
did recombinant human MetAP2. These experiments establish the common 67 kD
binding protein for TNP-470 and ovalicin to be MetAP2.
The initial photoaffinity labeling studies implicated the interaction between
MetAP2 and ovalicin/TNP-470 to be covalent. This interaction is likely to be mediated
by one or both of the expoxide groups common to the two drugs. To confirm the
covalent nature of the complex, the biotin-fumagillin and biotin-ovalicin conjugates were
incubated with recombinant human MetAP2 either alone or in the presence of excess
competitor drug. The complexes were then boiled in SDS-containing buffer and subjected
to SDS-PAGE followed by electrophoretic transfer to nitrocellulose membrane. Probing
of the membrane with streptavidin conjugated to horseradish peroxidase allowed for
covalent incorporation of biotin into proteins to be detected by enhanced
chemiluminescence (Figure 2.7). SDS-stable incorporation of biotin could be detected
only in MetAP2 incubated with biotin-fumagillin or biotin-ovalicin alone, and not with
protein incubated with either free biotin or with the biotin-drug conjugates in the presence
of either ovalicin or TNP-470. Maintenance of the drug-protein complexes under highly
denaturing conditions as demonstrated with both the biotin-drug conjugates and
photoaffinity label strongly suggests the interaction to be covalent.
MetAP2 is a bifunctional protein. It catalyzes the co-translational removal of N-
terminal methionine residues from nascent proteins (22). The protein also inhibits the
phosphorylation of eIF-2a by inhibitory kinases, thus acting as a positive regulator of
translation (21,23,24). To better understand how binding of TNP-470 and ovalicin to
MetAP2 might lead to inhibition of cell growth, we examined the effect of the drugs on
both activities in vitro. First, we tested whether the drugs could inhibit the
aminopeptidase activity of MetAP2. Using a tetrapeptide substrate, we found that
preincubation of purified recombinant human MetAP2 with either drug potently inhibited
the aminopeptidase activity. The IC 50 values were estimated to be 1 nM for TNP-470
and 0.4 nM for ovalicin when tested against 1 nM MetAP2 (Table 2.1).
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Figure 2.6. Western blot analysis confirms the identity of p67 as MetAP2. Samples
were prepared as in Figure 2.3, transferred to nitrocellulose and incubated with rabbit
anti-human MetAP2 polyclonal antibodies followed by incubation with anti-rabbit
IgG-HRP. Lane 1, biotin-fumagillin conjugate alone; 2, biotin-fumagillin conjugate
with TNP-470 competition; 3, biotin-fumagillin conjugate with ovalicin competition;
4, biotin-ovalicin conjugate alone; 5, biotin-ovalicin conjugate with TNP-470
competition; 6, biotin-ovalicin conjugate with ovalicin competition; 7, 10 pg recom-
binant MetAP2.
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Figure 2.7. The biotin conjugates of fumagillin and ovalicin form stable adducts
with MetAP2. Recombinant human MetAP2 was incubated with the biotin conju-
gates in the presence or absence of competitors. Samples were denatured, boiled in a
SDS and b-mercaptoethanol-containing buffer, transferred to nitrocellulose. The
biotin conjugates bound to the protein were detected using streptavidin-HRP (panel
A), and MetAP2 was detected using anti-human MetAP2 followed by anti-rabbit
IgG-HRP (panel B). Abbreviations: B-F, biotin-fumagillin; B-O, biotin-ovalicin;
AGM, TNP-470; Oval, ovalicin.
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To determine whether TNP-470 and ovalicin could potentially affect the ability of
MetAP2 to regulate translation, we studied the effect of the drugs on the activity of
MetAP2 towards inhibiting the phosphorylation of eIF-2a by the heme-regulated
inhibitor kinase (HRI). Our initial attempts to assess the effects of the drugs in this assay
were complicated as the drugs appeared to stimulate both the autophosporylation of HRI
and its phosphorylation of eIF-2a. We attribute this effect to non-specific modification
of cysteine sidechains of HRI by the epoxide groups of both drugs, as a number of thiol-
modifying reagents have been shown to stimulate HRI kinase activity (25). To
circumvent this problem, we first incubated MetAP2 with TNP-470 and then subjected
the drug-protein complexes to extensive dialysis to remove unreacted drug. When
assayed for methionine aminopeptidase activity, this drug-protein complex was
completely inactive, whereas a sample treated with carrier solvent alone and dialyzed in
an identical manner retained full activity. The TNP-470-MetAP2 complex was then
tested for its ability to inhibit eIF-2a phosphorylation by HRI. We found that MetAP2
bound by TNP-470 is equally as effective as free MetAP2 at inhibiting the
phosphorylation of eIF-2a, while neither the free nor bound protein inhibited HRI
autophosphorylation (Figure 2.8). This experiment appears to rule out the possibility
that misregulation of translation underlies the inhibition of endothelial cell proliferation by
TNP-470 and ovalicin.
Eukaryotes possess two homologous MetAPs, MetAPl and MetAP2 (22,26). In
the yeast Saccharomyces cerevisiae, deletion of the gene encoding either MetAP alone
results in slow growth, while deletion of both MetAPs is lethal. Because we did not
detect binding to MetAPI by either photoaffinity labeling or by affinity chromatography,
TNP-470 and ovalicin appear to specifically inhibit MetAP2. To further explore the
specificity of the compounds for MetAP2 over MetAP1, we tested the compounds for
their ability to inhibit the growth of various yeast strains. Both wild type yeast and
yeast strains lacking either MetAPI (map]) or MetAP2 (map2) were plated onto media
containing either 50 nM TNP-470, 50 nM ovalicin, or no drug (Figure 2.9). Although
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Figure 2.8. Drug binding does not alter the protective effect of MetAP2 on eIF-2a
phosphorylation. (A) Autoradiogram of eIF-2a phosphorylation by HRI. Lane 1, eIF-2c
+ HRI; 2, eIF-2x + MetAP2 + HRI; 3, eIF-2a + MetAP2-TNP-470 + HRI. (B) Quantita-
tion of HRI autophosphorylation. (C) Quantitation of eIF-2ax phosphorylation.
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Figure 2.9. TNP-470 and ovalicin specifically inhibit MetAP2
in vivo in yeast. Wild type (WT), map], and map2 yeast
strains were plated on the yeast growth medium YEPD, or
YEPD containing either 50 nM TNP-470 or 50 nM ovalicin.
The plates were incubated at 30'C for four days before being
photographed.
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wild type and map2 mutant yeast were resistant to the drug, the growth of map] mutant
yeast was completely inhibited under these conditions. These results indicate that
MetAP2, but not MetAPI, is inhibited by the drugs in vivo.
As both TNP-470 and ovalicin inhibit the aminopeptidase activity of MetAP2
without affecting its ability to regulate translation, we suspected that inhibition of
MetAP2 might mediate the effect of these drugs on cell proliferation. As an initial step
towards testing this hypothesis, we examined the activity of a series of TNP-470 and
ovalicin analogs for their abilities to inhibit MetAP2 aminopeptidase activity in vitro and
to inhibit the growth of cultured BAECs (Table 2.1). A significant correlation (P>0.001)
was found between the potency of compounds in the inhibition of BAEC proliferation
and the inhibition of MetAP2 activity (Figure 2.10). Importantly, no derivative was
found which showed high potency in one assay but no activity in the other. This
correlation provides support for the notion that inhibition of MetAP2 underlies the anti-
angiogenic effects of TNP-470 and ovalicin.
Discussion
The covalent inactivation of MetAP2 by TNP-470 and ovalicin is the first demonstration
of a cellular binding protein for this class of angiogenesis inhibitors. MetAP2 is a cobalt-
dependent peptidase which catalyzes the co-translational removal of amino-terminal
methionine residues from nascent polypeptides (22). All eukaryotes appear to possess
two homologous methionine aminopeptidases, MetAP1 and MetAP2 (22,26). TNP-470
and ovalicin inhibit MetAP2 potently and specifically, as the growth of yeast possessing
only MetAP 1 is not inhibited by the drugs. Furthermore, the correlation among drug
analogs between inhibition of MetAP2 in vitro and inhibition of cultured endothelial cell
growth suggests that MetAP2 is the physiological target of these drugs.
MetAP2 is a bifunctional protein, which raises the question as to whether the
growth inhibitory effects of TNP-470 and ovalicin are mediated by decreased protein
synthesis, which would occur if the ability of the protein to prevent the phosphorylation
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Table 2.1. Potency of Fumagillin and Ovalicin Analogs for Inhibition
of BAEC Proliferation and MetAP2 Enzymatic Activity.
Compound Proliferation IC50 (nM) MetAP2 IC 50 (nM)
TNP-470 0.037 ± 0.0024 1.0 ± 0.3
Ovalicin 0.018 ± 0.0059 0.4 ± 0.2
FOS-72 0.013 ±0.0015 6 ± 2
FOS-68 0.46 ± 0.26 2.0 ± 0.8
FOS-69 0.31 ± 0.066 0.10 ± 0.03
FOS-70 0.12 ± 0.01 3.5 ± 1.8
FOS-37 9.5 ±4.6 8 ± 2
FOS-34 2.2 ± 1.4 4 ± 1
FOS-64 110 ± 18 3,000 ±1,000
FOS-67 40 ± 4 400 ± 200
FOS-201 56 ±34 45 ± 12
FOS-202 2,800 ±2,300 5,000 ± 2,000
IC 50s were calculated as the average of at least three experiments
fit using Deltagraph Pro 3.5 software.
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Figure 2.10. Pharmacological correlation between inhibition of the methion-
ine aminopeptidase activity of MetAP2 and inhibition of BAEC proliferation
using fumagillin and ovalicin analogs. Values were taken from Table 2.1.
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of eIF-2a were compromised by drug binding (23,24). Previous studies with ovalicin
have indicated a decrease in protein synthesis in drug-treated cells, but that this decrease
occurs subsequent to decreases in DNA synthesis, suggesting that it is a consequence and
not a cause of decreased proliferation (27). In addition, TNP-470 was reported to have
no overall effect on protein synthesis (12). These reports are consistent with our
observation that the in vitro phosphorylation of eIF-2a is not effected by the drugs.
TNP-470 possesses three potentially reactive groups, a chloroacetyl moiety and
two epoxides, any of which might mediate the covalent interaction with MetAP2. Since
the covalent interaction was shown using derivatives with either a biotin moiety or
radioactive label at the C6 position, the chloroacetyl group appears to be dispensable for
covalent binding. The fact that ovalicin and other compounds bearing a keto, hydroxyl, or
chlorobutoyl group at the C6 position can be highly potent, as inhibitors of both
MetAP2 and endothelial cell proliferation argues that the chloroacetyl group is
dispensable for activity as well. In contrast, compounds in which the spiro epoxide
group (indicated by an arrow in Figure 2.lA) has been opened with thiomethane are much
less potent than their unmodified derivatives in both assays. This suggests that an intact
spiro epoxide is required for high activity, perhaps because it mediates the covalent
interaction between the drugs and MetAP2. Studies subsequent to the work described in
this chapter have confirmed this prediction. The use of modified biotin-fumagillin
conjugates in which the ring epoxide, the sidechain epoxide, or both were converted to
alkenes were tested in the covalent drug binding assay depicted in Figure 2.7 (28). Only
analogs with an intact spiro epoxide formed specific covalent adducts with MetAP2. In
addition, the recently solved X-ray crystal structure of MetAP2 bound to fumagillin
indicates that formation of the covalent adduct involves opening of the ring epoxide (29).
The structure has also been solved with bound TNP-470, and in this case the protein also
forms a covalent adduct via the ring epoxide, with the chloroacetyl group remaining
unmodified (J. Clardy, personal communication). Together these results confirm the
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importance of the ring epoxide for the potent and covalent inactivation of MetAP2 by
TNP-470 and ovalicin.
The selectivity of this class of drugs for MetAP2 over MetAP1 is interesting
given the structural similarity between the two classes of enzyme, particularly in the
active site where drug binding occurs (29,30). Fumagillin in fact has been found to form
an adduct with MetAP from E. coli, which is most closely related to the MetAPI
enzymes of eukaryotes, though comparatively high concentrations of drug and long
incubation times are required (31). Characterization of this adduct revealed that fumagillin
forms a covalent bond with H79 of E. coli MetAP, a residue which is conserved among
both MetAP families. Indeed, a fluorescent fumagillin derivative was found to form a
covalent adduct with the corresponding residue in human MetAP2, H231 (28).
Furthermore, the crystal structure of the MetAP2-fumagillin adduct indicates that a
covalent bond forms by the nucleophilic opening of the ring epoxide by H231 (29). Site-
directed mutagenesis has confirmed that this residue is essential for both covalent drug
binding and catalysis (28). The selectivity of the drugs for MetAP2 is therefore not due
to the absence of a suitable reactive group in MetAP . Modeling of the active site
residues of MetAP2 bound to fumagillin superimposed with free E. coli MetAP (whose
crystal structure has also been solved) provides an explanation for the observed
specificity (29,30). Accommodation of fumagillin into the E. coli MetAP binding pocket
results in a configuration in which His-79 (equivalent to human MetAP2 His-23 1) is too
far away from the ring epoxide to allow covalent bond formation. Theoretical movement
of fumagillin to enable covalent adduct formation results in steric clashes between
functional groups of the drug and protein side chains, and also would break favorable
interactions, such as the one between the ring-opened epoxide oxygen and one of the
cobalt atoms. Covalent reaction of fumagillin, TNP-470, and ovalicin with the MetAP 1-
type enzymes would therefore be expected to occur much less efficiently than with
MetAP2.
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Methionine aminopeptidase activity appears to be essential for cell growth.
Prokaryotes are inviable if their single MetAP is deleted (32). In yeast, deletion of the
gene encoding either of the two MetAPs alone results in slow growth, whereas yeast
lacking both genes are inviable (19). The majority of cytosolic proteins appear to undergo
removal of their amino-terminal methionine, and such processing is essential for the
activity of certain proteins. Amino-terminal protein myristoylation requires prior
removal of the initiator methionine and is important for the function of proteins such as
the Src-family tyrosine kinases, ADP ribosylation factor, and endothelial nitric oxide
synthase (33,34). The amino-terminal residue of a protein can also dramatically effect its
rate of degradation according to the N-end rule, so that loss of MetAP activity could lead
to aberrant levels of certain proteins (35). Failure to undergo amino-terminal processing
could also affect the ability of a protein to fold or function properly.
While possession of a single active MetAP is likely to be a general requirement for
cell growth in humans, different cell types and cell lines exhibit varied sensitivity to TNP-
470, suggesting differences in their degree of dependence specifically on MetAP2 (8).
Primary endothelial cells cannot grow in low concentrations of TNP-470, for example,
while transformed endothelial cell lines tend to be resistant to the drug (36). Similarly,
mitogen-stimulated primary T cells are sensitive to ovalicin, whereas the transformed
Jurkat human T cell line is resistant (27, B. E. Turk and J. 0. Liu, unpublished
observations). Drug resistance does not always accompany transformation, however, as a
variety of transformed cells sensitive to TNP-470 have been described, including the
mouse T cell lymphoma S49.1 (27). In at least one instance, a transformed cell line has
been reported to be fumagillin-sensitive, while a non-transformed revertant cell line was
resistant (3 7). In addition, some primary cell types, such as mouse embryonic
fibroblasts, are not sensitive to TNP-470 (E. C. Griffith and J. 0. Liu, unpublished
observations).
Sensitivity to TNP-470 and ovalicin might occur by one of several mechanisms.
As MetAP activity appears to be essential for cell growth, sensitive cell types may
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exclusively express MetAP2. MetAP activity would thus be eliminated by drug
treatment. In such cases the acquisition of resistance by transformation or otherwise
would be associated with increased MetAP 1 expression. Alternatively, MetAP 1 and
MetAP2 may process different substrates in cells. Initiator methionine processing
appears to depend principally on the identity of the second translated residue, with
efficient cleavage generally occurring when it is relatively small and uncharged, though
exceptions to this rule have been found (38,39,40,41). The substrate specificities of yeast
MetAPI and MetAP2, porcine MetAP2, and human MetAP2 have been examined in
vitro using peptide substrates, though a systematic comparison using identical substrates
has not been performed (19,26,42,43). Each enzyme appears to have substrate
specificity which parallels the general rules for methionine removal in cells, though the
yeast MetAPI cleaves peptides in which the second residue is valine or threonine
somewhat less efficiently than those in which the second residue is glycine. How this in
vitro behavior might correspond to in vivo specificity is not clear. The slow growth
phenotype of yeast lacking MetAP1 indicates that these cells are compromised in their
ability to process substrates essential for optimal growth. This could be due either to a
decrease in overall nonspecific MetAP activity or due to a partial or complete defect in
the ability to process MetAP1 specific substrates. Overexpression of MetAP2 reverses
the growth defect in MetAP 1 deficient cells, whereas low level expression of MetAP2
cannot, suggesting that while MetAP2 can process MetAP1 substrates important for
optimal growth, it probably does so less efficiently than MetAPI (19,44). These
observations point to the existence of substrates at least partially specific to either
MetAP whose processing is essential for optimal growth in yeast. Direct evidence for
the existence of specific substrates, however, is lacking. The ability of yeast deficient in
either MetAP 1 or MetAP2 alone to process various substrate proteins, for example, has
not been examined.
The existence of substrates efficiently processed only in the presence normal
levels of MetAP2 activity in mammalian cells is therefore plausible. Under this
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assumption, there are several ways in which a mammalian cell may be sensitive to TNP-
470 and ovalicin. One way is for there to be a specific MetAP2 substrate essential for
cell growth whose activity or stability is dependent on removal of its amino-terminal
methionine. In this scenario, the acquisition of resistance to the drugs would reflect a loss
in the requirement for this protein for cell growth. Loss of dependence on particular
growth promoting pathways commonly occurs as a consequence of transformation, which
might explain the association sometimes observed between transformation and drug
resistance. Alternatively, an inhibitor of cell growth could be stabilized or activated by
aberrant amino-terminal processing as a consequence of decreased MetAP2 activity. Loss
of such an inhibitor could contribute to both transformation and drug resistance. The
identification of such target substrates will further elucidate the mechanism of action of
TNP-470 and ovalicin, and may reveal novel proteins involved in the regulation of cell
growth.
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Chapter 3
Inhibition of MetAP2 by TNP-470 and ovalicin in endothelial
cells
Abstract
The angiogenesis inhibitors TNP-470 and ovalicin specifically inhibit methionine
aminopeptidase 2 (MetAP2) in vitro. Inhibition of MetAP2 and changes in initiator
methionine removal in drug-treated endothelial cells has not been demonstrated. Both
drug-sensitive and insensitive endothelial cell lines express MetAP1 and MetAP2,
indicating that drug sensitivity in mammalian cells is not simply due to the absence of
compensating MetAP activity. With a single exception, detectable protein N-
myristoylation is unaffected in sensitive endothelial cells treated with TNP-470,
indicating that for proteins destined to be myristoylated, MetAPI activity can generally
compensate when MetAP2 is inactive. Analysis by two-dimensional gel electrophoresis
of total protein extracts from cells pulse-labeled with [3 5S]-methionine following TNP-
470 treatment revealed changes in the migration of several newly synthesized proteins.
Two of these proteins were identified by mass spectrometry to be glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and cyclophilin A. Purification and amino-terminal
sequencing of GAPDH from TNP-470-treated cells revealed partial retention of its
initiator methionine compared to untreated cells. Amino-terminal processing of
glutathione S-transferase-n (GST- n) was unaffected by TNP-470 treatment, indicating
that methionine removal from some, but not all proteins is affected by inactivation of
MetAP2. These studies indicate the possibility that amino-terminal processing defects of
specific proteins resulting from TNP-470 treatment may result in decreased cell growth.
Introduction
The majority of proteins produced by both prokaryotes and eukaryotes bear
modifications to their amino-termini (1,2). Among the most common of such
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modifications for cytosolic proteins is removal of the initiator methionine residue. In
prokaryotes, protein synthesis is initiated with N-formyl methionine (3). Removal of the
formyl group occurs co-translationally on a subset of proteins and is a requirement for the
subsequent co- or post-translational cleavage of the N-terminal methionine residue.
Methionine removal is catalyzed by a single cobalt-dependent enzyme, methionine
aminopeptidase (MetAP), which is essential for cell growth (4). In eukaryotes, where
translation begins with free methionine, initiator methionine removal generally occurs co-
translationally, when the nascent polypeptide chain is between 20 to 40 residues long (5).
All eukaryotes appear to possess two MetAPs, a type 1 enzyme (MetAPl) and a type 2
enzyme (MetAP2) (6,7). Though conventionally regarded as cobalt-dependent, MetAPI
from yeast is in fact optimally activated by zinc under physiological glutathione
concentrations, suggesting that MetAPs in general utilize zinc in vivo (8). Both enzymes
bear a carboxy terminal catalytic domain homologous to prokaryotic MetAPs, including
five absolutely conserved residues involved in metal coordination (Figure 3.1). MetAPI
and MetAP2 are distinguishable by having highest sequence homology to the
corresponding prokaryotic MetAPs of eubacteria and archaebacteria, respectively. In
addition, the two enzymes possess unique N-terminal domains not present in their
prokaryotic counterparts. In MetAP 1, this domain contains two zinc finger motifs, while
the amino-terminal domain in MetAP2 contains two polybasic stretches and one
polyacidic stretch (6,7,9). The functions of these amino-terminal domains are not known,
though they appear to be essential for proper activity as a yeast MetAP1 mutant lacking
the amino-terminal zinc finger domains, while catalytically active in vitro, cannot function
in vivo (10). These amino-terminal domains are though to be involved in mediating
protein-protein or protein-nucleic acid interactions which could target the MetAPs to
their site of action on the ribosome.
Individual deletion of the gene encoding either MetAP in S. cerevisiae results in
viable yeast with a slow growth phenotype, while yeast in which both genes have been
removed are inviable, suggesting that methionine aminopeptidase activity is necessary for
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Figure 3.1. Two families of MetAP. The homologous catalytic domains are
aligned with each other, with the residues involved in metal coordination
shown. The two zinc finger motifs (Zn) of MetAPi are indicated, as are the
polybasic (+) and polyacidic (-) stretches of MetAP2.
63
survival in eukaryotes (7). MetAP2 was originally cloned in yeast as a high copy
suppressor of the slow growth phenotype of MetAPI mutants, though low levels of
expression cannot complement the growth defect (7,11). These observations suggests
that at wild type levels, MetAPI and MetAP2 have different functions, perhaps in the
processing of overlapping but distinct sets of protein substrates. Interestingly expression
of a dominant negative MetAP 1 mutant in yeast also interferes with the function of
MetAP2, suggesting that the two enzymes might bind to a common set of regulatory
proteins or compete for a common binding site on the ribosome (11).
Removal of the initiator methionine occurs for most but not all cytosolic proteins
in eukaryotes. As indicated by studies of initiator methionine processing of amino-
terminal hemoglobin mutants translated in vitro in a rabbit reticulocyte lysate system,
cytochrome c and plant thaumatin mutants expressed in yeast, and surveys of proteins
with known amino-terminal primary structure, the major determinant for methionine
removal appears to be the identity of the second translated residue of a protein
(12,13,14,15). Typically, the initiator methionine is removed only if the second residue is
relatively small and uncharged, in particular if it is glycine, alanine, serine, threonine,
valine, proline or cysteine. Exceptions to the rule exist, however, and indicate that in
some cases further sequence context is likely to be important (14,16). Whether the two
MetAP isoforms are responsible for cleaving different subsets of these substrates in vivo
is not known. Studies on peptide substrates in vitro using purified protein indicate that
yeast MetAP1 processes tripeptide substrates bearing valine or threonine in the
penultimate position approximately 20-fold less efficiently than a tripeptide bearing
alanine in the same position (17). Where tested, porcine, human, and yeast MetAP2
assayed against peptide substrates follow the expected trend with regards to the
penultimate residue (7,18,19). While these studies suggest that some nascent protein
substrates may be less efficiently processed by MetAPl than by MetAP2 in vivo, it is
not clear how these differences in activity in vitro might translate into differences in
substrate specificities in vivo. For example, no studies have been done to examine the
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substrate specificity for initiator methionine retention in the yeast mutants lacking one or
the other MetAP.
There are several ways in which initiator methionine removal can affect the
activity of cellular proteins (Figure 3.2). It is required, for example, for subsequent
amino-terminal protein modifications, such as acetylation and myristoylation (1,2). N-
terminal myristoylation, which is specific to eukaryotes, occurs co-translationally, is
generally irreversible, and requires prior removal of the initiator methionine to produce a
substrate bearing an amino-terminal glycine residue (20). Other sequence determinants,
such as the presence of serine in position 5 and basic amino acid residues at positions 7
and 8, are not individually crucial but increase the tendency for myristoylation to occur.
Myristoylation affects the function of different proteins in different ways. For some
proteins myristoylation confers either constitutive or regulated membrane localization,
which can be essential for proper function. Mutants of the protein kinase encoded by the
v-src oncogene which cannot be myristoylated retain their kinase activity, but fail to
become membrane-associated and lose the ability to transform cells (21). In some cases
myristoylation does not direct proteins to the membrane but is crucial for protein-protein
interactions, as in the case of many viral coat proteins, where myristoylation is required
for assembly of infectious viral particles (22). For other proteins, such as the regulatory
B subunit of the protein phosphatase calcineurin and the catalytic subunit of protein
kinase A, myristoylation does not appear to be essential for function and its role is not
clear. Yeast in which the gene encoding N-myristoyl transferase have been deleted are not
viable due to the presence of proteins essential for growth which require myristoylation
to function properly (23). It is thus conceivable that the lack of viability observed in
MetAPI/MetAP2 double knockout yeast is entirely due to the requirement of methionine
removal for subsequent myristoylation.
The majority of mature cytosolic proteins in eukaryotes, perhaps as many as
80%, are N-terminally acetylated (24). Acetylation also occurs co-translationally, either
subsequently or alternatively to methionine removal, depending on the substrate (2,25).
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Figure 3.2. Removal of the initiator methionine from proteins
their activity in a number of ways.
can potentially affect
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Acetylation substrates tend to either have small, uncharged residues (glycine, alanine,
serine or threonine) at their amino-termini, or bear methionine at the amino-terminus and
have glutamate, aspartate, or asparagine in the penultimate position (12-16). Analysis of
model substrates in yeast and a survey of eukaryotic proteins with known N-terminal
structure indicate that these rules do not hold as rigidly as the trends discussed above for
methionine removal, indicating that residues in positions other than the first two are likely
to dictate specificity of acetylation. While the significance of amino-terminal acetylation
is not well understood, it is generally believed to be related to protein stability and
turnover (1). Thus acetylation of the amino-terminus may protect a protein from
degradation by exopeptidases and prolong its half-life, though there is no indication that
acetylated proteins are generally turned over more slowly than non-acetylated ones. The
notion that acetylation can affect protein turnover is supported by the observation that a
hypoxanthine phosphoribosyltransferase variant which bears an amino-terminal proline
residue turns over more rapidly than a variant bearing an acetylated alanine residue in the
same position, though this difference cannot be unambiguously tied to acetylation (26). It
is feasible, however, that inappropriate retention of a protein's amino-terminal
methionine could prevent it from being acetylated, thereby reducing its half-life, which
could result in lower levels of the affected protein.
The residue present at the amino-terminus of a protein can dramatically affect the
rate of protein turnover in several ways that appear unrelated to acetylation. Studies by
Varshavsky and co-workers in yeast have elucidated a pathway for protein degradation
by what is termed the N-end rule (27). Expression of protein constructs bearing the
protein ubiquitin fused to the amino-terminus in yeast leads to rapid proteolytic removal
of the ubiquitin moiety at the site of fusion. This method allows for the production of
proteins with any desired amino-terminal residue. Studies with this system indicate that
the half life of a protein so produced depends entirely on the identity of the unmasked N-
terminal residue. Generally, small amino-terminal residues (glycine, alanine, serine,
threonine, valine and methionine) are stabilizing, producing proteins with half-lives on the
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order of days, while larger residues are destabilizing, resulting in the rapid ubiquitin-
dependent degradation of the protein within minutes. The observed trend appears to be
thereby complementary to the trend for methionine removal, which indicates that the
majority of cytosolic proteins are unlikely to be targets for this degradation pathway.
However, the existence of MetAP substrates which are exceptions to the general rules for
methionine removal raises the possibility that N-end rule substrates may exist which are
produced by the standard protein maturation pathways employed in cells.
Residues at or near the amino-terminus of a protein may be important in
determining protein half-life by mechanisms distinct from the N-end rule. Levels of the
protein kinase encoded by the c-mos proto-oncogene (Mos) are controlled in part by
changes in its rate of turnover, and the wild type protein (which bears an amino-terminal
proline residue) is degraded rapidly when produced in Xenopus oocytes by microinjection
of its mRNA (28). Using the microinjection assay to produce a series of mutants in the
second codon, Sagata and co-workers showed that the turnover rate of the protein
produced was dictated by the nature of the second translated residue in a manner
unrelated to the predicted pattern for an N-end rule substrate. These mutations were
found to affect the phosphorylation of a serine residue near the N-terminus which seems
to be important for regulating the stability of Mos. Though not explicitly shown, it
seems possible that retention of the amino-terminal methionine residue could also lead to
differential phosphorylation and turnover, illustrating a mode of regulation of protein
stability which could be employed for other proteins as well. The levels of several
proteins involved in carbohydrate metabolism are rapidly degraded in yeast following
shift from growth on a non-fermentable to a fermentable carbon source in a process called
catabolite inactivation. Interestingly, mutation of the amino-terminal proline residue to
serine or tryptophan eliminated catabolite inactivation of the enzyme fructose-1,6-
bisphosphatase (29). The presence of proline at the amino-terminus of several other
enzymes degraded during catabolite inactivation suggests that involvement of the amino-
terminus may be a general feature of this process.
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Processing of the amino-terminal methionine residue may be crucial for a protein
to function properly. The refolding yield and solubility of wild type hen egg-white
lysozyme produced in bacteria under conditions where the amino-terminal methionine is
retained is poor compared to the native enzyme, which does not have methionine at its
amino-terminus (30). This observation raises the possibility that some proteins may be
unable to fold properly without correct removal of their initiator methionine. Human a-
and P-globin chains normally undergo removal of their amino-terminal methionine residues
to yield valine at their amino-termini. Hemoglobin prepared from a bacterial source which
fails to undergo processing retains the ability to bind oxygen cooperatively, but binding is
less sensitive to pH or the presence of organic phosphates (31). The N-terminal DNA
binding domain of the transcription factor MEF2C displays increased binding specificity
and bends DNA more sharply when a short extension (gly-gly-met) is appended to the
amino-terminal glycine residue (32). These studies indicate that minor modifications to
the amino-terminus of a protein can alter its biochemical behavior in potentially
significant ways.
For a variety of reasons therefore the nature of the amino-terminus of a protein
can be essential for its function, indicating that failure to cleave the initiator methionine of
certain proteins will result in loss of function. The absolute requirement for MetAP
activity for viability of both yeast and prokaryotes provides evidence that substrates
essential for cell growth exist which do not function properly without proper amino-
terminal processing. We and others have found that TNP-470, ovalicin, and fumagillin all
covalently and specifically inactivate MetAP2 (Chapter 2, 33,34). As the growth of
most mammalian cells and cell lines is not inhibited by these drugs, it would appear that
unlike yeast, most mammalian cells do not require MetAP2 for optimal growth. Why the
growth of endothelial cells and T lymphocytes is inhibited by TNP-470 and ovalicin is
not clear. The simplest possible explanation is that these cell types do not express
MetAP1, and thus inactivation of MetAP2 results in complete loss of MetAP activity
necessary for cell growth. Alternatively, there may exist proteins essential for the growth
69
of drug sensitive cells which can be processed solely by MetAP2 and not by MetAP 1,
and whose activity or stability, for any of the reasons outlined above, requires removal of
its initiator methionine. Alternatively, a protein which inhibits the growth of these cells
may be stabilized by retention of its initiator methionine leading to its accumulation and
cell cycle arrest. Herein we show that MetAP2 activity is inhibited in intact cells.
Furthermore such inhibition is shown to result in altered amino-terminal processing of a
subset of cellular proteins. These observations confirm the existence of specific MetAP2
substrates in vivo which cannot be processed in the absence of the enzyme, which
suggests that that inhibition of MetAP2 by TNP-470 and ovalicin is a plausible
mechanism leading to cell cycle arrest.
Materials and Methods
[Methyl- 3H] Thymidine, EXPRESS [3 5S] methionine/cysteine mixture, [y-32P] ATP, and
ENHANCE fluorographic enhancer were purchased from DuPont/NEN Life Science.
[9,1 0(n)-3H] myristic acid was obtained as an ethanolic solution from Amersham and was
concentrated to dryness and resuspended to 10 mCi/mL in EtOH prior to use.
Antibodies to GAPDH were obtained from Biodesign International. Antibodies to GST-
n were from Medical and Biological Laboratories (Nagoya). BioMax and XOMat AR5
film for autoradiography were from Kodak. IX SSC solution is 15 mM sodium citrate
with 150 mM NaCl, pH 7.0. IX Denhart's reagent is 0.02% Ficoll type 400, 0.02%
polyvinylpyrrolidine, and 0.02% BSA.
Cell Culture. Unless otherwise indicated, cells were grown an a humidified incubator at
37'C in an atmosphere of 5% CO2 . Bovine aortic endothelial cells (BAECs) were
cultured in DME (low glucose) containing 10% fetal bovine serum (FBS) and 50 units/mL
penicillin plus 50 gg/mL streptomycin (P/S). Human umbilical vein endothelial cells
(HUVECs) were obtained from Clonetics and cultured in EGM-2 (Clonetics). HUV-EC-
C cells were obtained from the American Type Culture Collection (ATCC) and cultured
in Kaign's modification of Ham's F12 media containing 10% FBS, 100 gg/mL heparin,
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and 30 gg/mL endothelial cell growth supplement (Sigma or Clonetics), and P/S. Flasks
and plates were pretreated with endothelial cell attachment factor (Sigma). ECV-304 cells
(ATCC) were maintained in M199 with 10% FBS and P/S. EA.hy926 cells, a generous
gift of Dr. Cora-Jean Edgell (University of North Carolina, Chapel Hill), were grown in
DME containing HAT and 10% FBS.
Cell proliferation assay (MTT). HUV-EC-C cells (5000 per well), BAECs, or
EA.hy926 cells (2000 per well) were seeded into 96-well plates and grown for 96 h in the
presence of varying concentrations of drugs or carrier alone (0.5% ethanol). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 25 pL, 10 mg/mL in
PBS) was added during the final 4 h after which cells were extracted with 100 gL of 10%
SDS with 0.1 M HCl per well for 16 hr at 37*C. Plates were read at 600 nm.
Cell proliferation assay ([3HJ thymidine incorporation). Cells prepared as described
above were seeded into 96-well plates and grown in the presence of drug or carrier alone
(0.5% EtOH) for 72 hr. Cells were pulsed with [3H] thymidine (6.7 Ci/mmol, 1 gCi per
well) for the final 6 to 18 hr of culture and harvested with a semiautomated cell harvester
onto glass fiber papers for scintillation counting.
Labeling of probe for Northern blot analysis. Purified restriction digested probe (50
ng) was labeled using High Prime DNA labeling mix (containing Klenow enzyme,
Boehringer Mannheim) with 50 gCi [3 2P]-dCTP in a volume of 20 gL for 10 min at 37"C.
Probes were purified using NucTrap size exclusion columns (Stratagene) and incorporated
radioactivity determined by scintillation counting.
Northern blot analysis. Total RNA was prepared from a single confluent flask of
HUV-EC-C, ECV304, or EA.hy926 cells by direct lysis in 10 mL Tri Reagent (Molecular
Research Center, Inc.). After incubating at room temperature 5 min, the extract was
washed with 0.2 volumes of CHCl3, allowed to separate 5 min and then centrifuged at
12,000 x g for 15 min at 4*C. RNA was precipitated from the aqueous layer by adding
0.5 volumes isopropanol, mixing, incubating at room temperature 5 min and centrifuging
at 12,000 x g for 8 min at 4'C. The pellet was washed with 75% EtOH, air-dried, and
71
suspended in 50 gL diethyl pyrocarbonate treated water. A total of 8.4 gg RNA from
each sample was electrophoresed in a 1% agarose gel run in 20 mM MOPS, pH 7.0, 8
mM NaCl, 1 mM EDTA with 16.2% formalin. RNA was transferred to nitrocellulose
overnight by capillary action. The membrane was heated at 80*C for 2 hr in vacuo. To
probe for RNA expression, the membrane was treated with prehybridization fluid (50%
formamide, 5X SSC, 5X Denhart's reagent, 500 gg/mL salmon sperm DNA, and 2% SDS)
for 2 hr at 42'C and then treated with 32P-labeled specific DNA probe (5 x 106 cpm) in
hybridization fluid (50% formamide, 5X SSC, IX Denhart's reagent, 100 gg/mL salmon
sperm DNA, 2% SDS, and 10% dextran sulfate) overnight at 42*C. The membrane was
then washed twice with 2X SSC plus 0.1% SDS, once with 0.2X SSC plus 0.1% SDS,
and once with 0.1X SSC plus 0.1% SDS prior to exposure to X-ray film. Prior to re-
probing for a different message, the membrane was first boiled in 1% SDS, 10 mM Tris
HCl, pH 7.4, 1 mM EDTA for 10 min and rinsed with 4X SSC.
Electrophoresis. SDS-PAGE was performed as described by Laemmli (35), using 2%
SDS, 50 mM Tris HCl, pH 6.8, 5% P-mercaptoethanol, with 0.1% bromophenol blue as
loading buffer. Isoelectric focusing (IEF) and non-equilibrium pH gradient electrophresis
(NEPHGE) were performed as described (36,37) except that ampholytes used were
purchased from Bio-Rad Laboratories. For IEF, samples were made up to 1% SDS with
20 mM DTT, heated in a boiling water bath for 3 min, and cooled to ambient temperature
after which 1/10th volume of 2D gel loading buffer (9M urea, 4% CHAPS, 1% DTT, 2%
ampholytes, pH 3-10) was added.
Analysis of protein myristoylation. BAECs were trypsinized from confluent plates,
seeded into plates (105 cells/cm2) and allowed to recover 4 hr at 37'C. After drug or
EtOH carrier treatment for the indicated time, the media was removed and replaced with
labeling media (DME with low glucose, 5% dialyzed FBS, and 5 mM sodium pyruvate)
containing drug or carrier. [3H] myristic acid (54 Ci/mmol, 10 mCi/mL in EtOH) was
added to a final concentration of 50 gCi/mL and cells were incubated for the indicated
times. After washing once with PBS, cells were harvested by direct lysis into either SDS-
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PAGE loading buffer or 2D gel loading buffer. Extracts were incubated at room
temperature for 2 hr, frozen on dry ice/EtOH and stored at -20'C until analysis by either
one- or two-dimensional gel electrophoresis as described above. Gels were stained with
Coomassie blue, impregnated with an autoradiography enhancer (NEN Enhance), dried,
and exposed to X-ray film to visualize spots.
Analysis of total protein synthesis and turnover. BAECs were plated into 6-well
dishes and grown to 50% confluence. Cells were treated for 4 hr with TNP-470 (50 nM)
or EtOH carrier alone (0.5 %), at which time the media was removed and replaced with
labeling media (methionine-free DME containing 5% dialyzed FBS, ImL). After
incubating 10 min at 37'C, media was replaced with fresh labeling media (0.5 mL)
containing 0.5 mCi/mL [35S] methionine (NEN EXPRESS label, >1000 Ci/mmol) including
TNP-470 or carrier. Cells were incubated 30 min at 37'C, washed once with complete
media, and then cultured in fresh complete media for various times. Cells were washed
with PBS and harvested directly into 150 gL 2D gel loading buffer either immediately or
at 1 hr, 4 hr, or 16 hr following the pulse. Extracts were kept at room temperature 1 hr,
frozen on dry ice EtOH, and stored at -20*C until analysis by two dimensional gel
electrophoresis (NEPHGE/SDS-PAGE). Gels were silver stained, dried, and exposed to
BioMax film.
Mass spectrometry. Samples were prepared from silver-stained polyacrylamide gels and
analyzed by MALDI-TOF mass spectrometry as described in Chapter 2 by Susan Wolf
in the laboratory of Klaus Biemann.
Purification of GAPDH for amino-terminal sequence analysis. BAECs were plated
at 1/3 confluence and treated with either 50 nM TNP-470 or 0.1% EtOH carrier alone in
15 cm plates (six of each type) for 72 hr. Cells were detached by treating with 1 mM
EDTA in PBS, pelleted, washed once with PBS and lysed by homogenization in
hypotonic buffer as described in Chapter 7. Lysates were centrifuged at 16,000 x g for 10
min at 4'C. Supernatants were dialyzed for 18 hr with one change into dialysis buffer (30
mM sodium phosphate, pH 6.0, 1 mM DTT, and 1 mM EDTA). Samples were assayed
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for protein by Bradford assay (Bio Rad), and 1 mg of protein was brought to a volume of
2 mL with dialysis buffer and added to 0.35 mL of AMP-agarose beads. Samples were
incubated at 4'C for 20 hr with rotating. The bead suspensions were transferred to
columns, drained, washed with 5 column volumes of dialysis buffer, and then eluted with
four 350 iL portions of elution buffer (30 mM sodium phosphate, pH 7.5, 1 mM DTT,
1 mM EDTA, and 1 mM NAD'). Eluates were concentrated to 125 gL under reduced
pressure, and then subjected to SDS-PAGE. Samples were transferred to PVDF
membrane in 10 mM CAPS, pH 11, 10% MeOH at 20 V for 2 hr at 4'C. The membrane
was stained with Ponceau S (0.2% in 1% HOAc), destained with ddH20. Bands were
excised and submitted to the MIT Biopolymers laboratory for sequence analysis.
Purification of GST-7t for amino-terminal sequence analysis. BAECs were plated at
low density (20% confluence) and allowed to grow to confluence in the presence or
absence of 50 nM TNP-470. Cells treated with TNP-470 were exchanged into fresh
media containing drug after 3 days. Cells were washed once with cold PBS and then
extracted into lysis buffer (0.5% triton X100, 50 mM HEPES, pH 7.3, 250 mM NaCl, 1
mM DTT, 1 mM EDTA, 1 gg/mL aprotinin, 25 gM leupeptin, 1 mM PMSF, 1 mL per
15 cm plate) by scraping into a microcentrifuge tube and incubating at 4'C for 30 min
with rotating. Extracts were centrifuged 10 min at 16,000 x g at 4*C to remove debris,
frozen on dry ice/EtOH, and stored at -80'C until use. To purify GST, 1.2 mL of each
lysate was incubated with 100 gL glutathione sepharose 4B (Pharmacia) for 2 hr at 4*C
with rotating. Beads were pelleted and washed 3 times for 5 min at 4'C with lysis buffer,
suspended in SDS-PAGE loading buffer, and heated in a boiling water bath for 10 min.
Samples were prepared for N-terminal analysis as described above for GAPDH, except
that blots were stained with Coomassie Brilliant Blue (0.1% in 1% HOAc, 40% MeOH)
to visualize protein bands.
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Results
Primary endothelial cells and T lymphocytes are sensitive to TNP-470 and ovalicin, but
most other cell types, including many transformed cells, are not. A possible explanation
for this observation would be that endothelial cells lack MetAP1, which would mean that
treatment with TNP-470 or ovalicin would result in complete loss of MetAP activity in
these cells. Cells would be thereby unable to proliferate, by analogy with map] mutant
yeast. To address this possibility, we examined expression levels of both MetAP 1 and
MetAP2 mRNA in a series of endothelial cell lines, each derived from human umbilical
vein endothelial cells (HUVECs). While proliferation of the cell line HUV-EC-C is
inhibited by TNP-470, growth of ECV304 cells is largely unaffected, and EA.hy926 cells
are only partially sensitive to the drug (Figure 3.3). All three cell lines, however, express
MetAPI and MetAP2 mRNA at comparable levels by Northen blot analysis (Figure 3.4).
It is therefore unlikely that TNP-470 treatment completely inhibits MetAP activity in
sensitive cells or that resistance is conferred by high levels of expression of either protein.
If inhibition of MetAP2 peptidase activity underlies cell cycle arrest induced by
TNP-470 and ovalicin, then protein substrates must exist which cannot be efficiently
processed by MetAPl. Several approaches were therefore taken to determine if cells
treated with the drugs have specific defects in methionine processing. First, protein
myristoylation was examined. Bovine aortic endothelial cells (BAECs) were pretreated
with TNP-470 and then labeled with [3H] myristic acid, which is metabolically converted
to myristoyl CoA and incorporated into proteins as N-myristoyl groups (38). Labeled
cell extracts were subjected to SDS-PAGE followed by fluorography. Samples were run
in duplicate and one set of lanes each was treated with either Tris buffer or 1 M
hydroxylamine, which cleaves thioester bonds, to ensure that the incorporated
radioactivity was due to myristoylation and not due to S-palmitoylation as a consequence
of metabolic conversion of the labeled myristate to palmitate. A series of myristoylated
protein bands could be detected by this procedure (Figure 3.5). For most of the detected
proteins, no differences in the intensity of labeling were observed between untreated cells
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Figure 3.3. Sensitivity of various endothelial cell lines to
TNP-470. Cells were grown in 96-well plates in the presence
of varying concentrations of TNP-470 for 3 days and then
proliferation was analyzed by either [3H] thymidine incorpo-
ration (A, HUV-EC-C and ECV-304) or MTT assay (B,
HUV-EC-C and EA.hy926).
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Figure 3.4. Human endothelial cell lines express comparable
levels of both MetAP 1 and MetAP2 mRNA regardless of sen-
sitivity to TNP-470. Levels of MetAP1 mRNA, MetAP2
mRNA, and control 18S rRNA expression in HUV-EC-C (lane
1), EA.hy926 (lane 2), and ECV-304 (lane 3) cells were deter-
mined by Northern blot analysis.
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Figure 3.5. Analysis of protein myristoylation in BAECs in the pres-
ence or absence of TNP-470 by one dimensional SDS-PAGE. Cells
were pretreated with 50 nM TNP-470 or carrier solvent alone as indicat-
ed for 48 hr prior to labeling for 4 hr with [3H] myristic acid. Extracts
were run on SDS-PAGE (10%), and lanes were treated either with 1M
Tris HCl, pH 7.0 or 1M hydroxylamine, pH 7.0 as indicated prior to
fluorography. The band of roughly 150 kD molecular weight which
decreases with TNP-470 treatment is indicated with an arrow.
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Figure 3.6. Analysis of protein myristoylation in BAECs in the presence or
absence of TNP-470 by two dimensional gel electrophoresis. Cells were pre-
treated with 50 nM TNP-470 or carrier solvent alone (0.1% EtOH) for 4 hr fol-
lowed by [3H] myristic acid labeling for 16 hr. Extracts were analyzed by two
dimensional electrophoresis, using isoelectric focusing for the first dimension
and SDS-PAGE (12%) for the second dimension. This page: A. Extracts from
cells treated with carrier solvent alone. Following page: B. Extracts from
TNP-470 treated cells.
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and cells treated with TNP-470. The only exception is a single protein band of
approximately 150 kD molecular weight, which is decreased approximately two-fold in
intensity from cells treated with TNP-470. To determine whether the myristoylation of a
subset of proteins which could not be visualized by one-dimensional electrophoresis was
affected by TNP-470 treatment, extracts were analyzed by two-dimensional
electrophoresis as well (Figure 3.6). No proteins could be detected which appeared to be
differentially myristoylated in TNP-470-treated cells. Though it is possible that there are
scarce myristoylated proteins which could not be detected by this method, it would
appear that for the great majority of proteins destined for myristoylation, MetAPI can
compensate in the absence of MetAP2 activity.
Given the precedent for effects on turnover rate consequent to changes the amino-
terminus of a protein, we examined whether TNP-470 treatment affected the half-life of
any cellular proteins. To do this, cells were pre-treated with TNP-470 or carrier solvent
alone and then pulse labeled with [35S] methionine. Following the pulse, cells were
exchanged into fresh media containing excess cold methionine and extracts prepared at
various times thereafter. To allow observation of as many proteins as possible, extracts
were analyzed by two dimensional electrophoresis followed by autoradiography.
Autoradiograms for samples collected immediately following the pulse and 16 hr later are
shown in Figure 3.7. Despite detection of several rapidly degraded proteins (with half-
lives less than 16 hr), clear differences in the turnover rate of any protein due to TNP-470
treatment were not observed. However, several protein spots, which migrated at roughly
16 kD, 37 kD, and 56 kD molecular weight, displayed altered mobility when visualized
by autoradiography from cells treated with TNP-470 (Figure 3.7). Interestingly, these
changes in mobility were not evident when proteins from extracts prepared immediately
following the pulse were visualized by silver stain, but the mobility of the 37 kD and the
56 kD protein began to change at later time points (20 hr following initiation of drug
treatment) (Figures 3.8 and 3.9). This observation suggests that the altered mobilities
observed are due to modifications which occur to proteins synthesized only subsequently
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Figure 3.7. TNP-470 affects the migration of several protein spots by two
dimensional electrophoresis. Cells were pretreated with 50 nM TNP-470
for 4 hr prior to pulse labeling with [35S] methionine. Extracts were
prepared either immediately following the pulse (A) or after a 16 hr chase
with excess cold methionine (B). Proteins with altered migration are
indicated with arrows in panel A.
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Figure 3.8. Two dimensional electrophoretic analysis followed by silver
staining of protein extracts from cells treated with or without TNP-470.
The same gels shown in Figure 3.6 were silver stained prior to drying and
autoradiography.
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Figure 3.9. Two dimensional electrophoretic analysis followed by silver
staining of protein extracts from cells treated with or without TNP-470.
Enlarged view of the gels shown in Figure 3.8 reveals altered migration of
the 38 kD protein at the later time point.
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to drug treatment. The ability to detect a partial change in mobility of the 37 kD and 56
kD proteins by silver stain at later times probably indicates that turnover of a detectable
fraction of the protein has occurred by that time.
To study this modification further, the 37 kD and 16 kD proteins, which were
relatively abundant as judged from intensity of silver staining, were identified by
MALDI-TOF mass spectrometry analysis of in-gel tryptic digests (39). Mass spectra of
tryptic peptides from the 37 kD protein revealed 16 peptides, which were used to search
the protein databank. Of the 16 masses, nine matched predicted peptides from the
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with high accuracy
(Table 3.1). Two additional peptides appear to result from modification of cysteine
residues of GAPDH with monomeric acrylamide. The nature of the remaining five
peptides is not known, but may reflect allelic differences between the isolated protein and
the sequence in the protein databank, or possibly unknown post-translational
modifications to GAPDH. The assignment of this protein as GAPDH is also consistent
with its observed molecular weight of 37 kD. The mass spectrum from the tryptic digest
of the 16 kD protein contained 12 peaks distinct from background. Of these, 11 matched
peptides derived from the peptidyl prolyl cis-trans isomerase cyclophilin A, including
three which were modified by acrylamide as above (Table 3.2).
Interestingly, both GAPDH and cyclophilin A from bovine sources have their
initiator methionine residues removed co-translationally to yield mature proteins with
unmodified valine residues at their amino-termini, raising the possibility that their shifts
in mobility following drug treatment are due to retention of the initiator methionine. To
investigate this possibility we chose to purify and determine the amino-terminal sequence
of GAPDH from cells treated with TNP-470. GAPDH was chosen over cyclophilin A as
its rate of turnover appeared to be more rapid (Figure 3.9). BAECs were treated for 72 hr
with either 50 nM TNP-470 or carrier solvent alone and extracts prepared by hypotonic
lysis. GAPDH was purified by affinity chromatography on AMP-agarose (40). As
judged by immunoblotting, TNP-470 treatment had little effect on levels of the enzyme,
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Table 3.1. Molecular weights of tryptic peptides from the 37 kD protein indicate that it
is identical to GAPDH. Peptides predicted to be modified on cysteine residues by
monomeric acrylamide are indicated with an asterisk (*).
Measured Calculated Location in
mass (Da) mass (Da) GAPDH peptide sequence
783.344 - -
795.426 795.425 LTGMAFR 225-231
806.397 - -
977.55 977.542 KAITIFQER 70-77
1033.61 - -
1213.58 - -
1358.71 1358.681 VVDLMVHMASKE 321-332
1369.78 1369.744 GAAQNIIPASTGAAK 198-212
1461.87 1461.832 LEKPAKYDEIKK 246-257
1556.83 1556.811 VPTPNVSVVDLTCR 232-245
1570.88 1570.826 VPTPNVSVVDLTCR 232-245*
1615.93 1615.881 AITIFQERDPANIK 70-83
1763.83 - -
1795.83 - -
1848.01 1848.936 IVSNASCTTNCLAPLAK 143-159*
2213.08 2213.11 VIISAPSADAPMFVMGVNHEK 116-136
Table 3.2. Molecular weights of tryptic peptides from the 16 kD protein indicate it to be
cyclophilin A. Peptides predicted to be modified on cysteine residues by monomeric
acrylamide are indicated with an asterisk (*).
Measured Calculated Location in
mass (Da) mass (Da) Cyclophilin A peptide sequence
686.371 686.399 HVVFGK 125-130
737.349 737.358 TAENFR 31-36
777.341 777.347 GSCFHR 49-54*
1055.53 1055.541 VSFELFADK 19-27
1132.61 1132.604 KITIADCGQI 154-163*
1140.57 1140.558 FDDENFILKH 82-90
1379.79 1379.758 VSFELFADKVPK 19-30
1505.78 1505.746 VKEGMNIVEAMER 131-143
1564.76 - -
1612.76 1612.761 IIPGFMCQGGDFTR 55-68*
1817.95 1817.896 SIYGEKFDDENFILK 76-90
1946.01 1946.002 VNPTVFFDIAVDGEPLGR 1-18
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Figure 3.10. Purification of GAPDH from BAECs treated with or without
TNP-470. Cells were treated for 72 hr with 50 nM TNP-470 or carrier solvent
alone. GAPDH was isolated from extracts by AMP-agarose affinity
chromatography. A, Silver stain of purified material. B, Western blotting
with GAPDH antibodies. Equal proportions of the extracts, AMP-agarose
bead supernatants, column wash, and 1 mM NAD elution fractions were load-
ed in each lane.
Figure 3.11. Two dimensional electrophoresis of GAPDH purified from
TNP-470-treated and untreated BAECs. Purified material identical to that
shown in figure 3.9A was subjected to two dimensional electrophoresis
(NEPGE/SDS-PAGE). Gels were silver stained to visualize protein. Left
panel, GAPDH isolated from control cells. Right panel, GAPDH isolated
from TNP-470 treated cells.
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Table 3.3. Amino terminal sequence analysis of GAPDH purified from
TNP-470-treated and untreated BAECs. The remainder of protein samples
shown in figure 3.11 was run on SDS-PAGE, blotted to PVDF membrane,
and sequenced by Edman degradation. The picomolar amount of each amino
acid is given for each cycle.
Literature TNP-470-
Cycle sequence Control cells treated cells
1 V V (44.1), M (0) V (13.6), M (17.0)
2 K K (47.7), V (0) K (19.1), V (10.6)
3 V V (42.2), K (3.0) V (15.7), K (17.0)
4 G G (34.3), V (2.0) G (17.2), V (12.2)
5 V V (36.7), G (2.4) V (16.4), G (14.8)
6 N N (23.1), V (4.8) N (9.9), V (13.5)
and recovery from both drug-treated and untreated cells was nearly quantitative (Figure
3.10). Two dimensional gel analysis of the purified protein from TNP-470-treated cells
revealed an approximately one to one mixture of the two closely migrating forms, while
the material from untreated cells was almost exclusively a single species (Figure 3.11).
Purified material from both preparations was separated by SDS-PAGE,
electrophoretically transferred to PVDF membrane, and their amino-terminal sequences
were determined by Edman degradation. While the N-terminal sequence of the protein
purified from untreated cells was identical to the predicted sequence for bovine GAPDH
with complete removal of the initiator methionine (41), the protein from TNP-470-treated
cells appeared to be a mixture of GAPDH with the methionine retained and with the
methionine removed in roughly equal amounts (Table 3.1). This establishes that complete
processing of the N-terminal methionine from GAPDH requires MetAP2 activity, and
that this activity is inhibited in intact cells by TNP-470. Taken together with the
observation that protein myristoylation is not generally effected by the drug, this result
indicates that the amino-terminal processing of some, but not all, proteins is diminished in
TNP-470 treated cells. It is formally possible, however, that the defect in GAPDH
processing was simply due to an overall decrease in MetAP activity in cells, which may
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have led to subtle decreases in myristoylation which could not be detected in our
experiments.
In order to observe directly whether MetAP2 was required for complete amino-
terminal methionine removal from all proteins, we chose to examine the amino-terminus of
other cytosolic proteins. Bovine glutathione S-transferase-n (GST-n) is normally
processed by removal of its initiator methionine to produce the mature protein with an
unblocked amino-terminal proline residue (42). We isolated GST-n from cells treated
with or without 50 nM TNP-470 by affinity chromatography on glutathione sepharose
(Figure 3.12). In order to ensure that the protein analyzed was synthesized subsequent
to drug treatment, cells were plated at low density and allowed to grow to confluence
under both conditions. As TNP-470 decreases the growth rate of BAECs dramatically,
drug treated cells did not reach confluence until 7 days following replating, while carrier
treated cells reached confluence after only 2 days. Western blotting confirmed that
approximately 75% of the protein present in extracts was synthesized during the last 6
days of drug treatment, as there was four-fold more GST-n present in equal proportions
of extracts prepared 7 days after initiating drug treatment compared with extract from an
identical plate made one day following drug treatment (Figure 3.12). Amino-terminal
sequencing of the purified protein revealed that approximately 80% of the protein had its
initiator methionine removed, while roughly 20% retained the methionine, regardless of
whether it was from drug treated or untreated cells (Table 3.2). This indicates that in
contrast with GAPDH, MetAP2 activity is dispensable for normal processing of GST-n,
illustrating that specific MetAP2 substrates do exist within cells.
Discussion
All endothelial cell lines tested, regardless of their degree of sensitivity to TNP-470, were
shown to express the genes encoding both MetAPI and MetAP2 at comparable levels.
This result indicates that the situation in mammalian cells is likely to be more complex
than in map] mutant yeast, where inhibition of MetAP2 by drug cannot be compensated
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Figure 3.12. Purification of GST-n from BAECs treated with or
without TNP-470. BAECs plated at equal densities were grown to
confluence in the presence or absence of TNP-470 or harvested after
24 hr TNP-470 treatment. GST-m was isolated from extracts with
glutathione-agarose beads. As indicated, equal proportions of crude
protein extracts, glutathione-agarose bead supernatants, or material
retained on glutathione-agarose beads was separated by SDS-PAGE
and analyzed by Western blot with anti-GST-n antibodies. Lane 1,
plate harvested after 24 hr TNP-470 treatment. Lanes 2-7, plates
treated as indicated and harvested at confluence.
95
Table 3.4. Amino terminal sequence of purified GST-n from cells grown to
confluence in the presence or absence of TNP-470. The remainder of the
samples shown in figure 3.12 was electrophoresed, blotted onto PVDF
membrane, and sequenced by Edman degradation. The molar amount of each
amino acid present in each cycle is indicated.
Literature
Cycle sequence Control cells TNP-470-treated cells
1 P P (11.7), M (1.6) P (19.2), M (2.8)
2 P P (12.7) P (19.5)
3 Y Y (13.4), P (2.1) Y (20.5), P (3.8)
4 T T (9.7), Y (3.3) T (14.1), Y (5.5)
5 I I (13.6), T (1.9) I (22.8), T (3.3)
6 V V (10.8), I (2.8) V (17.6),I (5.9)
for by other MetAP activity. An attractive possibility is that specific proteins exist
which can only be efficiently processed by MetAP2. Analysis of GAPDH isolated from
TNP-470-treated cells indicates this to be the case. Though only half of the GAPDH
isolated from drug-treated cells had failed to undergo amino-terminal processing,
thefraction of the enzyme with altered mobility by two dimensional electrophoresis
appears closer to 70% when examined by autoradiography, a ratio which reflects the
constitution of protein synthesized only during the pulse period in the absence of
MetAP2 activity and not pre-existing protein (see Figure 3.7). Thus a portion of the
protein isolated was likely to be present prior to drug treatment, indicating that an even
smaller fraction the protein (perhaps 30%) synthesized in the absence of MetAP2
activity undergoes methionine removal.
The fact that GAPDH has a valine residue in its second translated position may
indicate that nascent proteins with penultimate valine residues are generally poor
substrates for MetAP1. In this regard it is interesting that the other protein identified
whose mobility is altered on two dimensional gels by drug treatment, cyclophilin A, also
bears a valine residue in the same position, though it is not known whether this aberrant
migration also results from failure to remove the initiator methionine. These observations
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concur with studies on the substrate specificity of yeast MetAP 1 on tripeptide
substrates in vitro (17). In the same study, it was found that tripeptides containing serine
or threonine residues in the second position are cleaved with similarly poor efficiency
(roughly twenty fold lower than an optimal tripeptide with an alanine residue in position
two). Whether initiator methionine retention of proteins with serine or threonine in the
second translated position will turn out to be compromised in cells treated with TNP-470
remains to be seen. Such a possibility is particularly intriguing given the tendency for
proteins with amino-terminal serine or threonine residues to be acetylated (12-16).
Failure to remove the initiator methionine in this situation would result in the presence of
an abnormal positively charged group at the amino-terminus, which may contribute to
changes in activity.
We observed a decrease in incorporation of labeled myristate for only a single
detectable protein upon with TNP-470 treatment. While this is likely to reflect decreased
myristoylation of this unknown protein, it may also reflect the presence of lower levels
of the protein in TNP-470-treated cells. In either case, our observations indicate that at
least for most proteins destined to be myristoylated, MetAP 1 can compensate in the
absence of MetAP2 activity. This may be due to the fact that all myristoylated proteins
bear glycine residues at their amino-termini and thus the nascent proteins are processed
equally well by either MetAP, as suggested by in vitro studies with peptide substrates
(7,17-19). Given that it appears in some cases that sequence context beyond the second
translated residue is important for determining the fate of the initiator methionine, it is
possible that the substrate specificities of MetAP 1 and MetAP2 also bear subtle
differences from one another which are dictated by other residues as well, which may
account for the single myristoylated protein of 150 kD whose labeling is decreased by
drug treatment, and may mean that there are other such proteins outside of our limits of
detection which fail to be myristoylated in the presence of TNP-470. It was recently
reported that myristoylation of endothelial nitric oxide synthase (eNOS) is decreased by
50% in BAECs treated with TNP-470 (43). However, high concentrations (5 gM),
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which correlated with cytotoxicity rather than growth arrest, were used in this study,
indicating that inhibition of eNOS myristoylation (and cell death) may have resulted from
non-specific effects such as inhibition of MetAP1 as well as MetAP2. The molecular
weight of eNOS is consistent with it being identical to the protein observed in our
experiments, indicating the possibility that eNOS myristoylation is hampered by specific
inhibition of MetAP2. Experiments to examine this possibility are currently underway.
A crucial component to understanding the mechanism of action of TNP-470 and
ovalicin lies in the identity of these specific MetAP2 substrates whose activity is affected
by'differential methionine removal. At this time it is not known what fraction of cellular
proteins are specifically processed by MetAP2. A number of proteins involved in cell
cycle regulation, such as cyclin E, pRb, and Cdk4, are predicted to have their initiator
methionine residues removed as judged by the identity of their second translated residues
(44), though it is not known if maintenance of the amino-terminal methionine on any of
these proteins would affect their activity. The Src family protein tyrosine kinases, which
are myristoylated, play an essential role in cell cycle progression, and are likely to be
inactive in this regard without proper localization (21,45). Such kinases may be
expressed at low levels and were thus below the limit of detection in our endothelial cell
protein myristoylation assay. The possibility that the myristoylation of various Src
family kinases is diminished by TNP-470 treatment is the subject of current investigation.
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Chapter 4
A common mode of action for the anti-angiogenic and
immunosuppressive properties of TNP-470 and ovalicin
Abstract
TNP-470 (1), a synthetic derivative of the natural product fumagillin (2), potently
inhibits angiogenesis in vivo and the growth of endothelial cell cultures in vitro. The
structurally related natural product ovalicin (3) also inhibits angiogenesis but possesses
potent immunosuppressive activity. The recent finding that all three drugs bind and
inhibit the same target, methionine aminopeptidase 2 (MetAP2), raised the question of
whether TNP-470 is also immunosuppressive and whether inhibition of MetAP2
underlies both activities of ovalicin. To address these questions, we synthesized a series
of analogs of TNP-470 and ovalicin and tested them for their abilities to inhibit the
proliferation of either endothelial cell or mixed lymphocyte cultures. TNP-470 and its
analogs were found to possess both immunosuppressive and anti-angiogenic activities. A
strong correlation was observed between the ability of compounds to inhibit bovine and
human endothelial cell growth and their ability to inhibit the mouse mixed lymphocyte
reaction (MLR), implying that the two activities share a common molecular basis, i.e.,
inhibition of MetAP2. Interestingly, ovalicin and several other compounds behaved
differently in the human MLR than in either the mouse MLR or human endothelial cell
proliferation assays, pointing to possible species-specific and cell type-specific
differences in the metabolism or uptake of these compounds. Ovalicin and TNP-470
were not found to inhibit IL-2 production or upregulation of CD25, but rather to inhibit
IL-2-dependent T cell proliferation.
Introduction
The success of organ transplantation is generally limited by rejection of the graft by the
host immune system (1). Whereas only a small fraction of naive T lymphocytes carried
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by the host organism are specific to a typical infectious agent, a relatively large
proportion will be reactive against a graft from a genetically distinct individual, largely due
to the presence of foreign major histocompatibility complex (MHC) molecules (2). This
incompatibility gives rise to a rapid and strong immune response. For this reason,
successful organ transplantation requires the use of immunosuppressive drugs, which
inhibit the expansion of T cells reactive against the donor graft (3,4). Early
immunosuppressive therapy employed combinations of cytotoxic compounds, which are
selectively toxic to rapidly dividing cells, and corticosteroids, which are both cytotoxic
and modulate cytokine production by lymphoid cells (3,4). As immunosuppressive
therapy must be maintained indefinitely for most organs, serious side effects associated
with these drugs prevented their widespread use.
The development of cyclosporin A in the early 1970s revolutionized the practice
of transplant medicine and allowed both the number of transplants performed and the
number of organ types suitable for transplantation to increase dramatically (4,5). While
unequaled in its selectivity for the immune system, cyclosporin A is also restricted by
side effects such as nephrotoxicity, which has stimulated the search for a next generation
of less toxic immunosuppressive drugs which may be applicable to a wider range of
disorders, such as autoimmune diseases.
T cell activation, the primary event in a graft rejection response, can be regarded as
a stepwise process (6). Engagement of the T cell receptor by its cognate ligand, the
MHC-peptide complex, triggers a signal transduction cascade culminating in the activation
of genes required to drive cell proliferation. A crucial part of this response is the
production of the autocrine growth factor interleukin-2 (IL-2) (6,7). The effects of
cyclosporin A are largely attributed to its ability to inhibit IL-2 production by activated
T lymphocytes; addition of excess IL-2 can reverse the effects of the drug on T cell
proliferation in vitro (8). The molecular basis for inhibition of IL-2 by cyclosporin A has
been elucidated in recent years (9). The drug binds to a protein called cyclophilin, which
possesses peptidyl-prolyl cis-trans isomerase activity. Interestingly, the more recently
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discovered drug FK506, which also inhibits IL-2 production though it bears no structural
similarity to cyclosporin A, binds to a distinct protein (FKBP) which has the same
enzymatic activity. Suppression of IL-2 production, however, does not occur by
inhibiting the rotamase activity of these enzymes. Both the cyclosporin A-cyclophilin
and FK506-FKBP complexes bind to and inhibit the protein phosphatase calcineurin.
Calcineurin plays a key role in relaying signals from the T cell receptor to the nucleus
during T cell activation. T cell receptor engagement results in an influx of calcium ions to
the cell cytosol, and calcineurin is thereby activated by binding to the calcium sensing
protein calmodulin. An important substrate for calcineurin is the transcription factor NF-
AT (nuclear factor of activated T cells) which translocates to the nucleus following
dephosphorylation by calcineurin where it participates directly in the induction of the IL-
2 gene (10).
Other immunosuppressive compounds appear to act at distinct steps in the T cell
activation cascade. The marine natural product discodermolide has been shown to
downregulate the IL-2 receptor by an unknown mechanism, thereby preventing cells from
responding to IL-2 (11). Rapamycin, which bears structural similarity to FK506, blocks
IL-2-dependent T cell proliferation (12). Like FK506, rapamycin binds to FKBP, but the
complex does not inhibit calcineurin. Rather, the rapamycin-FKBP complex binds to and
inhibits a protein kinase called FRAP (also known as RAFT) (13). FRAP acts as an
intermediary in the growth factor-mediated regulation of the translation of specific
proteins which presumably play a role in promoting cell cycle progression through the G1
phase.
The fungal metabolite ovalicin (3) was discovered in the 1960s and showed
promise as a potent immunosuppressive drug prior to the development of cyclosporin A
(14). It has been shown to inhibit antibody responses, reduce spleen weight, and prolong
skin graft survival in mice, and to inhibit the development of experimental allergic
encephalomyelitis in rats (15,16). In addition, ovalicin was shown to inhibit the
proliferation of mouse and human mixed lymphocyte cultures, a cellular assay measuring
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alloantigen-stimulated T cell proliferation (17,18). Ovalicin went as far as to be tested in
human clinical trials but was discontinued due to serious side effects (14). The
mechanism of action of the drug has never been determined. The emergence of the
structurally similar compounds TNP-470 (1) and fumagillin (2) as angiogenesis inhibitors
led to the observation that ovalicin inhibits the growth of endothelial cells as well (19,20).
This structural similarity begs the speculation that TNP-470 may also possess
immunosuppressive activity, which could have implications for its use in the clinic.
Paradoxically, TNP-470 has been shown to enhance, rather than inhibit, T-cell dependent
B lymphocyte proliferation in vitro and in mice (21,22).
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Figure 4.1. Structures of TNP-470 (1), fumagillin (2), and ovalicin (3), illustrating the
atom numbering system referred to in the text.
Recently, we and others showed that TNP-470, fumnagillin, and ovalicin all
covalently bind and inactivate a common target, MetAP2 (23,24, see Chapter 2). Using a
series of drug analogs, we found a strong correlation between the ability of compounds to
inhibit the growth of cultured endothelial cells and to inhibit MetAP2 activity. However,
it remains unknown whether MetAP2 inhibition also mediates the immunosuppressive
activity of ovalicin. As both TNP-470 and ovalicin appear to share the same molecular
target, it is even more puzzling that the aforementioned difference exists between the
apparent immunostimulatory activity of TNP-470 and the immunosuppressive activity
of ovalicin. To explore the relationship between the anti-angiogenic and
immunosuppressive properties of these compounds, we tested a variety of TNP-470 and
ovalicin derivatives for their effects on mouse and human mixed lymphocyte cultures. We
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report that TNP-470 possesses potent antiproliferative activity against both mouse and
human mixed lymphocyte cultures. We found a strong correlation between the activities
of all analogs tested in the endothelial cell proliferation assay and the MLR, implying that
there is a common molecular basis for the anti-angiogenic and immunosuppressive
activities of this class of drugs. Surprisingly, we also found that the activity of several
compounds diverged greatly between the mouse and human MLR. Inhibition of human
endothelial cell growth correlated better with inhibition of the mouse MLR than the
human MLR, indicating that there may be cell-type specific differences in availability and
metabolism of TNP-470, ovalicin and their analogs that vary between species.
Additionally, we investigated the site in the T cell activation pathway which is inhibited
by ovalicin and TNP-470. While IL-2 production is unaffected by drug treatment, IL-2-
induced cell proliferation is inhibited by TNP-470, indicating a mode of action similar to
rapamycin.
Materials and Methods
All compounds used were synthesized by Zhuang Su in the Liu laboratory. Solvents
were reagent grade and dried prior to use in most cases. Moisture-sensitive reactions
were carried out in a flame-dried apparatus under a N2 atmosphere. Column
chromatographic separations were performed with TSI Chemical silica gel 60 (230-400
mesh). The products were dried under high vacuum over night or over P20 5 at ambient
temperature. TLC was performed with Merck silica gel 60 F254 precoated plates and
products were detected with UV light, I2, 10% H2 SO 4 in MeOH, KMnO4 solution (2.0
g KMnO4 , 4.0 g Na2CO 3, 100 mL H2 0) or p-anisaldehyde solution (3.7 mL p-
anisaldehyde, 1.5 mL AcOH, 5 mL H2SO 4 , 135 mL EtOH). IR spectroscopy was
performed with a Perkin-Elmer FT IR spectrometer. NMR spectra were acquired using a
Varian VXR-500 spectrometer (1H, 500 MHz), in CDCl3; Chemical shifts are reported as
ppm downfield from TMS internal standard. MS was performed with Finnegan MATT-
8200 spectrometer. Compounds 1, 5, 8, 12, and 14 were prepared as described (25-27).
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(3S,4R,5R,6R)-4-[(1'S,2'S)-1',2'-Epoxy-1',5'-dimethyl-4'-hexenyl]-5-methoxy-6-O-
(N-chloroacetyl)carbamoyl-1-oxaspiro[2.5]octane-4,6-diol (6). To a stirred solution
of 9 (35 mg, 0.12 mmol) in 3 mL of CH2Cl 2 was added chloroacetyl isocyanate (56 mg,
40 mL, 0.47 mmol) at 0 *C. The reaction mixture was stirred for 1.5 h at room
temperature, then diluted with ethyl acetate and washed with saturated aqueous NaHCO 3
and brine. The organic phase was dried over anhydrous MgSO 4 and concentrated in
vacuo. The residue was chromatographed on silica gel (ether/hexane, 1:2 used as the
eluent) to give 39 mg (77.7%) of the product as colorless oil. IR (neat) cm-1: 3466, 3282,
2964, 2935, 1753, 1719, 1497, 1221, 1197, 1101, 1076; IH NMR (500 MHz, CDC 3):
8.16 (1H, S), 5.57 (1H, q, J= 3.4 Hz), 5.16 (1H, t, J 7.3 Hz), 4.48 (2H, s), 3.65 (1H, d,
J= 3.9 Hz), 3.48 (3H, s), 3.09 (1H, s), 2.99 (1H, t, J= 6.8 Hz), 2.97 (11H, d, J= 4.4 Hz),
2.54 (1H, d, J= 4.4 Hz), 2.50-2.36 (2H, m), 2.18-2.10 (1H, m), 2.06-1.90 (2H, series of
m), 1.73 (3H, s), 1.65 (3H, s), 1.33 (3H, s), 1.08 (1H, m); MS (FAB) m/z: 440.2
(M+Na+, 100).
(3S,4R,5R,6R)-4-[(1'S,2'S)-1',2'-Epoxy-1',5'-dimethyl-4'-hexenyl]-5-methoxy-6-O-
(4"-chlorobutyryl)-1-oxaspiro[2.5]octane-4,6-diol (7). 4-Chlorobutyryl chloride (18
mg, 14 mL, 0.13 mmol) was added to a magnetically stirred solution of 9 (25 mg, 0.084
mmol) and dimethylaminopyridine (DMAP, 15 mg) in CH2Cl 2 (4 mL) at 0 'C. After
stirring for overnight, the reaction was diluted with CHCl 3 and which was washed with
saturated aqueous NH4C1 solution. The organic phase was dried, filtered, and evaporated.
Chromatography of the residue on silica gel (eluted with 25% ethyl acetate in hexanes)
resulted in 31 mg (91.5%) of the product as a colorless oil. IR (neat) cm-1: 3514, 2935,
1728, 1443, 1376, 1245, 1202, 1173, 1144,1101,1004,956,927; 1HNMR(500 MHz,
CDCl 3): 5.60 (1H, dd, J= 3.4 and 7.8 Hz), 5.18 (1H, t, J= 7.5 Hz), 3.63 (1H, d, J= 3.9
Hz), 3.61 (2H, t, J= 6.5 Hz), 3.46 (3H, s), 3.02 (1H, t, J= 6.5 Hz), 2.96 (1H, d, J= 4.4
Hz), 2.87 (1H, s), 2.55 (1H, d, J= 6.8 Hz), 2.53 (1H, d, J= 7.3 Hz), 2.51 (1H, d, J= 4.4
Hz), 2.43-2.33 (2H, series of m), 2.18-2.07 (3H, series of in), 1.80-1.84 (2H, series of m),
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1.74 (3H, s), 1.65 (3H, s), 1.34 (3H, s), 1.14 (1H, dt, J= 4.4, 13.7 Hz); MS(FAB) m/z:
425.1 (M+Na+, 100).
(3S,4R,5R,6R)-4-[(1'S,2'S)-1 ',2'-Epoxy-1',5'-dimethyl-4'-hexenyl]-5-methoxy-1-
oxaspiro[2.5]octane-4,6-diol (9). To a stirred solution of ovalicin (3, 100 mg, 0.34
mmol) in 5 mL of 1,4-dioxane was added sodium borohydride (25.5 mg, 0.67 mmol) at 0
*C. The reaction mixture was stirred for 30 min at room temperature, after which the
reaction was quenched by adding saturated aqueous NH4Cl and extracted with CHCl3.
The combined organic extracts were dried, filtered, and evaporated, and the residue was
chromatographed on silica gel (elution with 50% ether in hexane). There was 95 mg
(93.7%) of the desired product as a colorless oil. IR (neat) cm-1: 3442, 2925, 1439, 1415,
1381, 1201, 1137, 1108, 1030, 981, 923, 801; 1H NMR (500 MHz, CDCl3): 5.16 (1H,
t, J= 7.5 Hz), 4.45-4.38 (1H, m), 4.02 (1H, d, J= 9.3 Hz), 3.57 (1H, s), 3.50 (1H, t, J=
3.4 Hz), 3.50 (3H, s), 2.95 (1H, d, J= 4.4 Hz), 2.87 (1H, t, J= 6.35 Hz), 2.52-2.50 (1H,
m), 2.54 (1H, d, J= 4.4 Hz), 2.44-2.35 (lH, m), 2.18-2.10 (1H, m), 2.07-2.00 (1H, 2m),
1.84-1.75 (1H, in), 1.73 (3H, s), 1.65 (3H, s), 1.33 (3H, s), 1.01-0.94 (lH, 2m);
MS(FAB) m/z: 321.4 (M+Na+, 100).
(1R,2S,3R,4R)-1-Methylthiomethylene-2-[(1'S,2'S)-1',2'-epoxy-1',5'-dimethyl-4'-
hexenyl]-3-methoxycyclohexane-1,2,4-triol (11). To a stirred solution of 9 (26 mg,
0.087 mmol) in 2 mL of DMF was added CH 3SH (18 mg, 0.26 mmol) at room
temperature. The reaction mixture was stirred for 1.5 h, then diluted with ethyl acetate
and washed with saturated aqueous NaHCO 3 and brine. The organic phase was dried
over anhydrous MgSO 4 and concentrated in vacuo, and the residue was chromatographed
on silica gel (ethyl acetate/hexane, 1:2 used as the eluent) to give 21 mg (70.0%) of the
product as colorless oil. IR (neat) cm-1: 3430, 2924, 1441, 1382, 1324, 1154, 1100, 1057,
1037, 833; IH NMR (500 MHz, CDC 3): 5.19 (lH, t, J= 7.3 Hz), 4.33-4.29 (1H, m),
3.70 (1H, br., s), 3.49 (3H, s), 2.97 (1H, t, J= 6.5 Hz), 2.90 (1H, d, J= 13.2 Hz), 2.76
(IH, d, J= 13.2 Hz), 2.60-2.40 (2H, m), 2.25-2.17 (1H, m), 2.14 (3H, s), 1.97-1.81 (3H,
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m), 1.73 (3H, s), 1.66 (3H, s), 1.62-1.54 (1H, m), 1.49 (3H, s); MS(FAB) m/z: 469.5
(M+Na+, 100).
(1R,2S,3R,4R)-1-Methylthiomethylene-2-[(1'S,2'S)-1',2'-epoxy-1',5'-dimethyl-4'-
hexenyl]-3-methoxy-4-O-(N-chloroacetyl)carbamoyl-cyclohexane-1,2,4-triol (13).
To a stirred solution of 11 (30 mg, 0.087 mmol) in 2.5 mL of CH 2Cl 2 was added
chloroacetyl isocyanate (11 mg, 8 mL, 0.094 mmol) at 0 *C. The reaction mixture was
stirred for 1.5 h at room temperature, then diluted with ethyl acetate and washed with
saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous
MgSO 4 and concentrated in vacuo. The residue was chromatographed on silica gel
(ether/hexane, 1:2 used as the eluent) to give 35 mg (86.3%) of the product as colorless
oil. IR (neat) cm- 1: 3485, 3263, 2964, 2925, 1753, 1719, 1501, 1376, 1202, 1158, 1105,
1072, 1028; 1H NMR (500 MHz, CDC 3): 8.26 (1H, br., s), 5.51 (111, d, J= 2.9 Hz),
5.18 (1 H, t, J= 7.3 Hz), 4.42 (2H, s), 3.81 (1 H, br., s), 3.43 (3H, s), 3.05 (1H, t, J= 6.6
Hz), 2.95 (1H, d, J= 13.7 Hz), 2.84 (1 H, m), 2.48-2.40 (1H, m), 2.23-2.16 (1H, m), 2.14
(3H, s), 2.04-1.97 (1H, dm), 1.95-1.80 (2H, series of m), 1.78-1.50 (3H, series of m), 1.72
(3H, s), 1.66 (3H, s), 1.47 (3H, s); MS(FAB) m/z: 488.1 (M+Na+, 100).
Cell Culture. To isolate splenocytes, mice were sacrificed by asphyxiation, and their
spleens were removed and pulverized between ground glass slides. Cells were filtered
through nylon mesh and erythrocytes lysed in 17 mM TrisHCIl/140 mM NaCl for 5 min
at 37 *C. Intact cells were washed several times in 4% fetal bovine serum (FBS) in PBS
and resuspended in culture medium (RPMI with 10% FBS, 50 gM P-mercaptoethanol, 50
units/mL penicillin and 50 gg/mL streptomycin). Human PBMCs were isolated by step
gradient centrifugation on Ficoll-Paque Plus (Pharmacia) and cultured in RPMI containing
10% human type AB serum, 50 [tM P-mercaptoethanol, 50 units/mL penicillin and 50
gg/mL streptomycin. HUV-EC-C cells were obtained from the American Type Culture
Collection and cultured in Kaign's modification of Ham's F12 media containing 10% FBS,
100 gg/mL heparin, and 30 gg/mL endothelial cell growth supplement (Sigma), 50
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units/mL penicillin and 50 gg/mL streptomycin. Flasks and plates were pretreated with
endothelial cell attachment factor (Sigma).
Mixed Lymphocyte Reaction. For the mixed lymphocyte reaction, splenocytes from
responder (Balb/c) and stimulator (C57/Black 6) mice (5 x 105 of each per well) or human
PBMCs from two donors (1 x 105 of each per well) were cultured in a volume of 200 gL
in U-bottom 96-well plates in the presence of varying concentrations of drugs or carrier
alone (0.5% ethanol) for either 96 h (mouse) or 154 h (human). Cells were treated with 1
gCi [methyl- 3H] thymidine (6.7 Ci/mmol) per well for the last 8 h of culture and then
harvested onto glass fiber paper for scintillation counting.
Preparation of T cell blasts. Mouse splenocytes or lymph node cells were plated into
24-well plates at a density of 2 x 10 6/mL and stimulated with 5 gg/mL concavanalin A
(Con A) for 48 hr. Cultures were expanded into media containing 100 U/mL IL-2
(Pharmacia). To measure IL-2 dependent proliferation, confluent T cell blasts were
diluted tenfold into 96-well plates in either media alone or media containing IL-2 plus
varying concentrations of drug or carrier alone (0.5% EtOH). Plates were incubated for
48 hr and labeled with [3H] thymidine, harvested and counted as described above.
Concavanalin A (Con A)-dependent proliferation. Mouse splenocytes or lymph
node cells were plated into 96-well plates at 10 6/mL (200 gL per well). Drugs and Con A
were added to the indicated concentration and plates were incubated 48 hr, labeled and
harvested as described above.
Analysis of IL-2 production and IL-2 receptor expression by murine splenocytes.
Single cell suspensions of splenocytes from a C57/Black 6 mouse were prepared as
described above. Cells were aliquotted into 96-well plates at 106 cells/mL (200 gL per
well) and treated with drug at the indicated concentration or carrier solvent alone (0.5%
EtOH) followed by Con A to a final concentration of 1 gg/mL. After 22 hr at 37 'C in a
humidified incubator, cells were harvested by centrifugation. Supernatants were analyzed
for IL-2 by enzyme-linked immunosorbent assay (ELISA). Cells pooled from two
identically treated wells were suspended in 47 gL 4% FBS in PBS. FcBlock (1 kL, 0.5
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mg/mL) was added, and cells were incubated 5 min on ice prior to the addition of FITC
conjugated anti-CD25 (1 gL, 0.5 mg/mL, Pharmingen) and PE conjugated anti-Thy 1.2 (1
pL, 0.2 mg/mL, Pharmingen). Cells were incubated on ice in the dark for 20 min. Cells
were washed by adding 3 mL 4% FBS/PBS, pelleted, and resuspended in 0.5 mL 4%
FBS/PBS containing 1 gg/mL PI, and analyzed by flow cytometry.
Endothelial Cell Proliferation Assay. HUV-EC-C cells (5000 per well) or BAECs
(2000 per well) were seeded into 96-well plates and grown for either 96 h HUV-EC-C) or
72 hr (BAECs) in the presence of varying concentrations of drugs or carrier alone (0.5%
ethanol). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 25 gL,
10 mg/mL in PBS) was added during the final 4 h after which cells were extracted with
100 gL of 10% SDS/0.1 M HCl per well for 16 h at 37 'C. Plates were read at 600 nm.
Results
To explore the relationship between inhibition of MetAP2, and the anti-angiogenic and
immunosuppressive properties of TNP-470 and ovalicin, we synthesized a series of
analogs with a wide spectrum of potencies for determining the degree of correlation
between those activities. In addition, as TNP-470 (1), fumagillin (2), and ovalicin (3)
have all been shown to covalently inactivate MetAP2, we were interested in evaluating
the relative contributions of the electrophilic chloroacetyl and epoxide groups of TNP-
470 (1) to the activity. Thus, compounds bearing a variety of substituents at the C-6
position of the cyclohexyl ring were prepared with either a hydrogen (fumagillin series) or
an hydroxyl group (ovalicin series) at the C-4 position of the ring (Scheme 4.1). In
addition, several analogs were synthesized in which the spiro (C-3) epoxide was opened
with thiomethane (Scheme 4.2). Compounds in the fumagillin series were prepared
according to published procedures (25-27); those in the ovalicin series were prepared
analogously as described in the Materials and Methods section.
We have shown previously that these compounds are active to varying degrees in
inhibition of both MetAP2 enzymatic activity in vitro and endothelial cell proliferation in
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cell culture (Chapter 2). In this study, we measured the activity of compounds 1-14 in
the mouse MLR (Table 4.1). TNP-470 and fumagillin were found to be potent inhibitors
of mouse MLR, indicating that they possess intrinsic immunosuppressive activity.
Interestingly, the fumagillin analog (4) in which the sidechain at C-6 was removed and
replaced with a keto group as in ovalicin is the most potent analog, rivaling ovalicin for
inhibition of mouse MLR. A similar trend was observed previously for endothelial cell
inhibition, suggesting that the chloroacetyl group of TNP-470 is dispensable for its
biological activity. Overall, there is a strong correlation between compounds that are
active in the mouse MLR and compounds that are active at inhibiting bovine aortic
endothelial cell (BAEC) proliferation (Figure 4.2), though compounds are in general
approximately one order of magnitude less potent in the MLR. In both assays,
compounds within either the ovalicin or the fumagillin series follow a predictable trend in
activity depending on the substituent at the C-6 position, with hydroxyl, chlorobutoyl,
chloroacetylcarbamoyl, and carbonyl being the order of ascending activity. In contrast, all
compounds in which the C-3 epoxide had been opened were much less active than their
corresponding analogs with intact epoxides. An intact spiro epoxide moiety also appears
essential for strong inhibition of MetAP2 by these compounds, which suggests that the
epoxide rather than the chloroacetyl group mediates covalent inactivation of the enzyme
(Table 4.1). These results imply that the inhibition of endothelial cell growth and the
inhibition of lymphocyte proliferation by these compounds shares a common molecular
basis, which is likely to be the inhibition of MetAP2.
As ovalicin has undergone and TNP-470 is currently undergoing human clinical
trials, a subset of their synthetic analogs were also examined in the MLR performed with
primary human peripheral blood mononuclear cells (PBMC, Table 1). Surprisingly, a
number of compounds differed significantly in potency from the analogous mouse MLR
and human endothelial cell proliferation assays. Most striking was-the
immunosuppressive parent drug ovalicin, which was over 1000-fold less active at
inhibiting the proliferation of human cells compared to mouse cells. In contrast, ovalicin
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Table 4.1. IC50 values for TNP-470 and ovalicin analogs in various assays.'
Compound mouse MLR (nM) human MLR (nM) HUV-EC-C (nM) BAEC (nM)b MetAP2 (nM)b
1.63 ± 0.56
2.32 ± 0.79
0.219 ± 0.011
0.128 ± 0.033
9.69 ± 0.54
7.23 ± 0.46
21.1 ±9.2
43.8 ± 12.4
59.9± 15.1
199 ± 75
108 ± 20
> 5000
810 ± 230
877 ± 158
1.42 ± 0.40
0.22 ± 0.07
601 91
0.29 0.05
0.41 0.38
5.25 5.78
ND
ND
89.8 ± 22.9
88.6 ± 26.3
> 10000
> 100000
ND
ND
0.0084 ± 0.0010
0.0616 ± 0.0088
0.00253 ± 0.00051
0.00202 ± 0.00045
ND
0.0296 ± 0.0231
ND
ND
0.187 ± 0.111
1.07 ± 0.33
23.7 ± 5.0
ND
ND
ND
0.037 ±0.0024
ND
0.018 ± 0.0059
0.013 ± 0.0015
ND
0.46 ± 0.26
0.31 ± 0.066
0.12 ± 0.01
2.2 ± 1.4
9.5 ± 4.6
65 ±34
2800 ±2300
40 ± 4
110 ± 18
1.0 ± 0.3
ND
0.4 ± 0.2
6 ±2
ND
2.0 ± 0.8
0.1 ± 0.03
3.5 ± 1.8
4 1
8 2
400 ± 200
5000 ±2000
400 ±200
3000 1000
1
2
3
4
5
6
7
8
9
10
11
12
13
14
aValues represent the mean ± SD for representative experiments performed in triplicate.
bFor details see Chapter 2. MetAP2 assays were done using recombinant human protein.
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Figure 4.2. Correlation between inhibition of endothelial cell proliferation
and the MLR for TNP-470, ovalicin and derivatives.
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exhibited little toxicity in rodents but was found to be severely neurotoxic in higher
animals. The opposing trends of the immunosuppressive activity and neurotoxicity may
account for the failure of ovalicin to have become a useful immunosuppressive drug.
Epimerization of the C-6 hydroxyl group of 10 generates 5, which was not only more
active against the MLR for both species but over 20-fold more potent in the human than
in the mouse MLR. The potency of 5 in the mouse MLR is similar to that (IC 50 = 34
nM) of a known immunosuppressive natural product, FR65814, which is structurally
identical to 5 except the 5-methoxy substituent is replaced by a hydroxyl group (28).
Despite these exceptions, there still appears to be a correlation between modifications
that enhance or diminish activity in the mouse MLR and those that do in the human
MLR. The C-3 epoxide group, for example, appears to be essential for activity in the
human MLR as well.
In order to determine whether the differences observed between mouse and human
lymphocyte proliferation were due entirely to species differences, we tested the same
subset of compounds for their ability to inhibit the growth of HUV-EC-C cells, a human
umbilical vein endothelial cell-derived line which is sensitive to TNP-470 (Table 1). We
found a stronger correlation between the activity of compounds in this assay and the
BAEC inhibition assay or the mouse MLR than the human MLR. Ovalicin (3), for
example, is among the most potent inhibitors of HUV-EC-C cell growth. These results
suggest that there is something unique about human lymphocytes that makes them
respond differently to a subgroup of ovalicin and fumagillin analogs.
To further explore the mechanism of immunosuppression by this class of drugs,
we chose to determine the step of the T cell activation pathway blocked by ovalicin and
TNP-470. We first examined IL-2 production from Con A-stimulated splenocytes
(Figure 4.3). Splenocytes were treated with Con A in the presence of either ovalicin or
TNP-470 and IL-2 levels in the supernatants were determined by ELISA. Neither drug
had any significant effect on Con A-induced IL-2 production at concentrations which
caused potent inhibition of Con A-induced proliferation (Figure 4.4). Under these
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Figure 4.3. Ovalicin and TNP-470 do not effect Con A-stimulated IIL-2 production.
Splenocytes were stimulated with Con A and culture supernatants were analyzed for
IL-2 by ELISA 22 hr later.
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conditions, rapamycin caused partial inhibition of IL-2 production, while FK506
completely abrogated IL-2 production.
To determine whether the drugs affected the IL-2 signaling pathway in a manner
similar to rapamycin, we examined the sensitivity of T cell blast proliferation to TNP-
470. Splenocytes treated with Con A proliferate vigorously for several days and then
rapidly stop due to consumption of endogenously generated growth factors. However,
cells can be maintained as blasts by the addition of exogenous IL-2. TNP-470 potently
inhibited the proliferation of T lymphocyte blasts, which was entirely dependent on
added IL-2 (Figure 4.5). During T cell activation, the p70 a chain of the IL-2 receptor,
CD25, is upregulated to allow assembly of the high affinity trimeric IL-2 receptor
complex (29). Failure to upregulate CD25 could theoretically prevent responsiveness to
IL-2 and IL-2 dependent proliferation. To test this possibility, we examined expression
of CD25 following Con A stimulation of splenocytes in the presence of TNP-470 and
ovalicin (Figure 4.6). Neither drug had any effect on the upregulation of CD25 in T cells
at concentrations sufficient to greatly inhibit proliferation. As anticipated, rapamycin
also had no effect, whereas FK506 caused a partial decrease in receptor expression.
These results indicate that TNP-470 and ovalicin, like the immunosuppressant
rapamycin, block the IL-2 dependent signaling pathway.
Discussion
The striking structural similarity between TNP-470 and ovalicin and the recent finding
that both bind to the common molecular target MetAP2 appears to contradict reports
that TNP-470 has immunostimulatory activity while ovalicin is immunosuppressive. In
this study, we measured the effect of both TNP-470 and ovalicin in the MLR and found
that TNP-470 does possess potent immunosuppressive activity. Though previous
reports have indicated that lymphocyte proliferation is in fact potentiated by TNP-470,
those experimental conditions differed from ours in several respects (21,22). Most
notably, PHA was used as a mitogen, whereas our experiments used allogenic stimulation.
119
CP
O~
 r
ico
fV900
9
08
no
 IL
-2
IL
-2 
alo
ne
0.5
 p
M 
TN
P-
47
0
5 
pM
 TN
P-
47
0
50
 pM
 T
NP
-4
70
50
0 p
M 
TN
P-
47
0
5 n
M 
TN
P-
47
0
50
 nM
 T
NP
-4
70
50
0 n
M 
TN
P-
47
0
No mitogen
97 3
0r
10
N
C
-
H-
N
0D
Con A + 10 nM TNP-470
31 69
10' 10"1
CD25
0
10 10
Con A
35 65
miW1
W . *.:V"P c--.
N
F-
CI)
N
Con A + 100 nM Rapamycin
37 63
101010 1 1
CD25
Con A + 10 nM Ovalicin
10
CD25
Con A + 100 nM FK506
CD
0~
N-
62 38
-I.
I
10 10 10
CD25
Figure 4.6. Ovalicin and TNP-470 do not effect expression of CD25 (IL-2Ra) in Con A-stimulated mouse
lymphocytes. Cells were isolated and stimulated as described in Materials and Methods in the presence of
the indicated drug, stained with FITC-labeled a-Thy1.2 and PE-labeled a-CD25, and analyzed by flow
cytometry. Numbers within the upper quadrants indicate the percentage of the Thyl.2 positive cells (T
lymphocytes) which have CD25 levels above or below the indicated threshold.
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Using PHA as a mitogen, we have also observed modest increases in human PBMC
proliferation caused by ovalicin (B. T. and J. L., unpublished data). Mitogenic stimulus-
dependent differences in the effect of TNP-470 on lymphocyte proliferation have been
observed by others as well (30). As PHA-induced mitogenesis is not mediated by a single
receptor but by nonspecific crosslinking of many cell-surface molecules, it is possible that
PHA treatment may trigger pathways that are not sensitive to inhibition by TNP-470 or
its analogs. Those pathways may not be activated during T cell receptor-mediated
signaling such as that provided by allogenic stimulus in the MLR.
Among the analogs we synthesized from fumagillin and ovalicin, compound 4 in
which the sidechain containing chloroacetyl group at C-6 of TNP-470 was replaced with a
carbonyl group is the most potent inhibitor of angiogenesis and the MLR. The
chloroacetyl group in TNP-470 is therefore not essential for either the anti-angiogenic or
the immunosuppressive activity of TNP-470. In contrast, opening of the spiro epoxide
group led to a dramatic decrease in the activity of TNP-470, suggesting a key role of the
epoxide group in the binding of these drugs to MetAP2.
The activities of TNP-470 and ovalicin analogs in the mouse MLR correlates well
(r2 = 0.83) with their activities for the inhibition of BAEC proliferation, though
approximately ten-fold higher concentrations of drugs were required to elicit the same
degree of inhibition in the MLR compared with the BAEC assay. The reason for this
discrepancy is unknown, but the high degree of correlation argues for a common
underlying molecular mechanism for both processes. This contention is consistent with
previous observations that inhibition of lymphocyte proliferation by ovalicin and
inhibition of endothelial cell proliferation by TNP-470 both result from cytostatic growth
arrest in the G1 phase of the cell cycle (17,18,31-33). Structural features important for
high potency in both cellular assays are also key to the inhibition of MetAP2 (see Table
1), suggesting that inhibition of this enzyme mediates both the anti-angiogenic and
immunosuppressive activities of the drugs. Our observation that IL-2 dependent
proliferation is inhibited by the drugs, whereas upregulation of IL-2 and CD25 are not,
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also bears similarity to the situation with endothelial cells, where proliferation induced by
growth factors (bFGF and VEGF) is blocked by the drugs (19). Interestingly, growth of
the IL-2-dependent transformed cell line CTLL-2 was not affected by ovalicin, which
parallels the tendency for transformed endothelial cell lines to lose sensitivity to TNP-
470. Blockade of IL-2-dependent proliferation suggests the mode of action of ovalicin
and TNP-470 to be similar to rapamycin (Figure 4.7), which also inhibits endothelial cell
growth (34). Whether the drugs effect the same translational regulatory pathway targeted
by rapamycin remains to be determined, though it seems unlikely given that ovalicin and
TNP-470 do not appear to directly affect growth-factor induced increases in overall
translation (17,31), while rapamycin does. TNP-470 does appear to arrest endothelial
cells at a similar point in the cell cycle as rapamycin (see Chapter 5), though it may do so
by interfering with a distinct pathway.
Interestingly, we also observed significant differences in the activity of several
compounds between the human and mouse MLR. The most striking decrease in activity
toward human cells was seen for ovalicin (3), even though this compound went as far as
human clinical trials, a fate undoubtedly based at least to some degree on the initial
demonstration of its potent immunosuppressive activity in rodents. Though such
observations might indicate species-specific differences in a drug's molecular target which
confer differential binding specificities for analogous drugs, this does not appear to be so
in the case of TNP-470 or ovalicin, as inhibition of human endothelial cell proliferation
correlates better with inhibition of the mouse MLR than with inhibition of the human
MLR (see Table 1). In contrast to ovalicin, compound 5 with an inverted
stereochemistry at C-6, inhibits human MLR more potently than the mouse MLR. It is
possible that there are cell type-specific differences in either the uptake,
compartmentalization or metabolism of these drugs that are particular to humans.
The activity of TNP-470 in the MLR warrants reconsideration of its possible
immunosuppressive properties in vivo. Immunosuppressive side effects, however, have
not been reported for TNP-470 in either animal models or human clinical trials (35). The
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Figure 4.7. Inhibition of cell proliferation by immunosuppressive drugs. Cyclosporin A
and FK506 prevent progression from Go to G, by blocking the production of the autocrine
growth factor IL-2. TNP-470 and ovalicin inhibit IL-2 dependent progression through G1
in a manner similar to rapamycin.
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apparent lack of immunosuppressive activity of TNP-470 in vivo may be attributed to a
combination of a lower sensitivity of lymphocytes to the drug and rapid clearance of
TNP-470 from the serum (36). We have shown that human lymphocytes are over 100-
fold less sensitive to TNP-470 than human endothelial cells (Table 1). In addition, it has
been demonstrated that TNP-470 has a short serum half life of less than one hour (36).
The lack of continuous exposure to TNP-470 may be sufficient to block endothelial cell
proliferation without significantly affecting lymphocytes, offering an effective therapeutic
window in which beneficial anti-tumor activity can be observed clinically without
undesirable immunosuppressive side effects. These observations also demonstrate that
despite an apparently common mode of action, it may be possible to find clinically useful
angiogenesis-inhibitory compounds which possess little immunomodulatory activity.
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Chapter 5
Effects of TNP-470 on the cell division cycle
Abstract
The angiogenesis inhibitor TNP-470 and the immunosuppressive drug ovalicin have been
shown to inhibit progression through the G1 phase of the cell cycle in human endothelial
cells and T lymphocytes, respectively, though the molecular details of this blockade are
unclear. Using the S49.1 T lymphoma cell line, we show that the drugs cause
prolongation of G1 phase but not a G1 arrest. While progression through G1 is effected
specifically in human umbilical vein endothelial cells (HUVECs), bovine aortic endothelial
cells (BAECs) appear to be delayed in both the G1 and G2/M phases when treated with
TNP-470, suggesting that the drug affects cell cycle progression varies among species. In
HUVECs, the G1 delay is associated with inhibition of cyclin E-dependent kinase
activity, suggesting that the TNP-470 effect occurs during mid to late G1, and providing a
possible molecular explanation for inhibition of cell cycle progression by the drug.
Introduction
Under appropriate conditions, growth factor stimulation of quiescent cells triggers them
to enter the cell division cycle (1). The cell cycle is divided into distinct phases: the S
phase, in which DNA synthesis occurs, the M phase, mitosis, and two intervening gap
phases, G1 and G2 (Figure 5.1). Growth factor withdrawal, terminal differentiation, and
loss of cell adhesion can cause normal cells to exit the cell cycle following mitosis and
enter a distinct quiescent state, Go. Growth factors are needed for cells to remain in the
cell cycle only during a portion of the G1 phase up to a point termed the restriction point,
after which cells will continue through the S, G2 and M phases even if growth factors are
withdrawn (2). Cell cycle entry and progression are controlled by the activity of a family
of protein serine-threonine kinases, the cyclin-dependent kinases (Cdks) (1,2). Distinct
Cdk family members are important for progression at different points in the cell cycle.
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Figure 5.1. The eukaryotic cell division cycle.
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Though Cdk protein levels are generally low in quiescent cells and rise during entry into
the cell cycle, they remain constant in cycling cells. Cdk activity, however, is periodic,
and is controlled by several factors. Association of the Cdk with a member of the cyclin
family of regulatory proteins, whose levels vary with position in the cell cycle, is required
for kinase activity and influences substrate specificity. The cyclin-Cdk complexes most
important for progression through G, and into S phase are complexes composed of cyclin
D bound to either Cdk4 or Cdk6, whose activities are the first to appear following growth
factor stimulation, and the cyclin E-Cdk2 complex, which is active later in G1 and early in
S phase (Figure 5.1).
Cdk activity is inhibited by binding of a member of one of two families of
inhibitory proteins, termed CKIs, to the cyclin-Cdk complex (2,3). The INK4 family,
composed of p16 INK4a, p15 INK4b 1 INK4c and p1 9 INK4d, specifically inhibit the cyclin D-
Cdk4 and cyclin D-Cdk6 complexes. The other family, which includes p2IWAF1 p2 7 KiP1
and p5 7  , inhibit both the cyclin D and cyclin E containing Cdk complexes. In
addition, Cdks are subject to positive and negative regulatory phosphorylation at distinct
sites (4).
Phosphorylation of specific substrate proteins by Cdks drives cell cycle
progression. A key target for Cdks during progression through G, is the protein product
of the retinoblastoma susceptibility gene (pRb) (2,5). During early G1, pRb is
hypophosphorylated and considered to be in the active state. Active pRb forms a
complex with E2F family transcription factors, rendering them unable to activate
transcription. As G, progresses, pRb is phosphorylated, first by cyclin D-dependent
kinases and then by cyclin E-Cdk2, on distinct sites. The resulting inactive
hyperphosphorylated protein dissociates from E2F, allowing transcription of E2F target
genes. These genes encode proteins important for cell cycle progression and DNA
replication, such as dihydrofolate reductase, cyclin E, and E2F itself. Phosphorylation of
pRb by cyclin D dependent kinases is critical to pRb inactivation. Cells lacking the Rb
gene can still progress to S phase in the absence of cyclin D dependent kinase activity,
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implying that pRb is the only substrate of these kinases important for cell cycle
progression (6,7). Prior phosphorylation of pRb by cyclin D dependent kinases appears
to be required for subsequent phosphorylation by cyclin E-Cdk2, and it is likely that
phosphorylation by both kinases is necessary for inactivation of pRb (8,9).
Phosphorylation of pRb by cyclin E-dependent kinase may inactivate the protein
towards as yet unidentified binding partners other than the E2F proteins (5). It is likely
that there are cyclin E-Cdk2 substrates other than pRb important for cell cycle
progression, including perhaps proteins at origins of replication which might directly
regulate initiation of DNA synthesis (2).
Signaling from growth factor receptors results in the activation of multiple
pathways which are important for the sequential activation of Cdks. Growth factor
receptors generally posses either intrinsic (as in the FGF and VEGF receptors) or
associated (as in the T cell receptor) tyrosine kinase activity in their cytoplasmic domains
(10). Receptor autophosphorylation triggers association of signaling molecules via
modular domains which recognize phosphotyrosine in the context of specific surrounding
sequence motifs. Binding of the adaptor molecule Grb2 via its SH2 domain to activated
receptor tyrosine kinases results in the recruitment of the associated Sos protein to the
plasma membrane, where it can act to catalyze guanine nucleotide exchange in the small
GTPase molecule Ras. Ras plays a crucially important role in progression through G1
(11,12). Ras activates the MAP kinase cascade, which results in the expression of the
immediate early genes c-Jun and c-Fos. The AP-I transcription factor, which is
comprised of the Jun/Fos heterodimer, is involved in induction of the cyclin D1 gene (13).
Increasing cyclin D1 levels is therefore an important function of Ras during early G1; a
requirement for Ras later in G, has also been inferred from microinjection experiments
though the target genes are not known (12).
Ras activation alone, however, is insufficient for entry into S phase, indicating the
need for other growth-promoting pathways. The immediate early gene c-Myc has been
shown to cooperate with Ras in the activation of cyclin E-dependent kinase activity and S
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phase entry (14,15). Activation of the c-Myc gene occurs independently of Ras and
appears to depend on the growth factor-induced activation of Src family tyrosine kinases
by an unknown mechanism (16). c-Myc is a transcription factor whose target genes
include those encoding ornithine decarboxylase and dihydroorotase, biosynthetic enzymes
important for S phase (14). In addition, c-Myc may directly affect the cell cycle
machinery via induction of cyclin E and the Cdc25a gene, which encodes the Cdk2-
activating phosphatase. c-Myc also cooperates with Ras to decrease levels of the p2 7KiP1
CKI by an unknown mechanism.
Other growth promoting pathways feed into the Cdk machinery. Activation of
phosphoinositide 3'-kinase (P13K) by Ras gives rise to phospholipid products which
activate several downstream targets, including the rapamycin-sensitive protein kinase
FRAP, which defines a translational control pathway (17). Though the FRAP-sensitive
mRNAs involved in promoting cell growth have not been established, it appears as if
downregulation of p2 7 Kip is an important downstream event (18). Growth factor-
induced activation of Rho, a small GTPase in the Ras superfamily, also appears to be
required for Ras-induced cell proliferation, perhaps due to its ability to decrease the level
of the CKI p21 WAF1 (19).
Small molecules which inhibit cell cycle progression can do so by any of a variety
of mechanisms. Some compounds act as direct inhibitors of the growth-regulating signal
transduction pathways. Examples include rapamycin, described above, wortmannin,
which inhibits PI3K, and Src family kinase inhibitors, such as herbimycin A (20,21).
Other compounds activate cellular checkpoint control pathways which exist to ensure
that cell cycle progression occurs in an orderly manner. DNA damaging agents arrest cells
in either G1 or G2 by activating distinct checkpoint pathways (4). One such pathway
involves activation of the tumor suppressor p53, which stimulates transcription of target
genes such as p21WAFl important for mediating cell cycle arrest. Compounds which
deplete deoxyribonucleotide triphosphate pools needed for DNA synthesis also activate a
p53-dependent checkpoint pathway which occurs during S phase. General inhibitors of
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protein or RNA synthesis and inhibitors of protein degradation typically cause cells to
arrest in more than one phase of the cell cycle, presumably due to either the
disappearance of rapidly turned over proteins which positively regulate growth or the
stabilization of negative regulators (22).
Another set of compounds acts indirectly by inhibiting biosynthetic pathways
necessary for the activity of growth-promoting molecules (22). Lovastatin, an HMG-
CoA reductase inhibitor, arrests cells in G1 by, among other things, cutting off the supply
of farnesyl pyrophosphate, thereby preventing farnesylation of Ras which is required for
its activity. TNP-470 and ovalicin, by virtue of their inhibition of MetAP2, can be
regarded as members of this class of compounds. Whereas MetAP2 is not likely to be
involved directly in a signaling cascade which promotes cell growth, its action may be
required to maintain a growth regulatory protein in an active state. The identities of such
target molecules remain unknown. The way in which TNP-470 and ovalicin affect cell
cycle progression, including their effects on the cell cycle machinery, is an important
aspect of their mechanism of action. Such information would reveal the point in the cell
cycle where the downstream targets of MetAP2 play a crucial role, either by virtue of
direct involvement in signal transduction or in the activation of known checkpoint
pathways. For example, upregulation of p21W1AF might point to activation of a p53-
dependent checkpoint pathway, whereas a failure to downregulate p2 7 Kip in response to
growth factors may indicate an effect on a signaling pathway similar to rapamycin.
Previous work on TNP-470 indicates that it cytostatically and reversibly arrests
endothelial cells in the G1 phase of the cell cycle in human endothelial cells (23).
Similarly, ovalicin prevents the initial onset of DNA synthesis in mitogen-stimulated
lymphocytes, consistent with a similar mechanism of growth inhibition by the two drugs
(24). Attempts to investigate effects of TNP-470 on the cell cycle machinery has met
with conflicting results. One study reported a failure to induce cyalin Dl in human
endothelial cells treated with TNP-470, though concentrations of drug much higher than
necessary to inhibit cell growth were needed (25). In another report, more moderate
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concentrations of TNP-470 caused a failure to induce the cyclin A gene, consistent with a
G1 arrest (26). A slight decrease in cyclin E mRNA was observed, along with a slight
decrease in Cdk2 activity. No effect on cyclin Dl mRNA induction was observed, nor
were effects on c-Fos or c-Myc induction. However, levels of cyclin E protein were not
investigated, and Cdk2 activity was only observed at a single time point following growth
factor stimulation. The regulation of Cdk2 by both cyclin E and cyclin A at different
points in the cell cycle also complicates the interpretation. Yet another report, which
studied the effects of TNP-470 on vascular smooth muscle cells, demonstrated an effect
on Cdk2 activity which was not apparent upon initial induction the kinase but occurred at
later time points following growth factor treatment (27). Cyclin Dl induction was
unaffected, but Cdk2 induction was impaired, though at a time when kinase activity was
unaffected. Levels of Cdk2 protein were not investigated, nor were cyclin E or cyclin A
levels. Sorting out the effects of TNP-470 on these various molecules involved in cell
cycle progression will be imperative in elucidating the mechanism of action of the drug.
Decreases in the activity of certain proteins may point to the identification of crucial
MetAP2 substrates in drug-sensitive cells, for example.
Materials and Methods
Cell Culture. BAECs and HUVECs were cultured as described in Chapters 2 and 3
respectively. S49.1 cells were grown in DME with 10% FBS and P/S. Cell proliferation
was measured by tritiated thymidine incorporation as described in chapter 4.
Cell cycle analysis. Adherent cells were harvested by trypsinization. Cells were
pelleted and resuspended to 2 x 10 6/mL in propidium iodide (PI) stain solution (3% PEG
8000, 50 gg/mL PI, 0.1% triton XlOO, 0.5 mg/mL RNase A, and 4 mM sodium citrate,
pH 7.2) and incubated 20 min at 37*C in the dark. An equal volume of PI salt solution
(3% PEG 8000, 50 gg/mL PI, 0.1% triton XI00, and 0.4 M NaCl) was added and the
suspension kept at 4'C in the dark for a period of 1 to 16 hr prior to analysis by flow
cytometry. Cell cycle data was fit using ModFit software.
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Cell synchronization. HUVECs were plated at 3000 cells per cm2 in complete medium
and allowed to recover for 30 hr. Cells were washed once with PBS, incubated in 0.25%
FBS in EBM-2 for 34 hr, and then restimulated with complete media (EGM-2). To
synchronize at the GI/S boundary, hydroxyurea was added to 1 mM at 12 hr post-
restimulation and cells incubated for a further 18 hr.
Immunoprecipitation and kinase assays. Modified from Ezhevsky, et al. (8). Cyclin
E antibodies (clone HE I11) and control mouse IgG were purchased from Santa Cruz
Biotechnology. Cells were washed once with cold PBS and extracted with lysis buffer
(0.1% NP-40, 50 mM HEPES, pH 7.3, 250 mM NaCl, 2 mM EDTA, 1 mM DTT, 1
gg/mL aprotinin, 1 gg/mL leupeptin, 1 mM PMSF, 0.5 mM sodium pyrophosphate, 0.1
mM Na3VO 4 , 5 mM NaF, 0.5 mL per 75 cm 2) by scraping into microcentrifuge tubes and
incubating at 4*C for 30 min with rotating. Debris were removed by centrifugation at
16,000 x g for 10 min at 4*C and supernatants were frozen on dry ice/EtOH and stored at
-80 *C until use. Protein concentration was determined by Bradford assay and equal
amounts of protein were used for analysis. Antibodies were added (2 gg per sample) and
incubated on ice for 2 to 4 hr prior to the addition of 20 pL of protein A/G agarose (for
mouse antibodies). After 1 hr at 4*C with rotating, the beads were pelleted by
centrifugation, washed three times for 5 min with 0.75 mL lysis buffer and then once with
kinase buffer (50 mM HEPES, pH 7.3, 10 mM MgCl 2, 1 mM DTT, 10 pM cold ATP)
and resuspended in 25 gL kinase buffer containing y-[ 32 P]ATP (10 gCi, 3000 Ci/mmol)
and 2 gg of Histone HI substrate. Mixtures were incubated at 30*C for 30 min and then
quenched by adding 15 gL of 4X SDS-PAGE loading buffer and heating in a boiling water
bath for 10 min. Samples were subjected to SDS-PAGE (12% acrylamide) as described in
Chapter 3, dried and analyzed by autoradiography.
Results
Sensitive cell types treated with TNP-470 have reduced yet detectable levels of DNA
synthesis (23). Consistent with this observation, we have observed that bovine aortic
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endothelial cells (BAECs) treated with TNP-470 remain capable of growing to confluence,
albeit at a much slower rate (see Chapter 3). Such observations are consistent with
several possibilities. One possibility is that a population of cells contains
subpopulations of drug sensitive cells, which undergo cell cycle arrest, and drug resistant
cells whose proliferation is unaffected by the drug. Drug resistance in this scenario could
either be a stable characteristic endowed by genetic variation or more transient in nature.
Alternatively, progression through the cell cycle could be slowed down but not arrested in
all cells within the population. Treatment of human endothelial cells with TNP-470 has
been reported to result in accumulation in the G1 phase of the cell cycle, though detectable
numbers of cells remain in S phase and G2/M phase (23). To distinguish between these
possibilities, we chose to treat sensitive cells with TNP-470 followed by treatment with
the drug nocodazole, which causes a solid cell cycle block during M phase (28). As cells
in M phase have a two-fold greater DNA content than cells in G1, the phases can be
distinguished by flow cytometry following staining with the fluorescent DNA intercalator
propidium iodide. As BAECs are primary cells and divide relatively slowly in culture,
treatment with nocodazole for a time sufficient to synchronize the population in M phase
was not possible due to cytotoxicity induced by prolonged drug treatment. We therefore
required a sensitive cell type with a shorter cell cycle. The S49.1 mouse T lymphoma has
been reported to be sensitive to low concentrations of ovalicin and divides approximately
twice a day during exponential growth (24). As expected, S49.1 cells are also sensitive to
TNP-470, and treatment with the drug caused accumulation of cells in G1 (Figure 5.2). A
short treatment with nocodazole was sufficient to completely synchronize cells in M
phase, as judged by DNA content. If cells are treated with TNP-470 for 24 hr and then
nocodazole is added to the culture for an additional 36 hr, virtually the entire population
accumulates in M phase. It therefore appears as if TNP-470 does not cause S49.1 cells to
arrest, but merely delays their progression through G1.
Treatment of subconfluent HUVECs results in an increase in the proportion of
cells in G1 with a decrease in the proportion of cells in both S and G2/M, consistent with
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Figure 5.2. S49.1 cells have a prolonged GI phase when treated with TNP-470.
S49.1 cells were analyzed for cell cycle distribution by propidium iodide fluores-
cence flow cytometry following various drug treatments. The two arrowheads
indicate the positions of the GI and G2/M phases. A, No drug. B, 10 nM TNP-
470, 24 hr. C, 100 nM Nocodazole, 12 hr. D, 10 nM TNP-470, 24 hr, followed
by 100 nM nocodazole, 16 hr.
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previous reports (data not shown, 23). TNP-470 treatment of BAECs, however, while
decreasing the S phase population, appears to cause both the G, and G2/M populations
to increase (Figure 5.3A). While this result suggests that progression through both G1 and
G2 or M is prolonged by TNP-470 in BAECs, the effect on G2/M is subtle compared to
the effect on G1. In order to establish whether the drug causes prolonged G2/M in
BAECs, we examined the behavior of synchronized cells as they pass through G2 and M
in the presence and absence of TNP-470. Treatment with hydroxyurea causes cells to
arrest at the GI/S boundary due to depletion of deoxyribonucleotide pools; drug washout
allows rapid and complete reversal of the block (29). BAECs were treated for 24 hr with
1 mM hydroxyurea, after which point drug was removed by washing the cells and
replacing the culture media. At this point, either TNP-470 or carrier solvent alone was
added to the cells. Cell cycle progression was analyzed over time by flow cytometry
(Figure 5.3B). Following washout a population of cells remained in G, due to either
incomplete synchronization or contact inhibition of cell growth. TNP-470 had no effect
on S phase entry of the synchronized population. Whereas the G2/M phase population
was maximal in cells without TNP-470 8 hr following release from the hydroxyurea block,
G2/M remained highly populated up to 34 hr following release into TNP-470, indicating
that passage through G2 and/or M phase is prolonged by drug treatment. In contrast,
transit through G2/M by human umbilical vein endothelial cells (HUVECs) synchronized
with hydroxyurea is unaffected by TNP-470 treatment, confirming that the drug
specifically effects the G, phase in these cells (Figure 5.4).
To clarify the molecular mechanisms of growth inhibition by TNP-470, we chose
to examine the effect of the drug on Cdk activities important for progression through G1
in HUVECs (Figure 5.1). Growth factor starvation for 36 hr renders HUVECs quiescent
as judged by a greatly reduced proportion of cells in S and G2/M compared with cells
maintained in complete media. Consistent with previous observations, growth factor
restimulation of quiescent HUVECs was found to result in asynchronous entry into S
phase as judged by either [3H] thymidine incorporation or by flow cytometry (29, data
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Figure 5.3. TNP-470 increases the G2/M phase in BAECs. BAECs were ana-
lyzed for DNA content by propidium iodide fluorescence flow cytometry foll-
wing various drug treatments. This page: A, Cells were analyzed following
24 hr treatments with either carrier solvent alone (left panel) or 10 nM TNP-
470 (right panel). Cell cycle distribution is indicated in the inset. Following
two pages: B, BAECs were synchronized by treating with hydroxyurea. Cells
were harvested and analyzed at the times indicated following release from the
block into media containing either carrier solvent alone (top panels) or 10 nM
TNP-470 (bottom panels).
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Figure 5.4. TNP-470 does not prolong the passage of HUVECs through G2 or M phase.
HUVECs were either left untreated (A), or synchronized by treatment with 1 mM
hydroxyurea for 24 hr (B through D). Cells were harvested and analyzed by PI
fluorescence flow cytometry either immediately following hydroxyurea treatment (B), or
24 hr following washout of the hydroxyurea into media containing either no drug (C) or
10 nM TNP-470 (D).
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not shown). To observe cyclin E dependent kinase activity, cells were treated with
hydroxyurea starting 12 hr following restimulation and harvested 16 hr later. Such
treatment results in a population of cells with about two thirds at the GI/S boundary (29),
a time when cyclin E dependent kinase activity is high (Figures 5.5 and 5.6). Addition of
10 nM TNP-470 during restimulation results in a significant decrease in S phase entry
(Figure 5.5). The same concentration of drug causes inhibition of cyclin E dependent
kinase activity (Figure 5.6). Taken together with previous observations that TNP-470
does not affect immediate early gene induction (25,26), this result indicates that TNP-470
causes a delay in cell cycle progression at a point in mid to late G1, prior to maximal
activation of cyclin E dependent kinases.
Discussion
The ability to trap TNP-470-sensitive cells in M phase by applying nocodazole
subsequent to TNP-470 indicates that all cells within the drug-treated population escape
G1 phase. These observations are consistent with prior work which indicated that a
detectable though reduced proportion of endothelial cells are in S phase following drug
treatment. The appearance of resistance to TNP-470, which would be expected if a
subpopulation of cells within a culture were stably drug resistant, has not been observed
previously, even with prolonged drug treatment in endothelial cells (23). These results
indicate instead that TNP-470 prolongs the G1 phase of sensitive cells but does not cause
G1 arrest.
Cell cycle prolongation as opposed to arrest may occur if the molecular target of
the drug contributes to but is not essential for cell cycle progression. Rapamycin
treatment for example also delays entry into S phase but does not result in G1 arrest (30).
This may indicate the presence of homologous proteins which can compensate for loss of
FRAP function, the existence of parallel pathways which regulate translational control
that are only partially redundant with the FRAP pathway, or that activated translation is
not an absolute requirement for S phase entry. A similar situation may apply to specific
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Figure 5.5. TNP-470 prevents entry of synchronized HUVECs into S phase. HUVECs were
rendered quiescent by growth factor starvation and then restimulated with complete growth
media containing 10 nM TNP-470 or carrier solvent alone. Hydroxyurea was added from 12
to 28 hr post-restimulation as described in Materials and Methods. Cells were harvested
either immediately or 2 hr after exchange into fresh media without hydroxyurea. Cells were
analyzed by PI fluorescence flow cytometry. A, Untreated asynchronous cells. B, Quiescent
cells harvested prior to restimulation. C, Cells treated with hydroxyurea alone and harvested
prior to washout. D, Cells treated with hydroxyurea alone and harvested 2 hr after washout.
E, Cells treated with hydroxyurea with TNP-470 and harvested 2 hr following washout.
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Figure 5.6. TNP-470 inhibits activation of cyclin E-dependent kinase. Cells
were synchronized by growth factor starvation and restimulated with growth
factors in the presence or absence of 10 nM TNP-470 or havested prior to
restimulation as indicated. Hydroxyurea was added to growth factor-
stimulated cells after 12 hr, and cells were harvested 16 hr later. Lysates
were analyzed by immunocomplex kinase assay using either control mouse
IgG (ctrl) or anti-cyclin E (cx-E) antibodies as indicated.
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MetAP2 targets that regulate cell growth which are inactivated or activated by TNP-470
treatment. Because TNP-470 acts indirectly via inhibition of MetAP2, however, other
scenarios are also possible. For example, a MetAP substrate crucial for cell growth may
be partially processed by MetAP 1 in the absence of MetAP2 activity, as in the case of
glyceraldehyde-3-phosphate dehydrogenase (see Chapter 3). The amount of active
protein would thus be decreased but not eliminated, which could prolong G1 if the target
protein were rate limiting for G1 progression. Alternatively, inhibition of methionine
processing may result in a protein which retains some but not all of its activity. In a
situation where methionine retention leads to increased stability and thus higher levels of
a CK, for example, levels may not be high enough to completely inhibit its target Cdk(s).
The observation that TNP-470 causes slower progression through G2/M as well
as G1 in BAECs is surprising given that it appears to exclusively arrest in G1 in all other
sensitive cell types that have been tested. This observation suggests that BAECs
exclusively require for MetAP2 activity for timely passage through either G2 , M, or both.
This requirement may reflect either multiple specific MetAP2 substrates which are
important in different phases of the cell cycle, or a single target (or set of targets) which is
important for progression through more than one phase. The protein kinase Src, for
example, is required for progression through both G1 and G2 and does not function
properly without amino-terminal methionine removal (31,32).
The differences between human and bovine endothelial cells could indicate that
MetAP 1 from the two species has different substrate specificities, which would result in
differences in the particular protein which are not processed in the absence of MetAP2.
Alternatively, the amino-terminal sequences of the key substrate(s) important for G2/M
progression may differ between species, such that the human protein is efficiently
processed by MetAP 1, whereas the bovine isoform is not. A further possibility is that
bovine and human endothelial cells differ in their requirements for a particular MetAP2
substrate in G2/M, or that endothelial cells from different tissues differ in such
requirements.
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We observed that TNP-470 causes a partial decrease in cyclin E-dependent kinase
activity. Previous reports indicate that early growth factor-mediated events, such as
immediate early gene induction, are not effected by TNP-470 (26). Taken together, these
results suggest that TNP-470 affects cell cycle progression in mid to late G1, prior to the
onset of full cyclin E-Cdk2 activity. Further experiments will be needed to determine
whether decreased cyclin E-dependent kinase activity reflects a cause or consequence of
growth inhibition. A survey of the molecules known to be involved in activating cyclin E-
Cdk2 should be particularly illuminating. For example, a failure to activate the kinase
could be a result of failure to induce the genes encoding either cyclin E or Cdk2 in a timely
manner, which would suggest that the TNP-470-mediated decrease in cyclin E-Cdk2
activity is secondary to failure to progress through G1. Inhibition of cyclin E-Cdk2 by
association of a CKI would also be informative. For example, the presence of p2 wAF
would suggest the activation of a checkpoint pathway and would implicate inhibition of
the kinase as a causative factor in delayed progression through G1. Inhibition of cell cycle
progression by rapamycin, which also occurs during mid to late G1, is associated with a
failure to downregulate p2 7KiP1, resulting in decreased cyclin E-dependent kinase activity
(18). The observation that cells from mice lacking the Kipi gene are still sensitive to
rapamycin raises questions as to the importance of the CKI in mediating growth
inhibition by the drug (33). It is possible, however, that the absence of p27 is
compensated for by other family members such as p5 7 . Possible roles for these CKIs
in TNP-470-mediated growth inhibition will be investigated in future studies.
Other possibilities include an effect on the phosphorylation state of Cdk2, which
may itself be associated with decreased levels of either the Cdc25 phosphatase or a Cdk
activating kinase. If an effect is observed on the level of a particular protein, it will be
interesting to see whether this effect is mediated at the transcriptional or post-
transcriptional level. In the context of MetAP2 inhibition, it is tempting to speculate that
the effect of TNP-470 is mediated through an effect on the level of a cell cycle regulatory
protein which is either stabilized or destabilized by failure to undergo proper amino-
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terminal processing. Identification of such specific MetAP2 substrates is a crucial
direction for future work in the field.
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Chapter 6
Binding of thalidomide to a-acid glycoprotein
Abstract
In addition to its well known sedative and teratogenic effects, thalidomide also possesses potent
immunomodulatory and anti-inflammatory activities, being most effective against leprosy and
chronic graft-versus-host disease. The immunomodulatory activity of thalidomide has been
ascribed to the selective inhibition of tumor necrosis factor-a from monocytes. The molecular
mechanism for the immunomodulatory effect of thalidomide remains unknown. To elucidate this
mechanism, we synthesized an active photoaffinity label of thalidomide as a probe to identify the
molecular target of the drug. Using the probe, we specifically labeled a pair of proteins of 43-45
kD with high acidity from bovine thymus extract. Purification of these proteins and partial
peptide sequence determination revealed them to be a,-acid glycoprotein (AGP). We show that
the binding of thalidomide photoaffmity label to authentic human AGP is competed with both
thalidomide and the non-radioactive photoaffinity label at concentrations comparable to those
required for inhibition of production of tumor necrosis factor-a from human monocytes,
suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.
Introduction
Thalidomide has a relatively simple chemical architecture (Figure 6.1), but exhibits a multitude of
physiological activities on mammals. In addition to its sedative and teratogenic effects (1,2),
thalidomide possesses significant and unique immunomodulatory and anti-inflammatory
activities. It has been found to be effective against several immune disorders including chronic
graft-versus-host disease (3), oral and orpharygal ulcers associated with HIV infection (4),
erythema nodosum leprosum in leprosy (5) and several other inflammatory skin diseases (6).
Most recently, thalidomide was found to have anti-angiogenic activity (7), raising the possibility
that it may be used to treat certain types of angiogenesis-dependent diseases such as diabetic
retinopathy and cancer.
The immunomodulatory effect and the related anti-inflammatory effect of thalidomide
have attracted much attention in recent years. In searching for the cellular targets of thalidomide,
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Figure 6.1. A. Structure of thalidomide (1). B. Preparation of thalidomide photoaffinity
labels AIPPOT (8) and [1251I]AIPPOT (9). Reaction conditions: (a) SOCl2, 1 equivalent in
dimethylformamide, 2 hr, -5 0C. (b) 30% HBr/HOAc, 80 min., RT. (c) Compound 4, 1
equivalent, and triethylamine, 1 equivalent, in dimethylformamide, 24 hr at 60 *C, 1 equivalent
dicyclohexylcarbodiimide and catalytic dimethylaminopyridine added, continued at 60 'C for
72 hr. (d) N-(t-Butoxycarbonyl)-aminoethyl bromide, 5 equivalents, and tetraethylammonium
fluoride, 1 equivalent, 72 hr, RT. (e) 25% trifluoroacetic acid/CH2Cl2, 30 min., RT. (f) Azi-
doiodophenylpropionic acid succinimidyl ester, 1 equivalent, triethylamine, 2 equivalents in
EtOAc, 40 hr, RT. (g) [12 51]Azidoiodophenylpropionic acid succinimidyl ester (carrier free)
100 pCi and 1 mg amine 7 in 0.5% Et3N/EtOAc, 16 hr, RT.
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several models of immune regulation have been examined. It was reported that the calcium-
dependent lymphocyte proliferation in response to mitogen and alloantigens is inhibited by
thalidomide (8). Neubert and coworkers uncovered several cell surface molecules whose
expression is either enhanced or inhibited by the drug in vivo (9). Kaplan and colleagues found
that thalidomide selectively inhibits the production of tumor necrosis factor-a (TNF-a) from
stimulated human monocytes both in vitro and in vivo (10,11), providing a possible mechanism
for both the immunomodulatory and the anti-inflammatory activities of the drug. This TNF-a
inhibitory effect has been ascribed to enhanced mRNA degradation by the drug (12). Blockade of
TNF-a production seems to underlie the inhibition of replication of the type 1 HIV in human
monocytes by thalidomide (13). Further delineation of the inhibitory mechanism has been
hampered, in large part, by the relatively low potency of the drug with an IC50 between 10 to
100 FM for TNF-a inhibition (12,13).
In an effort to elucidate the molecular mechanism of immunomodulation by thalidomide in
general and the molecular target responsible for its inhibition of TNF-a in particular, we have
synthesized an active photoaffmity label derived from the drug. Using this photoaffinity label,
we detected a pair of proteins that specifically bind to thalidomide. These thalidomide binding
proteins have been identified as isoforms of a-acid glycoprotein (AGP), indicating a potential
role for AGP as a mediator of the drug's immunomodulatory effect.
Materials and Methods
Fresh calf thymi were obtained from Research 87, Medford, MA. Human AGP and C.
perfringens Neuraminidase were from Sigma. Mouse anti-human TNF-a monoclonal antibodies
used for ELISA were from Pharmingen. Carboxymethyl sepharose was from Pharmacia. Cbz-
glutamine was purchased from Bachem Bioscience Inc. '251-labeled and unlabeled
azidoiodophenylpropionic acid succinimidyl ester (14) were purchased from Dr. A. Ruoho,
University of Wisconsin School of Medicine. NMR solvents were from Cambridge Isotope
Laboratories. Propranolol and alprenolol were from Research Biochemicals International. All
other chemicals were purchased from Aldrich Chemical Co.
General Synthetic Chemistry. Unless otherwise indicated, reagents were purchased from
Aldrich and solvents from Aldrich or Mallinckrodt and were reagent grade or better. NMR
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solvents were from Cambridge Isotope Laboratories. Dichloromethane was distilled under
nitrogen from calcium hydride. Flash column chromatography was performed using Merck silica
gel, 230-400 mesh. All compounds were analyzed by 'H NMR using a Varian XL 300 Mhz
spectrometer and by low resolution mass spectrometry. Where indicated, high resolution mass
spectra were taken on a Finnegan MATT 8200 spectrometer.
Thalidomide. N-Phthaloylglutaric anhydride (4.96 g, 19.1 mmol) and urea (0.62 g, 10.3 mmol)
were co-melted under an Ar atmosphere with stirring at 200 C (15). After 20 min the reaction
mixture was cooled to room temperature, and the resulting yellow solid was recrystallized from
2-ethoxyethanol (65 mL). Crystals were collected by suction filtration, washed three times with
Et2O, air dried, and then further dried in vacuo to afford 2.281 g thalidomide (46% yield). 'H
NMR (DMSO-d 6) 8 11.14 (s, 1H), 7.92 (m, 4H), 5.16 (dd, 1H), 2.89 (m, 1H), 2.52 (m, 2H), 2.07
(m, 1H).
N-Carbobenzoxy-2-aminoglutarimide. Cbz-glutamine (0.5 g, 1.8 mmol) was dissolved in
dimethylformamide under an atmosphere of Ar. The solution was cooled in an EtOH/dry ice
bath and thionyl chloride (160 pL, 2.2 mmol) was added dropwise by syringe with stirring. The
reaction vessel was transferred to an ice water bath and stirred for an additional 2 hr, after which
time the solution was added to 190 mL 10% KOAc (aq) and the resulting mixture extracted twice
with 200 mL Et2O. The organic layers were dried over MgSO 4, filtered, and the solvent removed
under reduced pressure. The residue was chromatographed on silica gel in 1:1 CHCl3/EtOAc.
Removal of solvent under reduced pressure provided the product as an oily reddish solid (214
mg, 46% yield). 'H NMR (CDCl3) 6 8.24 (s, 1H), 7.34 (m, 5H), 5.63 (d, 1H), 5.12 (s, 2H), 4.35
(m, 1H), 2.48-2.84 (m, 3H), 1.88 (ddd, 1H).
2-Aminoglutarimide hydrobromide. HBr (30% solution in HOAc, 6mL) was added via
syringe to a reaction vessel containing N-carbobenzoxy-2-aminoglutarimide (980 mg, 3.74 mmol)
in a nitrogen atmosphere. The mixture was stirred 1 hr 10 min, at which point diethyl ether (15
mL) was added. The solid was collected by suction filtration, washed twice with diethyl ether,
dried in air and in vacuo to provide 716 mg 2-aminoglutarimide hydrobromide as a pale green
powder (92% yield). 'H NMR (DMSO-d 6) 6 11.27 (s, 1H), 8.43 (s, 3H), 4.23 (d, 1H), 2.04-2.78
(m, 2H), 2.15 (m, 1H), 2.01 (m, IH).
3-Hydroxythalidomide. 2-Aminoglutarimide hydrobromide (200 mg, 0.96 mmol) and 3-
hydroxyphthalic anhydride (157 mg, 0.96 mmol) were dissolved in DMF under a nitrogen
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atmosphere. Triethylamine (133 gL, 0.96 mmol) was added via syringe and the solution heated
to 60 'C in an oil bath for 4 hr. The mixture was then cooled to room temperature to add
hydroxybenzotriazole (71 mg, 0.5 mmol) and dicyclohexylcarbodiimide (200 mg, 0.96 mmol), and
then returned to the oil bath for an additional 24 hr. After cooling to room temperature, the
reaction mixture was filtered and poured into brine, which was extracted twice with 3:5
CHCl 3/EtOAc. The organic fractions were dried with Na2 SO 4, filtered, and concentrated to an oil
under reduced pressure. The residue was chromatographed twice on silica gel by loading in
CHCl3/EtOAc and eluting with neat EtOAc. Removal of the solvent under reduced pressure and
in vacuo provided 109 mg of 3-hydroxythalidomide as a green-yellow solid (42% yield). 'H
NMR (DMSO-d6) 8 11.17 (br s, 1H), 11.09 (s, 1H), 7.64 (m, 1H), 7.27 (m, 2H), 5.06 (dd, 1H),
2.87 (m, 1H), 2.48-2.61 (m, 2H), 2.02 (m, 1H).
t-Butoxycarbonylaminoethyl bromide. Prepared by the reaction of di-t-butyl pyrocarbonate
with aminoethyl bromide as previously reported (16) (49% yield). 'H NMR (CDCl 3) 8 4.92 (br
s, lH), 3.50 (t, 2H), 3.43 (t, 2H), 1.42 (s, 9H).
3-(t-Butoxycarbonylaminoethoxy)thalidomide. 3-Hydroxythalidomide (12 mg, 0.044 mmol)
was added to a mixture of DMF (0.8 mL), tetraethylammonium fluoride dihydrate (8 mg, 0.044
mmol), and molecular seives (3 A) with stirring, followed by the addition of t-
butoxycarbonylaminoethyl bromide (30 mg, 0.132 mmol). The mixture was stirred under
nitrogen for 72 hr, diluted with EtOAc (12 mL) and filtered. This solution was washed once with
water and once with saturated aqueous NaHCO 3, dried with MgSO 4 and filtered. After removal
of the solvent under reduced pressure, the residue was chromatographed on silica gel in 3:2
EtOAc/hexanes. Removal of the solvent produced 7 mg of the desired product as an oily solid
(38% yield). 'H NMR (CDCl 3) 8 8.069 (s, 1H), 7.67 (m, 1H), 7.47 (d, 1H), 7.22 (d, 1H), 5.23
(br s, 1H), 4.94 (dd, 1H), 4.21 (t, 2H), 3.59 (d, 2H), 2.71-2.92 (m, 3H), 2.13 (m, 1H), 1.42 (s,
9H).
3-(2-(3-Azido-2-iodophenyl)propionamido)ethyoxythalidomide. t-Boc-aminoethoxy-
thalidomide (4 mg) was dissolved in methylene chloride (1 mL) and an equal volume of 50%
trifluoroacetic acid in methylene chloride added. The reaction was stirred for 30 min at room
temperature. After the addition of 2 mL toluene, the solvent was removed under reduced
pressure and the resulting oil was triturated twice with diethyl ether and dried in vacuo. The
resulting white solid was dissolved in 2 mL EtOAc, and triethylamine (2 gL) and 3-azido-2-
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iodophenylpropionyl succinimide were added in the absence of direct light. The reaction was
stirred in the dark for 40 hr and the product purified by chromatography on silica gel, eluting in
2% MeOH/EtOAc. Removal of the solvent under reduced pressure provided the product (4.0
mg) in 79% yield.
Thalidomide photoaffinity label, [12 513-(2-(3-Azido-4-iodophenylpropionamido)-
ethoxy)thalidomide ([12 5I]AIPPOT) (9). All procedures were performed in the absence of
direct light. [12 51]Azidoiodophenylpropionic acid succinimidyl ester (120 mCi in 120 ml ethyl
acetate) was concentrated under a stream of nitrogen to a volume of less than 5 ml. A suspension
of 1 mg 3-(aminoethoxy)thalidomide in 100 g1 ethyl acetate/0.5% triethylamine was added. The
reaction mixture was left overnight at room temperature in a closed container. The product was
purified by silica gel chromatography. Fractions were concentrated under a stream of nitrogen to
<5 ml and then the product was resuspended in 100 ml methanol and stored at -80*C.
Monocyte Isolation and TNF-a Secretion Assay. Peripheral blood mononuclear cells were
isolated from heparinized blood by centrifugation on Ficoll-Paque Plus (Pharmacia) step
gradients. Cells were washed three times in cell culture medium (RPMI 1640). A monocyte-
enriched fraction was isolated by suspending the cells to 2.5 x 10 6/ml in complete medium (RPMI
1640 plus HEPES with 5% human AB serum, 50 units/ml penicillin, 50 gg/ml streptomycin and
2.5 mM L-glutamine) and allowing cells to adhere to plastic tissue culture plates in a humidified
atmosphere of 5% C02 at 37 'C for three hours. Non-adherent cells were removed by washing
with serum-free medium, and adherent cells were detached by scraping and washed twice with
serum free medium. To assay for TNF-a production, cells were resuspended in complete
medium to 106 cells/0.9 ml and plated at 0.45 ml per well in 24-well plates. Cells were allowed to
adhere for two hours at 37 *C before drugs or analogs dissolved in dimethyl sulfoxide (DMSO)
were added with a final concentration of 0.2% DMSO. This was followed by addition of
lipopolysaccharide (LPS) (in 50 ml complete medium) to a final concentration of 1 pLg/ml. Plates
were incubated for 16 hours in a humidified incubator (37 *C/5% CO 2). Drug treatment did not
significantly affect cell viability compared to DMSO controls, as judged by trypan blue
exclusion. Culture supernatants were collected by centrifugation at 1300 x g for 6 minutes at 4
*C. TNF-a was assayed by ELISA using mouse anti-human TNF-a monoclonal antibodies from
Pharmingen according to the supplier's instructions. The levels of TNF-ac are derived from a
second order polynomial standard curve (r2>0.995 for each determination).
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Preparation of Tissue Extracts. Freshly prepared bovine thymus tissue was shipped on ice
and used the same day. Connective tissue was removed from organs and they were cut into small
pieces and frozen in liquid nitrogen. Frozen chunks were weighed, powdered and then suspended
in cytosol buffer (20 mM TrisHCl, pH 6.9, 100 mM NaCl, 2 mM P-mercaptoethanol, 0.02%
NaN3, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride), 1 mI/g of tissue, in a blender.
Suspensions were dounce homogenized with ten up-and-down strokes and centrifuged at 9000 x
g to remove most of the debris. The supematant was centrifuged at 100,000 x g and the S100
fraction stored in aliquots at -80*C until needed.
Photoaffinity Labeling. Crude or partially purified tissue extract containing 5-20 gg of total
protein or 0.1 gg of purified human AGP (Sigma) was diluted in labeling buffer (20 mM TrisHCl,
pH 7.0, 50 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.5 mM EDTA) to a final volume of 45 1A.
Drug or DMSO (0.5% volume) was added followed by incubation at 37 'C for 30 min.
Photoaffmity label (~1 gCi/l) was diluted five fold in labeling buffer in bulk immediately before
use and 5 ml was added to each labeling tube in the absence of direct light. Samples were mixed
and incubated at 37 0C for 30 minutes in the dark, and then irradiated in a Stratalinker (Stratagene)
at 254 nm with a total energy output of 3.3 J/m 2. For one-dimensional SDS-PAGE, reactions
were quenched by adding 3.5 p1 P-mercaptoethanol followed by 18 pl 4x SDS-PAGE sample
buffer (250 mM TrisHCl, pH 6.8, 40% glycerol, 5% SDS, 0.1 mg/ml bromophenol blue).
Samples were heated in a boiling water bath for 3 minutes before they were subjected to SDS-
PAGE. For two-dimensional electrophoresis, reactions were quenched by adding 5 R1 10%
SDS/1 50 mM dithiothreitol. Samples were heated as above, cooled and 5 p1 urea solution (65
mM dithiothreitol/4% CHAPS/9 M urea/5% Bio-Rad Bio-Lyte 3-10 ampholyte) was added.
Samples were loaded onto IEF gels (4.5% acrylamide/0.4% bis-acrylamide/9.2 M urea/l % Bio-
Lyte 5-7 ampholyte/4% Biolyte 3-10 ampholyte/1.5% CHAPS/0.5% NP-40, 14 cm x 2.5 mm)
and run for 12 hr at 400 V followed by 2 hr at 1000 V in a Bio-Rad Protean II apparatus with 6
mM phosphoric acid in the lower chamber and 20 mM sodium hydroxide in the upper chamber.
The SDS-PAGE dimension was 12% acrylamide/0.32% bis-acrylamide. Gels were stained with
Coomassie Blue, dried onto blotting paper and exposed to X-ray film (Kodak XAR 5) or to
phosphorimager cassettes (Molecular Dynamics). Labeling was quantified using ImageQuant
software.
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Protein Purification. All procedures were carried out at 4'C. To 20 ml of bovine thymus S100
fraction (9.2 mg/ml protein) was added 7.36 g (61%) ammonium sulfate with mixing. The mixture
was incubated on a rotator for 16 hr followed by centrifugation at 12,000 x g for 15 minutes. To
the supernatant was added 4.20 g (92%) ammonium sulfate and rotated for 8 hours. The mixture
was centrifuged as before. The pellet was resuspended in 2 ml buffer containing 20 mM TrisHCl
(pH 6.8) and 100 mM NaCl, and dialyzed into 20 mM sodium acetate, pH 4.1/20 mM NaCl
overnight. The resulting suspension was centrifuged at 16,000 x g for 10 minutes to remove the
precipitate and the supernatant was applied to a carboxymethyl sepharose column. The column
was washed with the dialysis buffer. The flow-through fractions were pooled and dialyzed into
50 mM ammonium carbonate for 24 hours with one change of buffer. The sample was
lyophilized overnight and resuspended in 20 p1 H20.
Neuraminidase Digestion and Protein Sequencing. The purified thalidomide binding
proteins (10 p1), 17 p1 0.1 M sodium acetate (pH 5.5) and 3 p1 C. perfringens neuraminidase
(Sigma Type V, 1 mU/pl) were mixed and incubated at 37'C for 5 hr. To the mixture were added
2.5 .1 p-mercaptoethanol and 10 .1 4 x SDS sample buffer. The sample was heated in a boiling
water bath for 3 minutes and subjected to SDS-PAGE as above. The proteins were then blotted
onto PVDF membrane. The blot was stained with Ponceau S and destained briefly in doubly
distilled water before the band corresponding to the thalidomide binding protein was sliced out.
The membrane was submitted for proteolytic digestion with either Lys-C or chymotrypsin.
Peptide fragments were separated by high performance liquid chromatography and sequenced by
Edman degradation at the Harvard Microchemistry Facility and the MIT Biopolymers Lab.
Results
The relatively low potency of thalidomide as an inhibitor of TNF-x production suggests that
thalidomide may have a low affinity for its target, making it difficult to employ conventional
affinity chromatography to identify and purify the potential target proteins. We therefore
resorted to the more sensitive method of photoaffinity labeling to identify thalidomide binding
proteins. To make an active thalidomide photoaffinity label, we needed to define a position in
thalidomide to which a radioactive photocrosslinking moiety may be attached without
significantly abrogating its activity. A survey of the literature indicated that C-3 of the
phthalimide group may be such a position as it has been shown that 3-hydroxythalidomide is
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Figure 6.2. Effect of thalidomide and AIPPOT on the secre-
tion of TNF-t by LPS-stimulated human peripheral blood
monocytes. Monocytes were treated with 1 pg/ml LPS for 16
hours in the presence of varying concentrations of drug or car-
rier alone (0.2% DMSO). The amount of TNF-x was deter-
mined in culture supernatants by ELISA. Results are
expressed as the percentage of TNF-a produced compared to
DMSO control and are the average of two experiments with
separate donors each performed in triplicate. Error bars refer
to SD.
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active in animal models for both graft-versus-host disease (17) and embryopathy (18). We
synthesized a non-radioactive photoaffmity label derived from thalidomide, 3-(2-(azido-
iodophenylpropionamido)ethoxy)thalidomide (AIPPOT), by attaching a 4-azido-3-
iodophenylpropionyl group onto 3-hydroxythalidomide via an ethanolamine linker (Figure 6.1).
When the activity of the non-radioactive photoaffinity label was determined, it was found to be
more active than thalidomide itself (Figure 6.2). While thalidomide inhibits TNF-a production
with an IC 50 of over 200 pM, its solubility limit in aqueous medium, the attachment of the side
chain onto the 3-hydroxy group in the photoaffinity label resulted in an increase in its potency,
with an IC 50 of less than 100 gM.
We subsequently synthesized the radioactive photoaffinity label containing 1251 (Figure
6.1) and used it to identify potential thalidomide binding proteins in membrane and soluble
extracts prepared from fresh bovine thymus, an abundant source of proteins from lymphoid cells.
Although no specific proteins were detected in the membrane fraction (data not shown),
treatment of the soluble extract with [125 1]AIPPOT followed by irradiation at 254 nm resulted in
specific labeling of two proteins with apparent molecular mass of ca. 45 and 43 kD (Figure 6.3).
This labeling can be competed with unmodified thalidomide at concentrations comparable to
those required for TNF-a inhibition in the cellular assay (Figures 6.2 and 6.3).
To find an optimal procedure for isolating the putative thalidomide binding proteins, we
determined, among other physical properties, their isoelectric points. Two-dimensional gel
electrophoresis of labeled thymus extract revealed the putative thalidomide binding proteins to be
extremely acidic with isoelectric points of ca. 3.5 (Figure 6.4). Moreover, the two labeled protein
bands on one-dimensional SDS-PAGE were resolved into a series of spots in the IEF dimension.
The unusually high acidity of the putative thalidomide binding proteins led us to search in the
literature for proteins with similar isoelectric points. Indeed, we found that AGP, also called
orosomucoid, was strikingly similar to the putative thalidomide binding proteins on a two-
dimensional gel electrophoresis map with few other proteins in its neighborhood (19). This
finding helped to simplify the isolation and identification of the thalidomide binding proteins.
Using the established purification procedures for AGP as a guide and the thalidomide
photoaffinity labeling as an assay, we purified the thalidomide binding proteins to near
homogeneity in two steps. Starting with crude bovine thymus extract, the thalidomide binding
activity was concentrated in 61-92% ammonium sulfate precipitate (20). After dialysis into
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Figure 6.3. Labeling of bovine thymus S 100 fraction with [12 1]AIPPOT.
Soluble bovine thymus extracts were preincubated with 200 PM cold com-
petitor thalidomide (+) or DMSO (-) carrier (0.5%) for 30 minutes before
the addition of 1 pCi [12 51]AIPPOT in the absence of direct light. After 30
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Figure 6.4. Two dimensional gel electrophoresis of [121]AIPPOT-labeled
bovine thymus extract.
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M
acidic sodium acetate buffer, the thalidomide binding protein-containing fraction was subjected to
weak cation exchange carboxymethyl sepharose chromatography (21). The thalidomide binding
proteins were present in the flow-through fraction at pH 4.1, virtually free of other proteins
(Figure 6.5, Lane 1). The N-termini of the proteins thus purified were blocked, in agreement with
the known N-terminal pyroglutamate moiety of AGP (22). Since AGP is also known to have a
high sialic acid content, we treated the purified thalidomide binding proteins with neuraminidase.
Upon neuraminidase treatment, the two thalidomide binding protein bands were converted into a
single protein band, suggesting that the two bands originated from the same protein with
differential sialylation (Figure 6.5). Removal of the sialic acids also allowed for the subsequent
proteolysis of the proteins and sequencing of the proteolytic fragments. The sequences of four
proteolytic fragments were determined. All show high homology with human AGP (Figure 6.6).
Although the bovine AGP has not been cloned, the four peptides sequences are 75% identical and
93% similar to human AGP (23). By comparison, rabbit AGP only bears 59% identity and 74%
similarity to human AGP in the same regions, suggesting that the thalidomide binding proteins in
bovine thymus extract are isoforms of the bovine AGP.
To confirm that AGP binds to thalidomide, we labeled commercially available AGP from
several species. The labeling of human AGP with thalidomide photoaffinity label is shown in
Figure 6.7. Indeed, [12 5 1]AIPPOT labels human AGP and this labeling is competed by both
thalidomide and the non-radioactive AIPPOT, with the latter being more potent. The potencies
of thalidomide and AIPPOT are in general agreement with the relative potency of these two
compounds in the TNF-a secretion assay (Figure 6.2).
AGP in the plasma is known to bind to a large number of basic and occasionally neutral
drugs and exert important effect on their pharmacokinetics (24). We compared the drug binding
site for thalidomide and several other drugs using a competition assay in which the labeling of
AGP by the thalidomide photoaffinity label was carried out in the presence of two known AGP-
binding drugs, propranolol and alprenolol. As shown in Figure 6.7B, both propranolol and
alprenolol compete effectively against the thalidomide photoaffinity label for AGP, with
alprenolol being more potent than propranolol. It is likely that thalidomide binds to AGP at the
same or an overlapping site as propranolol and alprenolol.
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Figure 6.5. Purified thalidomide binding proteins. Proteins were
purified as described in the Results section and aliquots incubated in
30 pl digestion buffer in the presence or absence of 3 mU C. perfrin-
gens neuraminidase for 5 hr at 37 C. Portions of the samples were
subjected to SDS-PAGE followed by silver staining.
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Figure 6.6. Comparison of peptide sequences derived from the purified
thalidomide binding protein and those of human AGP. "X" in Bovine
peptide-4 denotes unidentified residues.
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Figure 6.7. Labeling of human AGP with increasing concentrations
of cold competitors. A sample of 0.1 pg human AGP per tube was
preincubated with varying concentrations of competitor or with
DMSO carrier alone (0.5%). [1251]AIPPOT (1 pCi per tube) was
added, tubes were incubated 30 min, irradiated, quenched with p-
mercaptoethanol and subjected to SDS-PAGE followed by
autoradiography. A. Competition of labeling with thalidomide and
AIPPOT. B. Competition with the P-blockers propranolol and
alprenolol.
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Discussion
Thalidomide is known to possess immunomodulatory and anti-inflammatory effects.
However, the cellular and molecular mechanisms of these activities are not understood. Among
the various cellular effects of thalidomide, the inhibition of TNF-a seems to offer a plausible
mechanism for several known immunomodulatory activities of the drug. Using LPS-induced
TNF-ax secretion in human monocytes as an assay and an active thalidomide photoaffmity label
as a probe, we isolated and identified two thalidomide binding proteins as isoforms of AGP.
AGP belongs to the class of acute phase proteins that are known to be induced in the liver
in response to a wide variety of physiological stresses including inflammation, infection,
pregnancy and malignancy (25,26). It is distinct from other serum proteins by its high
carbohydrate content (over 40% by weight) and high acidity. Although it has been known for
more than a century (27), the precise biological function of AGP still remains unknown.
Nevertheless, a number of studies have pointed to potential roles of AGP in the regulation of the
immune system and in inflammation. AGP was shown to have immunosuppressive activity in
the mixed lymphocyte reaction (28) and an AGP-like immunosuppressive acidic protein was
found from ascites fluids of cancer patients (29). The potential role of AGP in inflammation has
been somewhat controversial. On the one hand, AGP was shown to exert a protective effect
against TNF-a and LPS-induced lethality when it is administered intraperitoneally in mice (30).
It has also been shown to inhibit platelet aggregation (31) and thus may be capable of preventing
secretion of other pro-inflammatory factors. On the other hand, AGP was shown to potentiate
LPS-induced secretion of such inflammatory cytokines as TNF-a and IL-I in human monocytes
in vitro (32). Since thalidomide inhibits LPS-induced TNF-a secretion, it will be interesting to
see whether thalidomide acts by inhibiting AGP's potentiating activity for LPS. It also remains
to be determined whether thalidomide has any effect on other immunomodulatory activities of
AGP.
As an abundant plasma protein, AGP binds to many drugs and can modulate their
metabolism (24). Those drugs include known p-blockers such as propranolol and alprenolol.
Competition experiments indicate that thalidomide binds to the same site in AGP as propranolol
and alprenolol. None of the drugs, however, possess the same unique immunomodulatory and
anti-inflammatory activities of thalidomide. Whether binding of thalidomide to AGP confers a
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unique conformational change to the protein leading to a gain of function remains to be
investigated.
The primary source of AGP is known to be hepatocytes (33). However, it has been
shown that lymphocytes, granulocytes and monocytes also express a membrane-associated form
of AGP (34). It has also been reported that monocytes can serve as a source of soluble AGP
(35). In fact, we have found that upon LPS stimulation, the promonocytic cell line THP-1
differentiated by treatment with lIa, 25-dihydroxy vitamin D3 produces large amount of AGP
along with TNF-a (B.T. & J.L., unpublished results). These observations are consistent with
the aforementioned immunomodulatory activities of AGP and suggest that AGP may play an
important role in immunoregulation. The fact that thalidomide binds to AGP with high
specificity implies that AGP may mediate the immunomodulatory effect of the drug.
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Chapter 7
Studies on the mechanism of action of tetrafluorophthalimide
inhibitors of cytokine induction in monocytes
Abstract
Analogs of thalidomide in which the four hydrogen atoms of the phthalimide ring were
replaced with fluorine were prepared in an effort to create more potent inhibitors of TNF-
a production. Fluorination of thalidomide led to an increase in potency of over 500 fold,
whereas the corresponding chlorinated and brominated compounds were much less active.
Unlike thalidomide, these compounds inhibit the production of both IL-I and IL-6 from
stimulated monocytic cells in addition to TNF-a, and appear to work at the
transcriptional level. As tetrafluorothalidomide does not bind to a-acid glycoprotein, a
known thalidomide binding protein, the existence of other possible target proteins was
investigated. Photoaffinity labeling revealed that the tetrafluorophthalimides bind
specifically to a 30 kD and a 40 kD protein. The 40 kD protein was affinity purified,
sequenced, and identified as a novel homolog of thioredoxin. The 30 kD protein was
purified and a tryptic digest subjected to mass spectrometry, which revealed it to be a
recently identified protein with homology to a rat glutathione-dependent
dehydroascorbate reductase. Binding of tetrafluorophthalimides to these proteins
suggests a possible effect on redox-sensitive signaling pathways leading to cytokine
induction in monocytes. The drugs had only a partial effect on activation of NF-KB, a
redox sensitive transcription factor known to be essential for TNF-a induction, pointing
to the possibility that the activity of other transcription factors involved in cytokine
induction are affected by the cellular redox environment.
Introduction
Interest in the teratogenic drug thalidomide (1) has increased in recent years due to its
anti-inflammatory properties (1). Thalidomide is currently used in the clinic to treat
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erythema nodosum leprosum (ENL) in leprosy patients, graft-versus-host disease, and
HIV-associated wasting and ulcers (2-5). Its activity as an anti-inflammatory agent has
been attributed to its ability to specifically inhibit the production of tumor necrosis
factor-a (TNF-a) from monocytic cells (6). Inhibition of TNF-a production appears to
be mediated by destabilization of the TNF-a mRNA (7).
Use of thalidomide is limited by side effects. In addition to being an extremely
potent teratogen, it is also a sedative and causes peripheral neuropathy in some patients,
which can become permanent if drug treatment is not immediately ceased (8-10).
Recently, effort has been directed towards the development of thalidomide analogs which
are more potent as TNF-a production inhibitors and might allow for therapeutic use in
inflammatory diseases without undesirable side effects. One such strategy has involved
consideration of the compound's chirality. Thalidomide has a single chiral center, at its a-
carbon (Figure 1). It has been reported that the s-(-)-isomer exclusively mediates the
teratogenic effects of thalidomide in rabbits, whereas the R-(+)-isomer is not teratogenic
(11,12). However, oral administration of either isomer causes birth defects, perhaps due
to acid-catalyzed epimerization of the drug in the stomach (13). In addition, a fast rate of
epimerization has been observed in neutral aqueous solutions, indicating that even
intravenous administration of the 'safe' isomer may cause birth defects in humans (14).
To circumvent this problem, several groups have prepared thalidomide analogs that
cannot readily epimerize. Replacement of the labile a-proton with a methyl group
produces an analog which maintains its activity as a TNF-a production inhibitor (14).
Studies with this compound indicate that the S-(-)-isomer is a much more potent TNF-a
production inhibitor than the other epimer, suggesting that it would be impossible to
separate the anti-inflammatory and teratogenic activities of the drug on the basis of
stereochemistry alone.
A group at Celgene Corporation has applied a more standard medicinal chemical
approach to the discovery of more potent thalidomide analogs. Finding that an intact
phthaloyl ring was essential for activity, the group prepared a series of analogs by
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modifying the glutarimide moiety (15). Accordingly, a series of phthalimidocinnamic acid
derivatives was produced and tested for their ability to inhibit lipopolysaccharide (LPS)-
stimulated TNF-cc production from monocytes. Among the most potent compounds in
this series was CC-1104 (5), which inhibits TNF-cc production with an IC50 of 6 gM,
approximately 30-fold more potently than thalidomide. A similar compound, CC-1069
(6), was found to be much more potent than thalidomide at protecting mice from lethal
doses of LPS (16). Further increases were noted by amino substitution at either position
on the phthalimide ring (15).
Hashimoto and co-workers have found that when the myelomonocytic cell line
HL-60 is treated with PMA, thalidomide actually potentiates rather than inhibits TNF-a
production (17). A series of phthalimides prepared in their laboratory, including analogs
in which the glutarimide moiety was replaced with o, o-dialkylphenyl groups, was
subsequently tested in this assay and found to have modestly increased activity
compared with thalidomide (18). Intriguingly, tetrafluorophthaloyldiisopropylaniline (8),
an analog in which each phthalimido proton was replaced with fluorine, was a highly
potent potentiator of TNF-cc production, with nanomolar concentrations of the
compound inducing a five-fold increase in secreted TNF-a levels. This observation raises
the question of whether 8 and other tetrafluorophthalimides, such as
tetrafluorothalidomide (2), might act as potent inhibitors of TNF-a production from LPS-
stimulated monocytic cells. Herein we find that tetrafluorothalidomide (2) is indeed a
potent inhibitor of TNF-oc production, with an IC 50 approximately 500-fold lower than
the parent compound. Substitution with other halogens did not result in compounds with
comparable activity. Compound 7, the tetrafluorinated analog of CC- 1104 (5), was even
more potent than tetrafluorothalidomide. The tetrafluorophthalimides appear to differ in
their mechanism of action from thalidomide, however, as 2 and 7 also inhibit the
production of IL-i 1P and IL-6 from stimulated monocytic cells. In addition, unlike
thalidomide, inhibition of TNF-a production appears to be mediated at the transcriptional
level. To understand the mechanism of action of this new class of TNF-a production
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inhibitors, two specific tetrafluorophthalimide binding proteins were purified and
identified as novel homologs of thioredoxin and glutathione-dependent dehydroascorbate
reductase, suggesting the possible regulation of redox-sensitive signaling pathways by
these compounds.
Materials and Methods
Unless otherwise indicated, reagents were purchased from Aldrich and solvents from
either Aldrich or Mallinckrodt and were reagent grade or better. NMR solvents were
from Cambridge Isotope Laboratories. Flash column chromatography was performed
using Merck silica gel, 230-400 mesh. All compounds were analyzed by 'H NMR using a
Varian XL 300 MHz spectrometer and by low resolution mass spectrometry. Where
indicated, high resolution mass spectra were taken on a Finnegan MATT 8200
spectrometer. Antibodies to p30 were obtained from Dr. Michael Story at the MD
Anderson Cancer Center at the University of Texas, Houston.
Tetrafluorothalidomide (2). Tetrafluorophthalic anhydride (43 mg, 0.2 mmol) and 2-
aminoglutarimide hydrobromide (41 mg, 0.2 mmol, preparation described in Chapter 6)
were dissolved in DMF in an Ar atmosphere. Triethylamine (27 gL, 0.2 mmol) was
added, and the solution stirred at 60*C for 16 hr. The solution was cooled in a dry
ice/EtOH bath and thionyl chloride (32 gL, 0.42 mmol) was added by syringe with
stirring. The reaction vessel was transferred to an ice water bath and stirred for an
additional 4 hr. The solution was poured into 10% aqueous KOAc (85 mL) and extracted
three times with diethyl ether and then twice with EtOAc. The organic layers were dried
with MgSO4, filtered, concentrated under reduced pressure, combined, and
chromatographed on silica gel in 3:2 hexanes/EtOAc. Removal of the solvent under
reduced pressure afforded 15 mg tetrafluorophthalimide (22% yield). 'H NMR (acetone-
d) 8 10.00 (br s, 1H), 5.18 (dd, lH), 2.91-3.02 (m, 1H), 2.67-2.80 (m, 2H), 2.20-2.27 (m,
1H).
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Tetrachlorothalidomide (3). Prepared by Satomi Niwayama in the Liu laboratory
analogously to tetrafluorothalidomide (2).
Tetrabromothalidomide (4). Prepared by Satomi Niwayama in the Liu laboratory
analogously to tetrafluorothalidomide (2).
p-Amino-3,4-dimethoxydihydrocinnamic acid (12). Procedure is carried out as
described (19) except that 3,4-dimethoxycinnamic acid is substituted for cinnamic acid,
and the procedure is carried out on a smaller scale (2 g acid). 21% yield: IH NMR (D20)
5 2.86 (m, 2H), 3.89 (s, 3H), 3.90 (s, 3H), 4.64 (t, 1H), 7.10 (m, 3H).
Methyl p-amino-3,4-dimethoxydihydrocinnamate hydrochloride (13). Thionyl
chloride (90 gL, 1.23 mmol) is added via syringe to 0.75 mL anhydrous methanol under
Ar in an ice/water bath. P-Amino-3,4-dimethoxydihydrocinnamic acid (150 mg, 0.666
mmol) is added in portions with thorough mixing. The suspension is stirred at 00C until
the material dissolves (15 min) and then overnight at RT. The solvent is removed under
reduced pressure and the product is suspended in ethyl ether, suction filtered, and washed
with several volumes of ethyl ether. The resultant white powder is collected and dried in
vacuo to yield 219.7 mg of the product (89% yield). 'H NMR (DMSO-d6) 6 3.05 (m,
2H), 3.56 (s, 3H), 3.74 (s, 311), 3.76 (s, 3H), 4.52 (br m, 1H), 6.93-7.01 (m, 2H), 7.23 (s,
1H), 8.56 (br s, 3H).
CC-1104 (Methyl 3-phthalimido-3-(3,4-dimethoxyphenyl)propionate) (5). This
procedure was adapted from a previously described method (20). Methyl 0-amino-3,4-
dimethoxydihydrocinnamate hydrochloride (45 mg, 0.16 mmol), carboethoxyphthalimide
(36 mg, 0.16 mmol), and sodium carbonate (22 mg, 0.16 mmol) were taken up in 1:1
acetonitrile/water (2 mL) and stirred at room temperature for 1 hr. The acetonitrile was
removed under reduced pressure. The resulting mixture is diluted with 20 mL water and
extracted twice with 20 mL ethyl ether. The combined organic layers are dried with
MgSO 4, filtered and the solvent removed under reduced pressure. The resultant clear oil
was chromatographed on silica gel in 1:1 hexanes/ethyl acetate to give 32 mg of an oily
white solid (53% yield). IH NMR (DMSO d) 8 3.23 (dd, 1H), 3.61 (s, 3H), 3.75 (dd,
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1H), 3.82 (s, 3H), 3.86 (s, 3H), 5.75 (dd, 1H), 6.79 (d, 1H), 7.09-7.11 (m, 2H), 7.55-7.80
(m, 4H). HR-MS 369.1211 (Calc. 369.1212).
Methyl P-tetrafluorophthaloyl-3,4-dimethoxydihydrocinnamate (7). Methyl p-
amino-3,4-dimethoxydihydrocinnamate hydrochloride (48 mg, 0.17 mmol) and
tetrafluorophthalic anhydride (38 mg, 0.17 mmol) were taken up in 5 mL glacial acetic
acid. The mixture was refluxed under an argon atmosphere overnight. After removal of
the solvent under reduced pressure, the residue is chromatographed on silica gel in 1:1
hexanes/ethyl ether to afford 43 mg of the product as a pale yellow powder (56%). 1H
NMR (CDCl 3) 8 7.04 (m, 2H), 6.79 (d, 1H), 5.67 (dd, 1H), 3.86 (s, 3H), 3.82 (s, 3H),
3.78 (m, 2H), 3.63 (s, 3H), 3.12 (dd, 1H). HR-MS 441.0835 (Calc. 441.0836).
t-Boc-Aminoethyl p-tetrafluorophthaloyl-3,4-dimethoxydihydrocinnamamide. 0-
Tetrafluorophthaloyl-3,4-dimethoxydihydrocinnamate (13 mg, 0.03 mmol), DCC (7.5 mg,
0.037 mmol), and DMAP (1 mg) were dissolved in 2 mL CH2Cl 2 under an Ar
atmosphere. t-Boc-aminoethylamine (5.9 mg, 0.037 mmol) was added, and the mixture
was stirred at room temperature for 16 hr. The reaction mixture was concentrated in
vacuo and chromatographed on silica gel in 1:1 hexanes/ethyl acetate. Removal of the
solvent under reduced pressure provided 5 mg of the product (30%). 'H NMR (CDCl3) 5
7.06 (m, 2H), 6.79 (d, 1H), 6.38 (br s, 1H), 5.72 (dd, 1H), 5.84 (br, 1H), 3.86 (s, 3H),
3.82 (s, 3H), 3.65 (dd, 1H), 3.10-3.38 (m, 4H), 2.92 (dd, 1H), 1.42 (s, 9H). HR-MS
569.17876 (Calc. 569.17851).
Cold tetrafluorophthalimide photoaffinity label. Synthesized by Satomi Niwayama
in the Liu laboratory. t-Boc-Aminoethyl P-tetrafluorophthaloyl-3,4-
dimethoxydihydrocinnamamide (6 mg, 0.01 mmol) was deprotected in 1 mL 25%
trifluoroacetic acid in CH 2Cl2 under an Ar atmosphere for 1.5 hr at RT. Toluene (1 mL)
was added and the solvent removed under reduced pressure. The free amine was
crystallized by the addition of ethyl ether and then reacted with an equimolar amount of
AIPPS in 1 mL EtOAc using triethylamine (1 equivalent) as the base. After 16 hr the
solvent was removed under reduced pressure and the product isolated by silica gel
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chromatography in 30% hexanes in EtOAc. Removal of the solvent provided 4 mg of the
product (40% yield). 'H NMR (CDCl 3) 8 7.61 (s, 1H), 7.22 (m, 2H), 7.03 (m, 2H), 6.79
(d, 1H), 6.20 (br s, 1H), 5.92 (br s, 1H), 5.66 (dd, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.62
(dd, 2H), 3.27 (m, 4H), 2.86 (m, 4H), 2.40 (t, 2H). HR-MS 768.08151 (Calc. 768.08147).
TNF-x production assay. Compounds were assayed by Satomi Niwayama in the Liu
laboratory as follows. THP-1 cells were cultured in RPMI containing 25 mM HEPES
(pH 7.3), 10 % FBS, penicillin and streptomycin, and were rendered LPS-responsive by
culturing for 72 hr in the presence of 100 nM 1,25-dihydroxy vitamin D3. Cells were
plated at 106 cells per well in 24-well tissue culture dishes. Drugs dissolved in DMSO (1
pL) were added to a final concentration of 0.2% DMSO, followed by the addition of LPS
in 50 kL culture medium to a final concentration of 1 pg/mL in 0.5 mL per well. Plates
were incubated for 16 hr in a humidified incubator (37'C, 5% C0 2). Drug treatment did
not significantly affect cell viability as judged by trypan blue exclusion. Culture
supernatants were analyzed by ELISA using mouse anti-human TNF-a antibodies from
PharMingen according to the supplier's instructions.
Northern blot analysis. Analysis was performed by Christine Loh in the Liu
laboratory. Cells were treated as described and then total RNA was prepared using a
Qiagen RNA preparation kit. RNA was electrophoresed, blotted to nitrocellulose and
probed as in Chapter 3.
Preparation of cell lysates. HL-60 cells were pelleted and washed twice with PBS and
once with hypotonic buffer (10 mM Tris HCl, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 1
mM PMSF, 1 mM DTT, 200 pg/mL aprotinin, 25 gM leupeptin, and 10 gg/mL
pepstatin A). Cells were resuspended in three packed cell volumes of hypotonic buffer,
incubated on ice for 10 min, and then lysed in a Dounce homogenizer with thirty up and
down strokes. Debris and unlysed cells were pelleted by centrifugation for 10 min at
16,000 X g. Supernatants were collected and 1/1 lth volume of loX cytosol buffer (100
mM Tris HCl, pH 7.9, 0.9 M NaCl, 2 mM EDTA, 50% glycerol) was added. Extracts
were centrifuged at 100,000 X g for 1 hr. Protein concentration in supernatants was
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determined by Bradford assay (Bio Rad). Extracts were frozen on dry ice/EtOH and
stored at -80*C until use.
Photoaffinity labeling. Preparation and use of the thalidomide photoaffinity label was
done as described in Chapter 6. Photoaffinity label 9 was prepared from t-Boc-
aminoethyl p-tetrafluorophthaloyl-3,4-dimethoxydihydrocinnamamide by deprotection
with trifluoroacetic acid and coupling with [12 5I]AIPPS in an analogous manner.
Photoaffmity labeling was performed as described in Chapters 2 and 6.
Detection of tetrafluorophthalimide binding proteins by affinity chromatography.
HL-60 hypotonic extract (5 mg/mL protein) was precleared with streptavidin-agarose
beads (Sigma) for 30 min at 4*C and then centrifuged to remove the beads. Precleared
supernatant (300 gL) was incubated with 3 gM biotin conjugate 10 (synthesized by
Satomi Niwayma in the Liu laboratory) in the presence of either 150 gM 7 or carrier
solvent alone (1% DMSO) for 2 hr on ice. Streptavidin-agarose beads were added (30 gL
in a volume of 75 gL 20 mM Tris HCl, pH 7.4, 100 mM NaCl), and incubated for 1 hr
with rotating at 4*C. Beads were pelleted and washed three times with wash buffer (0.6
mL 20 mM Tris HCl, pH 7.4, 100 mM NaCl, 5 min per wash). For detection of p40,
beads were resuspended in SDS-PAGE loading buffer (60 pL), heated in a boiling water
bath for 10 min, and samples were subjected to SDS-PAGE (10% acrylamide) followed
by silver staining. For detection of p30, protein was eluted from beads with five 100 gL
washes with SDS elution buffer (0.1% SDS, 10 mM Tris HCl, pH 7.5, and 1 mM DTT).
Elutions were dried in vacuo, resuspended in 50 gL water plus 2.5 gL P-mercaptoethanol,
heated in a boiling water bath for 10 min, and then subjected to two dimensional gel
electrophoresis (IEF/SDS-PAGE) and silver staining as described in Chapter 6. For
immunoblotting, beads were suspended in SDS-PAGE loading buffer, heated in a boiling
water bath for 10 min. Following SDS-PAGE (12% acrylamide), samples were blotted to
nitrocellulose and probed with p30 antiserum analogously to the procedure described in
Chapter 2.
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Purification of tetrafluorophthalimide binding proteins. HL-60 cells were grown in
suspension in RPMI with 10% FBS, penicillin and streptomycin. The culture used as a
source for p30 was grown by the Cell Culture Center (Minneapolis), and supplied as a
frozen cell pellet.
For purification of p40, hypotonic extract from 4.5 X 108 HL-60 cells (3 mL) was
precleared with immobilized streptavidin (Boehringer Mannheim) and then incubated
with 3 gM biotin conjugate 10 2 hr on ice. Complexes were collected on immobilized
streptavidin (500 gL) by rotating 1.5 hr at 4'C. Beads were washed four times with
hypotonic buffer, suspended in 400 gL 2X SDS-PAGE loading buffer, and heated 10 min
in a boiling water bath. The bead suspension was subjected to SDS-PAGE (10%
acrylamide). The gel was stained with Coomassie Blue for 2 hr, destained with 10%
HOAc, 10% MeOH for 16 hr, and then 30 min in 10% HOAc, 50% MeOH. After
washing in ddH20 for 30 min, p40 bands were excised. In gel digestion with Lys-C,
HPLC separation and Edman sequencing of the resulting peptides was performed by the
MIT Biopolymers laboratory.
For purification of p30, hypotonic extract from 4 X 109 HL-60 cells (8 mL) was
precleared with glutathione Sepharose 4B (800 gL) 45 min at 4'C with rotating. The
suspension was centrifuged at 2000 X g for 2 min, and the supernatant was applied to a
DEAE Sepharose column equilibrated to wash buffer (20 mM Tris HCl, pH 7.5, 100 mM
NaCl, 1 mM DTT, and 25 gM leupeptin). Flowthrough fractions were adjusted to 1
mM EDTA, 200 gg/mL aprotinin, and 10 gg/mL pepstatin A. Protein-containing
fractions were pooled and concentrated to 2 mL by centrifugal filtration using Centriprep
concentrators (Amicon). The concentrated sample was cleared with 225 gL immobilized
streptavidin for 1 hr at 4'C and centrifuged to remove beads. The supernatant was
incubated with 3 gM biotin conjugate 10 for 2 hr at 4'C, and then 90 gL immobilized
streptavidin beads were added followed by rotating for 1 hr at 4*C. The beads were
washed four times with 1.2 mL wash buffer containing aprotinin, EDTA, and pepstatin
A. Bound proteins were eluted by four 180 pL washes with buffer containing 0.1% SDS,
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12.5 mM Tris HCl, pH 6.8, 0.5% glycerol, and 1 mM DTT. Eluates were pooled and
concentrated to 70 gL in a speedvac, 3 gL P-mercaptoethanol added, and the sample
heated in a boiling water bath for 5 min. The sample was subjected to SDS-PAGE (12%
acrylamide). The gel was silver stained as described (21) and the 30 kD band excised,
digested with trypsin, and peptides extracted and subjected to MALDI-TOF mass
spectrometry as described in Chapter 2. Methylation of the carboxylic acid groups was
performed by suspending the peptide mixture in 10 piL of 1% SOCl2 in MeOH and
heating to 50C for 20 min, after which the sample was dried in vacuo (22).
Electrophoretic mobility shift assay (EMSA). Consensus NF-B binding site
oligonucleotide (50 ng, Santa Cruz Biotechnology) was end labeled using T4
polynucleotide kinase (New England Biolabs) with 50 gCi [y- 32 P] ATP (3000 Ci/mmol)
in 70 mM Tris HCl, pH 7.6, 10 mM MgCl 2, 5 mM DTT, and 0.1 mM EDTA (30 gL)
for 1 hr at 37'C. Labeled oligonucleotide was purified by electrophoresis in a 12%
polyacrylamide native TBE gel. Incorporation of radioactivity was determined by
scintillation counting.
THP-1 cells were treated with 1,25-dihydroxy vitamin D3 as described above and
suspended in fresh media to 106 cells per mL (10 mL per sample). Cells were pretreated
for 1 hr at 37 0C with drug (1 gM) or DMSO carrier control (0.1%) and then stimulated
with 1 pg/mL LPS for 30 min. Cells were harvested by scraping, pelleted at 40C, and
washed once with ice cold PBS. Nuclei were prepared by suspending cells in 900 gL
RSB (10 mM Tris HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2, 0.5 mM DTT, 25 gM
leupeptin, 1 gg/mL aprotinin, 1 mM PMSF, 0.1 mM EGTA) and then lysing by adding
5% NP40 (100 gL), mixing and leaving on ice for 5 min. Nuclei were pelleted at 1800 X g
for 5 min, washed with RSB, and repelleted at 4000 x g for 5 min. Nuclear extracts were
prepared by resuspending nuclei in 30 gL buffer C (23) (20 mM HEPES, pH 7.4, 420
mM NaCl, 1.5 mM MgCl 2, 0.2 mM EDTA, 25% glycerol, 0.01% NaN3 , 0.5 mM DTT, 1
mM PMSF, 25 gM leupeptin, 1 gg/mL aprotinin) and mixing for 30 min at 4*C. Extract
was centrifuged for 10 min at 16,000 X g and an equal volume of buffer D (20 mM
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HEPES, pH 7.4, 50 mM KC1, 0.2 mM EDTA, 0.0 1% NaN 3, 0.5 mM DTT, 1 mM
PMSF, 25 gM leupeptin, 1 gg/mL aprotinin) was added to the supernatant.
EMSA was performed by incubating nuclear extract containing 8 Rg total protein
with 20,000 cpm oligonucleotide probe and 2 jg poly dIdC in a volume of 15 gL for 20
min at room temperature. Complexes were electrophoresed on 4.5%
polyacrylamide/0.25X TBE native gels. Gels were dried immediately following
electrophoresis and analyzed by autoradiography.
Reporter gene assays. The TNF reporter construct contains nucleotides -614 to +20 of
the human TNF-a promoter upstream of the luciferase gene in the plasmid pGL2, and
was obtained from Dr. S. McKnight, Tularik, Inc. The NF-B reporter construct
contains three copies of the NF-B binding site from the mouse w light chain enhancer
upstream of the luciferase gene and was obtained from the laboratory of Dr. M. Karin,
Univerisity of California, San Deigo School of Medicine. THP-l cells were transfected
by the DEAE-dextran method with NF-kB-luciferase and TNF-luciferase reporter
plasmids prepared using Qiagen EndoFree kits, 10 gg/107 cells. 24 hr post-transfection,
cells were pelleted and resuspended to 106 cells per mL in fresh media and plated into 12-
well plates (1 mL per well). Cells were preincubated for 1 hr with drug (1 pM) or
DMSO carrier alone (0.2%) and then stimulated with 1 gg/mL LPS for 6 hr. Cells were
harvested by scraping, lysed and analyzed for luciferase activity by luminometry using a
luciferase assay kit (Promega).
Results
Tetrafluorothalidomide (2) was synthesized by coupling tetrafluorophthalic anhydride
with 2-aminoglutarimide (Figure 7.1). The compound was tested for its ability to inhibit
TNF-a production from the promonocytic cell line THP- 1. Tetrafluorothalidomide
potently inhibits TNF-a production with an IC 50 of -500 nM in this assay (Figure 7.2).
Compared with thalidomide (1), which has an IC5 0 of over 200 gM, this represents a 500-
fold increase in activity. To assess whether other halogen atoms have the same effect as
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Figure 7.2. Inhibition of TNF-oa production from LPS-
stimulated THP-1 cells by thalidomide and analogs. Cells
were rendered LPS responsive as described in text and treated
with varying concentrations of compounds as indicated plus 1
pig/rnL LPS. After 16 hr TNF-a was analyzed in culture
supernatants by ELISA.
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fluorine, tetrachlorothalidomide (3) and tetrabromothalidomide (4) were prepared in an
analogous manner. Both analogs are much less active than tetrafluorothalidomide at
inhibiting TNF-a secretion (Figure 7.2). These observations suggest that the increase in
potency is unique to fluorine substitution.
CC-1 104 (5) has been reported to inhibit TNF-a production at concentrations 30-
fold lower than thalidomide (15). To test the effects of combining this improvement with
tetrafluorine substitution, CC- 1104 and its tetrafluorinated analog (7) were prepared
(Figure 7.3). CC- 1104 was indeed found to be more potent than thalidomide, though we
did not observe as significant an increase in potency as previously reported, possibly due
to different assay conditions used (Figure 7.4). The tetrafluoro-substituted analog 7,
however, was found to be over 100-fold more potent than CC- 1104, with an IC50 of
approximately 100 nM.
The large increases in potency involved with tetrafluorine substitution raised
suspicions that the novel compounds might be acting by a mechanism distinct from
thalidomide. Thalidomide has been shown to be a specific inhibitor of TNF-a
production, and does not affect levels of other cytokines, such as IL-1 P and IL-6 (6).
Conversely, we found that tetrafluorophthalimides 2 and 7 are potent inhibitors of the
secretion of these other cytokines as well. Inhibition of IL-1 p production occurs with
IC 50 values of approximately 400 nM for either compound, and IL-6 production is half-
maximally inhibited at 700 nM and 300 nM for compounds 2 and 7, respectively. Like
thalidomide, 2 and 7 caused decreased levels of TNF-a mRNA to accumulate (Figure
7.5A). However, the tetrafluorophthalimides did not alter the turnover rate of the TNF-a
mRNA, in contrast with previous reports indicating that thalidomide destabilizes the
TNF-a message (Figure 7.5B) (7). These experiments suggest that
tetrafluorophthalimides decrease TNF-a production at the transcriptional level. Thus it
would appear that the tetrafluorophthalimides inhibit TNF-x production by a mechanism
distinct from thalidomide.
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Figure 7.3. Synthesis of thalidomide analogs. Abbreviations: CEP,
carboethoxyphthalimide; TFPA, tetrafluorophthalic anhydride.
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Figure 7.4. Inhibition of TNF-a production from LPS-
stimulated THP- 1 cells by compound 5 and its tetrafluori-
nated analog 7. Cells were treated and culture supernatants
were analyzed for TNF-a content as in Figure 7.2.
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Figure 7.5. Tetrafluorophthalimides affect TNF-x production at the transcrip-
tional level. A, Northern blot analysis of TNF-ix mRNA in THP-1 cells stimu-
lated with LPS in the presence or absence of tetrafluoropthalimides 2 and 7 as
indicated. Cells were pretreated with drug for 1 hr and then stimulated with
LPS for 1 hr prior to harvesting. B, Cells were first stimulated with LPS for 1
hr and then treated with actinomycin D in the presence or absence of tetrafluo-
rophthalimides 2 and 7 as indicated. Cells were harvested at various times
thereafter and analyzed for TNF-x mRNA by Northern blot analysis.
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That tetrafluorophthalimides operate by a different mechanism than thalidomide
suggests that they bind to a distinct target protein. Indeed, neither 2 nor 7 appears to
bind a, -acid glycoprotein, the only reported thalidomide binding protein (Chapter 6), as
determined by their inability to compete with a thalidomide photoaffinity label for
binding to the protein (Figure 7.6). In order to detect tetrafluorophthalimide binding
proteins, a photoaffinity label derived from 7, the most active compound, was prepared
(9, Figure 7.1). To ensure that modification of the drug did not result in loss of activity,
the corresponding compound containing non-radioactive iodine was prepared and tested
for its ability to inhibit TNF-a production from THP-I cells. The tetrafluorophthalimide
photoaffinity label maintained significant, though decreased, activity, with an IC50 of
approximately 2 gM in this assay.
Incubation of HL-60 cell extracts with photoaffmity label 9 followed by
irradiation resulted in the specific labeling of two protein bands, of 30 kD and 40 kD
molecular weight (referred to from this point on as p30 and p40, respectively), as judged
by the ability of excess cold 7 to compete for labeling (Figure 7.7). In contrast, neither
tetrachlorothalidomide (3) nor CC-1 104 itself (5) significantly inhibited labeling of either
protein, suggesting that these proteins might specifically mediate the effects of the
tetrafluorophthalimides.
To facilitate purification of p30 and p40, a derivative of 7 conjugated to biotin
was prepared (10, Figure 7.1). HL-60 cytosolic extracts were incubated with 10 in the
presence or absence of a 50-fold excess of competitor 7. Proteins bound to the biotin
conjugate were isolated on immobilized streptavidin beads. When the beads were
subjected to SDS-PAGE, only the 40 kD protein could be detected (Figure 7.8). The
presence of excess 7 during the binding reaction caused the 40 kD band to disappear. To
isolate p40, the affinity chromatography procedure was done on a scale which produced
approximately 1 jg of protein. The protein band was excised from a Coomassie-stained
polyacrylamide gel and digested with Lys-C endopeptidase. Peptides were extracted,
separated by HPLC, and subjected to Edman degradation sequencing.
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Figure 7.6. Tetrafluorophthalimides do not bind to al-AGP. al-AGP (2.5 Vg,
50 pg/mL) was incubated with the indicated concentrations of drugs for 40 min
prior to the addition of thalidomide photoaffinity label (1 pCi carrier free).
After 40 min the reactions were irradiated and fractionated on SDS-PAGE fol-
lowed by phosphorimager analysis.
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Figure 7.7. Detection of tetrafluorophthalimide binding proteins by photoaffinity
labeling. HL-60 cell extracts were incubated with the indicated concentrations of
tetrafluorophthalimide 7, tetrachlorothalidomide (3), or CC- 1104 (5) for 30 min
prior to the addition of photoaffinity label 9. After a further 30 min incubation in
the dark, samples were irradiated and subjected to SDS-PAGE followed by
autoradiography.
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Figure 7.8. Affinity purification of p40. HL-60
cell extracts were incubated with biotin conjugate
10 in the presence or absence of a 50-fold excess
of compound 7, and tetrafluoropthalimide bind-
ing proteins isolated on immobilized streptavidin
beads.
191
M
FK A
TA
- GWA E A A
N DW T S S E
P W A P QC A
Q W AD P C K
S WC G P C R
V A A EEV G A G FELEL L R L K A- -7 S L V H human p40
- - T V VEI K Q D T Q L T T T N A - A NKL I VL Y yeast 27.5K
E G Q_ F G C H K V E E W NW Y F K K G V E T K K L V V D tobacco Trx
QM NE A E LE L [ - - VS F L E GA E  V[P E human p40
T A V S E K V R E D VRIF LI ID A D E H P E yeast 27.5K
F I A P I& DIAKK M H -- _IF L K vLD VD E L K T tobacco Trx
76 S E K Y E I S V P T F Q K I L D A H A PE T K K V Q Ra human p40
69 I1 D L F E I A A V PEF VF I( T I V K E I S A AD P K E V KS L E -- yeast 27.5K
79 S A E W S V E AMP T F V F I K D K E V D R V V A K KEE Q Q T I V KW tobacco Trx
116 S S G S F L P S A N E HL K E D L N L R L K K L T H A A P C M L F M K G T P Q human p40
107 - - - - - I L S N A S A S L A N N A K - - - --- - OW- - - - - K S T S D yeast 27.5K
119 WA P A T V T A tobacco Trx
V
156 P R C G F S K Q M V E I L H K H N I Q F S S F D I F S DE E V R Q G L K A Y S human p40
128 E S S G S S D D - - - - - - - - - - - - - - - - - - - E E D - - - - - - - - - yeast 27.5K
196 S W P T Y P Q L Y V S G E L I G G L D I I K E L E]A S EEL D T I C P K A P K L human p40
140 - - - - - - - - - - - - - - - - - - - - - - - - T E E I N A - - - - - - - - yeast 27.5K
236 E E[RL K VD T N K A S V M L F M K G N
148- - V K V Q A A P V ML FM KG S
KQEAKCGFS K[Q I
P S E P K GFSR L
L E I L N S T G human p40
V G IL R E H Q yeast 27.5K
276 V E Y ET F D I L E E E V R Q G LKAY SN WP T Y PQL Y V K GEL V G G L human p40
186 I R F G F F D I L R N V R S K K F SD W PT F[PQ L Y I N F Q IG G L yeast 27.5K
316 D V - L KEN GEL L PI L ROE N
226 D I S I E D P E Y F Q-- H A L Q
human p
4 0
yeast 27.5K
Figure 7.9. Sequence of human tetrafluorophthalimide binding protein p40, aligned
with the yeast 27.5 kD homolog and tobacco thioredoxin. Residues shared by at
least two of the sequences are boxed. The tryptic peptides from the purified protein
which were sequenced and used for the database search are overlined. Conserved
cysteine residues in the thioredoxin repeat regions of p40 are marked with an
arrowhead. Alignment generated using the program MegAlign.
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The peptide sequence data was used to search the protein sequence databank. All
three peptides were found to be present within the sequence of a single 335 amino acid
protein of unknown function, which had been cloned by virtue of its high homology to a
putative yeast 27.5 kD protein identified from an open reading frame in the S. cerevisiae
genome (NCBI Entrez accession number 3646128, Figure 7.9). The closest relatives to
p40 of known function are the thioredoxins from plants, with the amino terminal portion
of p40 being 32% identical to tobacco thioredoxin. Thioredoxin has been suggested to be
important for activation of the transcription factor NF-B, which is known to be essential
for TNF-a gene induction in LPS-stimulated monocytic cells (24,25,26). The binding of
p40 by compounds which inhibit TNF-a induction raises the possibility that the novel
protein may play a specialized role in the context of NF-rB activation role similar to that
previously prescribed to thioredoxin. To investigate this possibility,
tetrafluorophthalimide 7 was tested for its ability to inhibit the LPS-induced activation of
NF-rcB in THP-I cells. As previously reported, LPS caused efficient activation of NF-YB
as judged by electrophoretic mobility shift assay (EMSA). Compound 7 caused only a
partial decrease in NF-KB activation in this assay at concentrations which completely
abolish TNF-a gene induction (Figure 7.1OA). Compound 7 was also tested for its effect
in an NF-KB-dependent reporter gene assay. THP-l cells were transfected with a
reporter plasmid containing the luciferase gene under the control of a multimerized NF-KB
binding site. Transfected cells were stimulated with LPS in the presence or absence of
tetrafluorophthalimide 7. Again, LPS-induced activation of the NF-KB reporter gene was
only partially reduced at concentrations which eliminate TNF-a production (Figure
7.1 OB). Furthermore, the same concentration of the compound also dramatically reduced
the activation of a reporter gene under the control of the TNF-a promoter. These results
indicate that tetrafluorophthalimides are likely to exert their effects on cytokine induction
by affecting transcription factors other than NF-cB.
Specific binding of p30 to biotin conjugate 10 could not be detected on one
dimensional gels due to the low abundance of the protein and background binding of
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Figure 7.10. Effect of tetrafluorophthalimide 7 on NF-KB activation. A, Electro-
phoretic mobility shift assay. THP-1 Cells were treated with or without 7 prior to
LPS stimulation. Nuclear extracts were prepared and analyzed for the presence of
NF-KB with a consensus binding site oligonucleotide. B, Reporter gene assay. THP-
1 cells were transfected with plasmids containing the luciferase gene under the con-
trol of either a multimerized consensus NF-KB site or the human TNF-c promoter.
Transfected cells were treated with 7 where indicated and stimulated with LPS for 6
hr prior to harvesting and analyzing for luciferase expression.
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Figure 7.11. Affinity purification of p30. Tetrafluorophthalimide binding proteins from HL-60 cell
extracts, isolated as in figure 7.8, were separated by two-dimensional gel electrophoresis (TEF/SDS-
PAGE) and visualized by silver staining. The 30 kD protein, which does not appear if extracts are
preincubated with excess tetrafluorophthalimide 7, is indicated with an arrow.
proteins of similar molecular weight. However, when eluates from beads were subjected
to two dimensional gel electrophoresis, binding of a 30 kD protein could be detected
which was abrogated by the presence of excess competitor 7 during the binding reaction
(Figure 7.11). Isolation of p30 in sufficient purity and yield to allow for its identification
required several purification steps. As it was determined that some of the background in
the 30 kD region was due to binding of glutathione S-transferases (GSTs, data not
shown), extracts were first cleared with glutathione Sepharose. GST-cleared extracts were
passed over a DEAE column, and the flowthrough fraction was concentrated and
incubated with biotin conjugate 10. Purified protein was isolated on immobilized
streptavidin. Under these conditions, a 30 kD band could be detected by one dimensional
electrophoresis which was not present if excess 7 was present during binding to 10
(Figure 7.12). The desired protein band was excised from silver-stained polyacrylamide
gels and digested with trypsin, and the extracted peptides were subjected to MALDI-
TOF mass spectrometry.
Seven of the nine peaks from the mass spectrum matched with high accuracy a
recently identified protein of 28 kD predicted molecular weight (Table 7.1). This protein
was cloned by virtue of its upregulation in cells which have lost the ability to undergo
apoptosis in response to ionizing radiation (R. Kodym and M. Story, personal
communication). The protein also bears high homology (80%) to a glutathione-dependent
dehydroascorbate reductase recently cloned from the rat (Figure 7.13, 27). The
assignment was confirmed in two ways. First, the remainder of the original tryptic digest
was treated with methanolic thionyl chloride, which transforms carboxylic acids into
methyl esters. The methylated peptides were again analyzed by mass spectrometry.
The major peaks in the resulting spectrum corresponded to the predicted quantitative
methylation products of peptides identified to be present in the mixture from the original
spectrum. Since false positive assignments in database searches with peptide masses
generally result from peptides of distinct amino acid composition which are close in
molecular weight and not from 'scrambled' peptides, the methylation data strongly
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Figure 7.12. Purified p30. The 30 kD protein was purified
from HL-60 cell extracts as described in the text. During the
final affinity chromatography step, either tetrafluorophthal-
imide 7 (right lane) or carrier solvent alone (left lane) was
included during binding to biotin-drug conjugate 10. Material
was subjected to SDS-PAGE and visualized by silver
staining.
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Table 7.1. The MALDI-TOF mass spectrum of a tryptic digest of p30 suggests identity
with a recently cloned homolog of rat glutathione-dependent dehydroascorbate reductase
(GDAR). The methylated mass refers to the major peak in the spectrum following
treatment with methanolic thionyl chloride. The number in parentheses refers to the implied
number of carboxyl groups in the peptide derived from the increase in mass upon
methylation (14 Da per carboxylic acid), which in each case corresponds exactly to the
predicted increase from the assigned peptide.
Measured Calculated Methylated GDAR Homolog Peptide
Mass (Da) Mass (Da) Mass (Da) Peptide Sequence Location
926.38 926.419 954.415 (2) FCPFAER 31-37
1074.561 1074.631 1088.62 (1) VPSLVGSFIR 123-132
1095.481 1095.563 1123.56 (2) NKPEWFFK 58-65
1320.621 1320.691 1348.71 (2) GSAPPGPVPEGSIR 12-25
1356.601 1356.644 none EDYAGLKEEFR 137-147
1813.811 1813.872 1883.92 (5) SQNKEDYAGLKEEFR 133-147
1941.871 1941.967 2011.96 (5) SQNKEDYAGLKEEFRK 133-148
1405.711 none 1433.8 (2) none -
2807.311 none none none
suggest that the isolated protein is indeed encoded by the recently cloned human gene.
Secondly, tetrafluorophthalimide binding proteins isolated by biotin-streptavidin affinity
chromatography alone were subjected to SDS-PAGE followed by immunoblotting with
antibodies raised against the novel protein (Figure 7.14). A protein of 30 kD which
reactswith this antibody was found to bind to the beads. Binding was abrogated by the
presence of excess competitor 7. Thus it would appear as if the tetrafluorophthalimide-
binding p30 and the novel dehydroascorbate reductase homolog are identical proteins.
Discussion
Our results demonstrate that fluorine substitution dramatically increases the potency of a
series of phthalimide inhibitors of TNF-a production. Fluorine is a close steric mimic of
hydrogen, and incorporation of fluorine into drugs often improves their biological activity
(28). Such improvements have been attributed to either the enhanced lipophilicity of
fluorinated compounds or to stereoelectronic changes imparted to compounds by fluorine
substitution resulting in more avid binding to their respective target molecules. Several
lines of evidence support the contention that fluorinated thalid-omide derivatives are an
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1 M R F C P F A[Q R T LM V L K A K G I R H E I I N I N L K N K P E W F F E K N P rat GDAR
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Figure 7.13. Alignment of human p30 with a recently cloned glutathione-
dependent dehydroascorbate reductase (GDAR) from rat. Residues in the rat
GDAR which differ from human p30 are boxed. Alignment was done using the
program MegAlign.
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Figure 7.14. Confirmation that p30 is identical to a recently
cloned homolog of GDAR. HL-60 cell extracts were preincu-
bated with or without tetrafluorophthalimide 7 as indicated
prior to the addition of either biotin-drug conjugate 10 or car-
rier solvent alone. Proteins bound to immobilized streptavi-
din beads were analyzed by immunoblotting against antibod-
ies to the GST homolog.
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exceptional case in which their mechanism of action bears apparently no relation to that
of the parent compound. For example, thalidomide, but not tetrafluorophthalimides,
destabilizes the TNF-a message. In addition, while thalidomide exclusively inhibits the
production of TNF-a from stimulated monocytic cells, 2 and 7 inhibit production of IL-
10 and IL-6 as well. Furthermore, tetrafluorophthalimides have been shown recently to
differ in their sterospecificity of action from thalidomide (29,30). These observations
suggest that nonfluorinated and fluorinated phthalimides mediate inhibition of cytokine
production by distinct mechanisms and through interaction with different target proteins.
Interestingly, recent reports also suggest that the non-fluorinated
phthalimidocinnamic acid derivatives developed at Celgene may operate through a
mechanism distinct from the parent compound, thalidomide. CC-3052, which differs
from CC- 1104 (5) only in that one of the phthalimide carbonyl groups has been reduced
to methylene, has also been shown to affect TNF-a production at the level of
transcription, and did not alter the stability of the TNF-a mRNA (31). Furthermore, this
compound, and not thalidomide, was shown to inhibit the type IV phosphodiesterase
(PDE IV) at concentrations close to those needed to inhibit TNF-a production. PDE IV
inhibitors have attracted interest as anti-inflammatory compounds due to the ability of
elevated cAMP levels to antagonize LPS-induced cytokine production, and a number of
such compounds are in clinical development to treat inflammatory diseases such as
rheumatoid arthritis (32). Tetrafluorophthalimides probably do not fall into this class of
compounds, as PDE IV inhibitors do not inhibit production of the broad spectrum of
cytokines affected by 2 and 7. In addition, the nonfluorinated CC- 1104 (5) does not
appear to bind the two tetrafluorophthalimide binding proteins, p30 and p40.
Two proteins from monocytic cells were identified which bind to tetrafluoro-
phthalimides. The 40 kD protein was identified as the product of a recently cloned gene
encoding a protein predicted to be 38 kD in molecular weight (Figure 7.9). The protein is
most homologous to the conceptual protein product of a yeast open reading frame which
was identified from the S. cerevisiae genomic sequence (being 52% identical and 70%
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similar at the amino acid level). The most closely related protein of known function is the
small redox protein thioredoxin; the amino terminal region of p40 has highest homology to
thioredoxins of plant origin (having 33% identity and 66% similarity to tobacco
thioredoxin). In fact, p40 can be depicted as being comprised of three 'thioredoxin repeat'
regions, each homologous to the entire thioredoxin sequence, with the two carboxy
terminal repeats having higher homology to glutaredoxin and being most closely related to
each other. The putative yeast homolog is smaller (27.5 kD), and bears only two
thioredoxin repeats (Figure 7.9).
The biochemical activity of p40 is at this point unknown. Thioredoxin catalyzes
the reduction of disulfide bonds in substrate proteins and thereby allows redox enzymes
such as ribonucleotide reductase to participate in multiple rounds of catalysis in vivo.
Reduction is mediated by an absolutely conserved pair of closely spaced cysteine
residues which become oxidized to a disulfide during the reaction (33). Thioredoxin is in
turn regenerated by an NADPH-dependent thioredoxin reductase. Thioredoxin has been
implicated in several signal transduction pathways. It is believed to be important for
maintaining members of the NF-B family of transcription factors, which are crucial for
inflammatory cytokine induction, in a reduced state required for activity (24,25). Thus it
is tempting to speculate that a thioredoxin homologous enzyme might have arisen to play
a more specialized role in signaling. The tetrafluorophthalimides, however, only partially
inhibit NF-KB activation in activated monocytic cells as judged either by NF-KB-
dependent reporter gene activation or by EMSA (Figure 7.10), suggesting that p40 does
not directly effect the redox state of NF-cB.
The arrangement of repeated regions found in p40 is reminiscent of the protein
disulfide isomerases which are important for proper disulfide bond formation for proteins
in the secretory pathway (34). Each thioredoxin repeat of p40, however, bears only the
carboxy terminal of the two cysteine residues (Figure 7.9). It therefore seems unlikely
that p40 has either disulfide reducing or oxidizing activity. Two groups of enzymes are
known which share structural homology with thioredoxin but lack one of the two
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conserved cysteine residues. These are the glutathione peroxidases (which bear a
selenocysteine residue at the analogous site) and the peroxiredoxins, which include
thioredoxin peroxidases (35-37). Both of these groups of enzymes catalyze the reduction
of peroxides, with the concomitant oxidation of the conserved cysteine or selenocysteine.
The enzymes differ with regard to their source of electrons, with the glutathione
peroxidases being regenerated by glutathione, thioredoxin peroxidases being regenerated
by thioredoxin, and an unknown reductant acting on the other peroxiredoxins. Whether
p40 has a similar biochemical activity to these enzymes and how such an activity might
play a role in TNF-a gene induction is the subject of future studies.
The 30 kD protein was cloned by virtue of its upregulation in cells which fail to
undergo apoptosis in response to ionizing radiation, though a role for the protein in
resistance to apoptosis has not yet been established. The protein has significant
homology to GST (29% identity and 49% similarity to soybean GST), binds to
glutathione, but has not been demonstrated to have GST enzymatic activity (R. Kodym
and M. Story, personal communication). Recently a glutathione-dependent
dehydroascorbate reductase was cloned from the rat which has 76% identity (87%
similarity) to p3 0 (27). This high degree of homology suggests that p30 is likely to have
this enzymatic activity as well. Future work will be required to determine if this is the
case and whether tetrafluorophthalimides are inhibitors of this activity. Though the role
for such an enzyme in cytokine induction is unclear, it is anticipated that the effects of
dehydroascorbate reductase inhibitors could be overcome by treating cells with excess
reduced ascorbate. Experiments to test the effects of reduced ascorbate on sensitivity to
tetrafluorophthalimides will constitute future work on these inhibitors.
Reactive oxygen species have been presumed to play a role in several signal
transduction pathways, including the mitogenic Ras pathway, by virtue of the ability of
antioxidants to diminish signaling (38,39). Antioxidants have been shown to prevent
activation of NF-icB as well in an indirect manner. In prokaryotes, two transcription
factors, SoxR and OxyR, are known to be activated by direct oxidation by reactive oxygen
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species (40,41). In the context of signal transduction and gene activation in mammalian
cells, however, the protein molecules involved both in mediating production of oxygen
species and in carrying such signals by acting as oxidative sensors in the context of signal
transduction have not been identified. The finding that compounds which block LPS-
mediated signal transduction in monocytic cells bind to two proteins which may play
roles in redox regulation raises the possibility that reactive oxygen species are involved in
unexplored aspects of this signaling pathway as well. Future work will be required to
establish what role if any these proteins play in the regulation of cytokine induction in
monocytes.
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